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Abstract
In October 2002, the complete sequence of the genome of the human malaria parasite 
Plasmodium falciparum was published. The data showed that as many as 60% of all 
identified open reading frames were unique to the parasite, with no known homologues in 
other species. Identification and characterization of novel molecules that may provide 
targets for drug and vaccine design is crucial to fight malaria.
The aim of this project has been to analyse a novel gene and protein in Plasmodium. A  
short nucleotide fragment was originally identified in Plasmodium chabaudi chabaudi 
(AS) and the complete sequence subsequently obtained using Vectorette PCR. A single­
exon gene was identified and Southern analysis showed the presence of a single copy in 
the P. chabaudi genome. Analysis of the protein secondary structure revealed a multi­
domain molecule consisting of an N-terminal secretion signal, two Scavenger Receptor 
Cysteine-Rich (SRCR) domains, three Limulus factor C, Coch-5b2 and Lgll (LCCL) 
modules and an LH2/PLAT domain. These motifs all have adhesive properties, and the 
protein was subsequently named Plasmodium ^RCR LCCL Adhesive-like Protein 
(PSLAP).
Multiple sequence alignment established that PSLAP is highly conserved within 
Plasmodium and also identified a paralogue in Toxoplasma gondii, suggesting it may 
play a specific and vital role in apicomplexan biology. Results from indirect 
immunofluoresence assays showed a punctate expression pattern contained within the 
parasite, indicating that the protein is distributed in vesicles. Northern analysis and 
immunofluorescence co-localisation studies showed transcription and expression in 
blood-stage gametocytes, demonstrating that PSLAP is a sexual stage protein.
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Chapter One 
Introduction
1.1 Malaria -  The current situation
Today approximately 40% of the world’s population is at risk of contracting malaria. 
Malaria is found throughout tropical and sub-tropical regions and is endemic in Africa, 
parts of Asia, Central and South America, Oceania, and certain Caribbean islands (Figure 
1.1). It causes an estimated 500 million cases of acute illness a year, and over one million 
deaths, 90% of which occur in sub-Saharan Africa (Breman, 2001). It has been estimated 
that 76% more productive life years are lost from malaria than from all cancers in all 
developed countries in the world taken together. Still, funding for malaria research is at 
best a tenth of that for cancer research (Malaria Foundation International). To make 
matters worse malaria is on the rise (WHO, 1998). Several factors have contributed to 
this: the emergence of drug resistance in the parasite and insecticide resistance in the 
mosquito, the creation of new mosquito breeding grounds due to road building, 
deforestation, mining, irrigation projects and new agricultural practices, and movements 
of non-immune populations to malarious areas and malaria-infected individuals to 
malaria-free areas.
Apart from the obvious human pain and suffering caused by a life-threatening disease, 
malaria has been shown to be a major constraint to economic development. Economists 
believe that malaria is responsible for a growth penalty of up to 1.3% per year in some 
African countries (Gallup and Sachs, 2001). Lost productivity and income, as well as 
direct public and personal costs for prevention and treatment, have a significant effect on 
the economy of countries heavily burdened by malaria.
1.2 Plasmodium taxonomy
Plasmodium belongs to the kingdom Protista, and the phylum Apicomplexa, a group of 
approximately 5000 species, all of which are parasitic. Apicomplexan parasites have a 
vast medical and economic impact as they infect both humans and domestic animals.
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Seven genera within Apicomplexa cause disease in man: Plasmodium, Toxoplasma, 
Cryptosporidium, Babesia, Isospora, Cyclospora and Sarcocystis. Host cell invasion in 
Apicomplexans is mediated by the apical complex, a set of structural and secretory 
organelles including the rhoptries and micronemes, present at the anterior end of the 
sporozoite, merozoite and ookinete stages (Section 1.3). The complex is believed to be 
involved in attachment to, and penetration of, host cell plasma membranes. Most 
Apicomplexans are intracellular, hence there is little need for movement and there are no 
specialized locomotor organelles (except for the microgamete flagella), although some 
species, including Plasmodium, possess gliding motility.
Over 100 species of Plasmodium infect organisms as diverse as mammals, birds and 
reptiles (reviewed by Garnham, 1966). Four species infect humans: Plasmodium 
falciparum, Plasmodium vivax, Plasmodium ovale and Plasmodium malariae (Section
1.5). Speeies used in experimental animal models, and therefore of scientific interest, 
include the simian malarias Plasmodium cynomolgi and Plasmodium knowlesi, the rodent 
parasites Plasmodium chabaudi, Plasmodium berghei and Plasmodium yoelii (Section
1.6), and the avian parasite Plasmodium gallinaceum.
Although the details vary greatly between species, all Apicomplexa exhibit a similar 
general life cycle that includes both sexual and asexual reproduction phases.
1.3 The Plasmodium life cycle
Plasmodium parasites have a complex life cyele, which involves passage through both a 
vertebrate host and an insect vector. The development includes asexual multiplication in 
the warm-blooded host, as well as sexual and asexual reproduction in the vector (Figure 
1.2).
Infection is initiated when sporozoites are injected with the saliva of an infected, feeding 
female mosquito. Within 45 minutes the sporozoites have been carried by the circulatory 
system to the liver, where they invade hepatocytes. The intra-cellular parasite undergoes 
growth and asexual reproduction (exo-erythrocytic schizogony) within the hepatoeyte, 
resulting in the production of thousands of merozoites. The merozoites are released back 
into the bloodstream where they infect erythrocytes, initiating the asexual blood stages 
that are associated with the characteristic symptoms and pathology of malaria. A period 
of growth, accompanied by an active metabolism that includes ingestion of host
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cytoplasm and proteolysis of hemoglobin into amino acids, then follows: the immature 
“ring-stage” parasite develops into a trophozoite, followed by nuclear and cytoplasmic 
division resulting in an erythrocytic schizont that contains four to 24 individual 
merozoites (depending on the species). The schizont finally ruptures and the merozoites 
are released into the blood, rapidly invading new erythrocytes and repeating the cycle. 
However, as the infection develops, conditions within the host become less favorable for 
parasite survival (fewer non-infected erythrocytes available, an increase in the host 
immune response). Some trophozoites will therefore instead of maturing into multi­
nucleated sehizonts, proceed to become sexual forms, developing into uni-nuclear male 
and female gametocytes (micro- and macro-gametocytes, respectively). Further 
development of these into gametes, gametogenesis, is dependent upon uptake by another 
mosquito. Gametogenesis is triggered by the environment in the mosquito gut: a drop in 
temperature, an increase in carbon dioxide and exposure to gametoeyte-aetivating factor 
(GAF), a mosquito-derived substance recently identified as xanthurenic acid (Billker et 
al, 1998).
Macrogamétocytes develop into macrogametes and ex-flagellation is induced in the 
microgamétocyte, generating eight haploid, motile microgametes. Each microgamete 
subsequently fertalises a macrogamete, producing a zygote. Within 24 hours the zygote 
has developed into a motile ookinete that penetrates the mosquito midgut wall and lodges 
between the basal lamina and the epithelial cells, where it matures into an oocyst. Each 
oocyst undergoes multiple rounds of asexual replication forming up to 8000 sporozoites, 
which upon rupture of the oocyst are released and migrate to the salivary glands of the 
mosquito, awaiting injection into another warm-blooded host (Fujioka and Aikawa et al, 
2002).
The liver-stage development does not elicit any symptoms in the vertebrate host, rather, 
clinical disease is caused by the exponential expansion of parasites during the 
erythrocytic stages.
1.4 Clinical manifestations of malaria
Symptoms of malaria appear six to 40 days (depending on the speeies) after an infectious 
mosquito bite and are almost exclusively caused by the asexual erythrocytic stage 
parasite. The infection starts off with flu-like symptoms such as fever, headaches, nausea,
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chills and vomiting. This is followed by periodic febrile attacks known as malarial 
paroxysms. Without medication the condition worsens and can become life threatening 
(WHO web site). The severity of disease is dependent on the infecting parasite species 
but in the case of P. falciparum, complications include renal failure (also in P. malariae 
infections), severe anemia, acidosis (excessive acids in the body fluids), liver 
dysfunction, hypoglycemia (low glucose levels), acute pulmonary edema and cerebral 
malaria (CM; White, 1998). CM is infection of the nervous system and accounts for a 
substantial proportion of the mortality associated with P. falciparum malaria. CM is 
mainly seen in young children (one to four years of age), pregnant women and non- 
immune travelers. Symptoms include convulsions, impaired coneiousness, delirium and 
coma, and once diagnosed has a mortality frequency of 30%, even with treatment 
(English and Newton, 2002). Patho-physiological characteristics include breakdown of 
the blood brain barrier, cerebral edema and cytoadhesion of parasitised erythrocytes in 
brain capillaries (Adams et al., 2002). Cytoadherenee, also termed sequestration, causes 
obstruction of blood vessels in the microvaseulature, leading to a reduced oxygen and 
substrate supply, with anaerobic glycolysis and lactic acidosis as a consequence (White 
and Ho, 1992). Sequestration is the direct cause of the multi-organ complications seen in 
P. falciparum malaria, however, it is not a feature of infections with the other human 
parasites. The overall severity of the disease depends on the Plasmodium species that is 
causing the infection.
1.5 Human malaria
Four species of Plasmodium cause malaria in man: P. falciparum, P. vivax, P. malariae 
and P. ovale. Although many general characteristics are shared, there are a number of 
significant differences between the species. These include blood-stage morphology 
(parasite and erythrocyte size and shape, number of merozoites), minor life cycle 
variations, ability to sequester in the host, hypnozoite formation, host erythrocyte 
preference and geographical distribution. These differences cause variations in disease 
and clinical manifestations, and ultimately in outcome of the infection.
Of the four human Plasmodia, P. falciparum  causes most morbidity and almost all 
mortality associated with malaria. This is due to the higher parasitemias seen in P. 
falciparum infections as compared with the other speeies, and the complications arising
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from sequestration of infected erythrocytes in various organs of the host (Section 1.4). 
Factors that contribute to the elevated parasite loads include a lack of erythrocyte 
preference, a greater number of merozoites produced per schizont and the parasite’s 
ability to sequester, resulting in fewer infected erythrocytes being cleared by the spleen. 
Complications in P. falciparum malaria are very serious and most notably include severe 
anemia, multi-organ failure and cerebral malaria (Section 1.4). The latter two are both 
associated with sequestration of infected erythrocytes in the host’s circulatory system. P. 
falciparum is widespread in tropical and subtropical areas but is most prevalent in sub- 
Saharan Africa and south-east Asia where it has a great impact on economy and 
development.
P. vivax is the most widespread malaria parasite worldwide and is found throughout most 
of South America. It causes a chronic disease due to the persistence of hypnozites - 
dormant forms of the parasite produced within hepatocytes during development in the 
liver (also seen in P. malariae). Although it does not have as high a mortality rate as P. 
falciparum, P. vivax inflicts debilitating morbidity and frequent relapses of disease, with 
a consequent negative impact on endemic communities due to the loss of productivity.
P. malariae causes the third most prevalent malaria infection, with a broad worldwide, 
but spotty, distribution. Because this species prefers senescent erythrocytes, which are 
relatively scarce in normal blood, parasitemias are generally low. However, P. malariae 
is the most chronic of the human malarias and recrudescences have been documented 
several decades after the initial infection. This chronicity is sometimes associated with 
renal complications, which are probably due to depositions of antigen-antibody 
complexes in the glomeruli of the kidneys (Eiam-Ong, 2003).
P. ovale is the rarest of the four malaria species that infeet humans, and is only common 
in the West African countries of Ghana, Liberia and Nigeria. Disease symptoms are mild 
and infections rarely cause complications.
1.6 Rodent models for studying malaria
For ethical reasons research involving malaria in the human host is very limited. Several 
species of non-human primates are partly susceptible to human Plasmodia but issues 
concerning ethics, methodology and cost make research in these speeies controversial and 
difficult. These problems have led to extensive use of other experimental model systems
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to Study Plasmodium  parasites, mainly rodent and avian malarias. Despite some 
similarities with human parasites, certain aspects of avian parasite biology are 
fundamentally different from the human situation. Avian parasites (P. gallinaceum and P. 
relictum) develop in culicine vectors (Aedes egypti) rather than anopheline mosquitos like 
mammalian parasites, and when entering a warm-blooded host the sporozoites invade 
macrophages instead of hepatocytes (Section 1.3). The immune system of birds also 
differs significantly from that of mammals, and has not been characterised in great detail. 
The availability of inbred and congenic strains of mice with defined MHC haplotypes and 
targeted genetic modifications allows for a controlled approach to studying interactions 
between host and parasite, and offers a great advantage over the avian parasite species. 
Thus, rodents have become the preferred model system for studying experimental 
malaria.
A major criticism for using animal models has been their uncertain phylogenetic 
relationship with human parasites. However, there is a substantial degree of similarity 
between the rodent and human parasite species. On a basic genetic level, chromosome 
numbers (14 nuclear chromosomes) are conserved, as is gene synteny (the chromosomal 
location of different genes) to a large degree, as shown by studies comparing P. 
falciparum with the rodent parasites P. chabaudi and P. yoelii (Carlton et al., 1998; 
Carlton et al., 2002). A comparative analysis of the recently completed P. falciparum 
genome and the five-fold covered P. yoelii genome found that 63% of all proteins 
identified in P. falciparum had orthologs in the rodent parasite (Carlton et al., 2002).
Naturally there are differences between the human and rodent parasites. However, a great 
deal of variation can also be seen between the different species that infeet man. 
Morphology, erythrocyte preference, length of the erythrocytic replication cycle, 
virulence and pathology are all characteristics that differ between the human malaria 
parasites P. falciparum, P vivax, P. malariae and P. ovale (Section 1.5). Studies on the 
phytogeny of Plasmodium based on comparisons of small subunit ribosomal RNA 
sequences have found that P. falciparum is more closely related to the chimpanzee 
parasite P. reichenowi than to P. vivax and P. malariae (P. ovale was not included in the 
study; Escalante and Ayala, 1994). Because the divergence of the human parasites 
predates the origin of hominids, the evolution of the different parasite species was
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initially host independent. This is consistent with the diversity of physiological and 
epidemiological characteristics of infections by these species (Section 1.5). Due to this 
plasticity of the parasite genome no experimental animal model is identical to the human 
disease, instead different rodent parasites are useful for studies of different aspects of 
malaria in man.
Four species of rodent parasites are used for experimental malaria: Plasmodium  
chabaudi, Plasmodium berghei, Plasmodium yoelii and Plasmodium vinckei. Originally 
isolated from African thicket rats {Thamnomys rutilans), they have all been adapted to 
grow in laboratory rodents (Killick-Kendriek and Peters, 1978). In the natural host, 
infections are chronic but with low virulence and parasitemias do not usually exceed a 
few percent. Infections in laboratory mice, on the other hand, are usually acute and either 
lethal or self-curing, depending on the parasite species and the mouse strain. Differences 
due to genetic polymorphisms in the rodent parasites exist both between and within 
species. Inter-species diversity includes variations in host cell preference, chronobiology 
(biological rhythm), virulence and morphology. For example, P. berghei ANKA causes a 
lethal infection in BALB/c and C57BL/6 mice, but death rarely occurs with P. chabaudi 
chabaudi (AS) infections in the same mouse strains (Neill and Hunt, 1992; Cross and 
Langhorne, 1998). Phenotypical differences between strains or clones are generally 
subtler, although there is a substantial degree of variation at the genomic level. A study 
locating parasite genetic markers to distinguish Plasmodium chabaudi chabaudi cloned 
isolates AS and AJ found over 800 loci present only in one of the two clones (Grech et 
al, 2001).
Maintenance of rodent parasites in vivo is relatively simple and follows well-established 
protocols. The parasites can be cultured either through the full life cycle using laboratory 
bred Anopheles stephensi for mosquito transmission, or exclusively at the blood stage 
phase. In the latter case blood from an infected animal is syringe passaged into a healthy 
one, usually via the intraperitoneal route. Blood stage infections in laboratory mice 
produces an initial, acute, primary parasitemia that increases exponentially. The parasite 
population is either synchronous {P. chabaudi and P. vinckei), with the majority of 
parasites at the same stage of development, or asynchronous (P. berghei and P. yoelii),
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where all developmental stages are present at all times. The parasitemia subsequently 
reaches a peak, referred to as crisis, at which point animals either die (susceptible 
strains), or start recovering as the parasitemia suddenly begins decreasing and after a few 
days reaches sub-patent levels (resistant strains). The post-crisis period is characterised 
by hemolysis, damaged parasites and asynchronous schizogony, also in synchronous 
species. In P. chabaudi chabaudi (AS) parasites later re-appear after a short period of 
sub-pateney, a phenomenon referred to as recrudescence. This secondary infection has a 
shorter duration and results in a parasitemia of only a few percent (Langhorne et al., 
2002).
The disease symptoms in mice are similar to those in humans and are partly parasite 
species dependent (Section 1.5). General features include anemia, hypoglycemia, a 
decrease in body temperature, loss of body weight and in some infections, cerebral 
malaria (reviewed in Langhorne et al., 2002). Differences between the rodent parasite 
speeies have made them suitable for investigating different aspects of human malaria. 
Plasmodium chabaudi has been used for studying the host immune response during the 
erythrocytic stages of the life cycle (reviewed in Langhorne et al., 2002), genetic 
determinants for disease susceptibility (Fortin et al., 2002), drug resistance (reviewed in 
Carlton et al., 2001) and antigenic variation (Phillips et al., 1997; Brannan et al., 1993; 
Gilks et al., 1990). Plasmodium berghei has been used extensively to investigate the 
causes of cerebral malaria (reviewed in Lou et al, 2001), and Plasmodium yoelii for in 
vivo drug testing and work on pre-erythrocytic immunity and vaccines (reviews in 
Hollingdale and Krzych, 2002, and Ballou et al., 2002). Many experimental procedures 
now used in P. falciparum were initially developed in rodent systems, such as stable 
genetic transformation in P. berghei (van Dijk et al., 1995). Targeting of specific genes 
has been extensively and successfully applied in P. berghei, and recently also in P. yoelii, 
in order to study the funetion and significance of specific proteins (Menard et al., 1997; 
et al., 2000; Tewari et al., 2002; Mota et al., 2001). As a result of the ongoing rodent 
malaria sequencing projects, functional genomics and proteomics studies on rodent 
malaria species are now also underway, similar to those carried out in P. falciparum 
(Carlton and Carueci, 2002; Section 1.10.1).
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1.7 Parasite -  Host Interactions
The malaria parasite is a complex organism with the ability not only to survive, but also 
to exploit and modify several different habitats in its two hosts. Its life cycle involves 
developmental stages in vertebrate hepatocytes and erythrocytes, as well as in the insect 
gut, circulatory system and salivary glands (Section 1.3). With this in mind it is perhaps 
not surprising that, compared to other eukaryotes, such a small part of the parasite 
genome encodes enzymes and transporter proteins, and a large proportion is devoted to 
proteins involved in parasite-host interactions. At least 1.3% of identified P. falciparum 
genes code for surface molecules involved in either cell-cell adhesion or immune evasion 
(Gardner et at., 2002; Section 1.9).
In the human host growth and multiplication takes place under the surveillance of a fully 
functional immune system, hence the parasite has developed sophisticated mechanisms to 
survive, such as sequestration and antigenic variation. Proliferation in the mosquito is 
equally challenging due to a vigorous innate immune response, resulting in large numbers 
of parasites being lost at each step of the developmental process.
1.7.1 Survival and development in the vertebrate host
It is estimated that between 10 and 100 sporozoites are injected with the bite of a malaria- 
infected mosquito (Rosenberg et al., 1990; Ponnudurai et a l, 1991). Specific interactions 
between the parasite and host, including the binding of sulphated glucosaminoglycans on 
hepatocytes to circumsporozoite protein (CSP) and thrombospondin-related adhesion 
protein (TRAP), guide the sporozoite to the liver (Müller et al., 1993; Frevert et al., 
1993). After invasion the parasite increases in size and finger-like projections develop 
from the parasitophorous vacuole membrane (PVM) into the hepatocyte cytoplasm, 
presumably to increase nutrient uptake from the host cell (Aikawa et al., 1984). Parasite 
antigens, such as liver-stage antigen-1 (LSA-1), glutamate-rich protein (GLURP) and 
merozoite surface protein-1 (MSP-1), are subsequently expressed and inserted into the 
parasite membranes or exported to the hepatocyte cytoplasm (Hollingdale & Krzych, 
2002). Rapid nuclear division ensues, giving rise to up to 20,000 merozoites, which after 
a few days (five to six days in humans) are released into the liver sinusoid where they 
invade red blood cells (Wolf et al., 1986).
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The invasion of red blood cells is a complex, multi-step process involving erythrocyte 
attachment, re-orientation and binding of the apical end of the merozoite to the 
erythrocyte, junction formation, invagination of the erythrocyte membrane and formation 
of the parasitophorous vacuole. MSP-1 is thought to be the major constituent on the 
merozoite and is bound to the surface via a glycosylphosphatidylinositol (GPI) anchor. A 
significant role for P. falciparum MSP-1 in merozoite invasion was indicated by the 
finding that antibodies which inhibit proteolytic cleavage of the C-terminal of the 
molecule also inhibited parasite invasion (Blackman et al., 1990). Monoclonal antibodies 
to several other P. falciparum merozoite antigens, including the surface-expressed 
merozoite surface protein-2 (MSP-2), serine repeat antigen (SERA) in the 
parasitophorous vacuole and rhoptry-associated protein-1 (RAP-1) have also been shown 
to inhibit erythrocyte invasion in vitro (Epping et al., 1988; Clark et al., 1989; Banyal 
and Inselburg, 1985; Perrin and Dayal, 1982; Hamyuttanakom et al., 1992; Howard et 
al, 1998).
During the erythrocytic phase of the parasite life cycle, any parasite-encoded proteins that 
are to interact with the environment have to be expressed on the surface of the infected 
red cell. However, the erythrocyte is essentially empty, containing hemoglobin but no 
organelles or protein machinery. Targeting of proteins to different locations is an 
especially complex process in Plasmodium. As a eukaryote the parasite cytoplasm is 
compartmentalized, with a nucleus and a number of membrane-bound organelles. 
However, at least a dozen additional parasite protein destinations are known, including 
the food vacuole, the micronemes, the rhoptries, the apicoplast, the parasite plasma 
membrane, the parasitophorous vacuole membrane, the erythrocyte cytosol and the 
erythrocyte plasma membrane. To reach beyond its own boundaries and into the host cell, 
the parasite has to transport the proteins past its plasma membrane, through the 
parasitophorous vacuole, and across the parasitophorous vacuole membrane. 
Transportation through the red cell cytoplasm then takes place through an extensive 
tubovesicular network, a structural system of internal membranes induced by parasite 
invasion (Elford et a l, 1995). The mechanisms of trafficking of parasite-encoded 
molecules in infected erythrocytes are not yet fully understood. Studies have shown both 
vesicles budding from the PVM and transport in the form of protein aggregates (Trelka et 
al, 2000; Kara et a l, 1988). In addition, there is evidence suggesting that the parasite
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encodes classical transport machinery molecules known from other eukaryotes to be 
involved in vesicle-mediated protein trafficking (Albano et al., 1999).
Although the parasite develops intra-cellularly and essentially is “hidden” from the host 
immune system, infected erythrocytes appear structurally different from un-infected ones 
and so are recognized as defective and destroyed as the blood passes through the spleen. 
To avoid this the parasite expresses receptors on the erythrocyte surface that bind to the 
endothelium of postcapillary venules in the host. This phenomenon is termed 
sequestration and is most pronounced in deep vascular tissues such as the kidneys, lungs, 
liver, brain and placenta (Section 1.4). Sequestration is a major cause of pathology in 
malaria and can result in obstruction, and ultimately failure, of major organs (Raventos- 
Suarez et al., 1985). Adhesion of parasitised red blood cells (pRBC) in the brain is 
believed to be involved in the development of cerebral malaria (CM), a severe 
complication in P. falciparum infections with a bad prognosis and high mortality rate. 
The sequestering phenotype seems to be critical for parasite virulence, as isolates that 
have lost the ability to bind cause milder disease in animal models (Langreth and 
Peterson, 1985). In addition, infections by the other human Plasmodia do not cause 
sequestration of asexual parasites or CM, and are also less severe with almost no 
mortality.
The most well-characterised parasite receptor involved in sequestration is Plasmodium 
falciparum  Erythrocyte Membrane Protein-l(PfEMP-l), a multi-domain protein 
expressed on the surface of the infected red cell. PfEMP-1 is coded for by the var multi­
gene family, comprised of 40-50 gene copies (Kyes et al., 2001). Although a number of 
host cell receptors have been identified as binding partners for PfEMP-1, their relevance 
in vivo has not been clearly established. The most studied host molecules are CD36 and 
Intracellular Adhesion Molecule-1 (ICAM-1; Berendt et al., 1989; Baruch et al., 1996; 
Oquendo et al., 1989). The genes coding for both of these show polymorphisms in 
African individuals, which may influence adhesion and disease severity, and may partly 
explain the variation in disease outcome (Femandez-Reyes et al., 1997; Omi et al., 2003). 
Sequestration also causes complications in pregnancies, due to binding of infected 
erythrocytes to the placenta. A different set of host receptors appear to be involved in
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these circumstances, with chondroitin sulphate A (CSA) and hyaluronic acid being the 
most important binding partners in the host (Duffy and Fried, 2003).
1.7.2 Survival and development in the mosquito host
As the parasite population expands within the vertebrate host the environment 
successively becomes less permissive for continuing growth, as un-infected erythrocytes 
become more scarce and the anti-parasitic immune response develops. Transmission into 
a new host becomes crucial. This is dependent on sexual-stage parasites, and thus a 
subset of parasites start developing into gametocytes. Sexual commitment is determined 
already in the merozoite, before erythrocyte invasion, and transcription of early sexual- 
stage specific genes takes place before any morphological sexual characteristics are 
evident. In P. falciparum expression of gametocyte-specific proteins is seen from 24 
hours post-invasion and onwards (Figure 1.3; Bruce et al., 1994). The earliest event in the 
sexual differentiation process described to date is the transcription of the gametocyte- 
specific gene pfsl6  (Dechering et al., 1997). The 7^16 protein is expressed 24 hours post 
invasion in sexually conunitted stage I gametocytes and localised in the parasitophourous 
vacuole membrane. Its function is not yet known. As the gametocyte matures, the genes 
coding for P/s230 and P^48/45 are activated. P/s230 and P/s48/45 belong to a family of 
sexual-specific molecules that all share unique structural motifs named six-cysteine 
domains. Transcripts for P/s230 and P/s48/45 can be detected immediately after 
erythrocyte invasion of a committed merozoite, with protein expression taking place in 
stage III gametocytes and onwards (Figure 1.3; Niederwieser et al, 2000; Kocken et a l,
1993). Biochemical studies have shown that as the parasite emerges from the erythrocyte 
in the mosquito gut, P/s230 undergoes proteolytic cleavage producing two polypeptides 
that stay associated with the newly formed gamete. It has been suggested that removal of 
the immunodominant region of the protein is an immune evasion strategy, protecting the 
parasite from antibodies carried over from the vertebrate host in the blood meal 
(Williamson et a l, 1996). However, the function of F/s230 remains to be discovered. 
Within ten to 20 minutes of gametocyte uptake, fertilization and zygote formation 
commence in the mosquito midgut. Pfs4SI45 plays a central role in male gamete fertility, 
as shown by gene disruption studies where greatly reduced numbers of ookinetes were 
produced due to impaired zygote formation (van Dijk et a l, 2001). Pjs4SI45 is expressed
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as a complex together with P/s230 on gametocytes, the surface of male and female 
gametes and on zygotes (Kaslow et al., 2002).
The pfs25 gene is induced following transmission to the mosquito and the protein is 
detectable on zygotes and ookinetes (Figure 1.3; Niederwieser et al., 2000; Kumar and 
Carter, 1985). Gene disruption studies in P. berghei recently showed that Pbs25 and 
another late sexual stage protein, Pbs2S, have partly redundant functions. Single knock­
out parasites (either pbs25  or pbs28 disrupted) showed only mildly compromised 
development in the mosquito, whereas double knock-outs (both genes disrupted) 
demonstrated a reduction in number of ookinetes, defects in gut penetration and oocyst 
formation, as well as impaired protection against proteases (Tomas et al., 2001). Also 
expressed in ookinates is CSP- and TRAP-related protein (CTRP; Figure 1.3). 
Immunofluorescence studies have shown that CTRP is located in the micronemes and 
disruption of the ctrp gene demonstrated that the protein is required for invasion of the 
midgut epithelium (Yuda et a l, 1999; Dessens et al., 1999).
In oocysts, curcumsporozoite surface protein (CSP) is the major surface marker on 
developing sporozoites (Figure 1.3). CSP contains extensive internal repeats and is 
attached to the membrane via a GPI anchor (Godson et al., 1983; Moran and Caras,
1994). It has been known for some time that CSP is essential for initiation of the liver 
stages in the vertebrate host, as it is involved in sporozoite attachment to hepatocytes 
through the binding of heparan sulphate (Frevert et al., 1993; Section 1.3). However, 
recent gene disruption studies have shown that CSP also is important for development 
during the insect stages, as CSP-negative parasites were able to infect mosquitoes but 
unable to produce sporozoites in developing oocysts (Menard et al., 1997).
1.8 The host immune response to Plasmodium infection
In its vertebrate host the parasite is exposed to the immune system only for very short 
periods of time: when sporozoites are first injected into the blood stream by a mosquito, 
when exoerythrocytic merozoites are released from the liver, and during the erythrocytic 
cycle when the mature schizont ruptures and merozoites are searching for new 
erythrocytes to invade (Section 1.3). The rest of the time, apart from a short period in the 
liver, the parasite resides inside red blood cells. Erythrocytes are often described as a site 
of immunological privilege since they lack expression of MHC molecules and a protein-
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processing machinery, preventing any direct antigen presentation to the immune system. 
However, after parasite invasion, red blood cells acquire a new set of properties, 
including expression of novel surface molecules and a more rigid cell structure. These 
changes are recognized by the host and elicit both innate and adaptive immune responses.
1.8.1 Innate resistance in the vertebrate host
Innate resistance in humans against Plasmodium  parasites includes genetic 
polymorphisms, natural killer (NK) cells and macrophages and monocytes. Human 
populations are genotypically very diverse and although innate resistance is rarely 
absolute, certain genetic variabilities may affect susceptibility and severity of disease. 
Thus, in malaria-endemic areas where certain alleles provide a survival advantage, they 
have been maintained and selected for. The sickle-cell trait is such an example, where the 
disadvantage of having a defective hemoglobin gene is out-weighed by the improved 
survival rate for the carrier, and the allele therefore exists in a state of balanced 
polymorphism (Lell et al., 1999).
NK cells and mononuclear phagocytes seem to be most important early in malaria 
infections. NK cells increase in numbers and have been shown to lyse P. falciparum 
infected erythrocytes in vitro (Orago and Facer et al., 1991). However, studies with P. 
chabaudi chabaudi (AS) suggest that their ability to produce large amounts of interferon- 
Y (IFN-y), a potent activator of macrophages, may be of greater importance, as mice 
carrying NK cells with defective cytotoxic function but normal IFN-y production, control 
infection as well as wild-type mice (Mohan et al, 1997). Macrophages and monocytes 
have the ability to phagocytose whole infected erythrocytes. Studies on opsonin- 
independent phagocytosis in acute phase infections with P. chabaudi showed a four-fold 
increase in phagocytic activity on day seven post-infection in resistant mice (C57B1/6), 
but no change in susceptible mice (A/J). In addition, there was an inverse correlation 
between phagocytic activity and parasitemia, indicating that opsonin-independent 
mechanisms of parasite killing is a crucial component of the innate immunity that 
controls parasite load during the early stages of infection (Su et a l, 2002).
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1.8.2 Acquired immune responses to liver stage parasites
Although individuals in endemic areas with repeated parasite exposure develop a certain 
degree of immunity, it is rarely clinical and infections usually result in low-grade 
parasitemias and episodes of disease throughout life.
Because injected sporozoites are extracellular, they are targets for antibody-mediated 
immune responses. It has been shown that immunization with high numbers 
(>1000) of gamma-irradiated sporozoites induces protective immunity in humans, mice 
and monkeys (Nussenzweig et al., 1967; Clyde et al., 1973). However, transfer of 
immune spleen cells, but not sera, from immunized animals confers protection, 
suggesting that this is a cellular-mediated mechanism (Sinnis and Nardin, 2002). This is 
initiated when the parasite invades hepatocytes and becomes intra-cellular and in rodent 
systems has been shown to be MHC class I restricted and dependent on cluster of 
differentiation (CD) 8  ^T cells (Nardin et al., 1999). In humans, several studies have 
linked protection against P. falciparum with immune responses to Liver-Stage Antigen-1 
(LSA-1), a molecule expressed exclusively during the liver-stages (Connelly et al., 1997; 
May et al., 2001; Kurtis et al., 1999; Hollingdale et al., 1990). In vitro studies have also 
shown perforin-mediated killing by cytotoxic T lymphocytes that recognise infected 
hepatocytes (Weiss et al., 1990).
1.8.3 Acquired immune responses to blood stage parasites
After hepatic schizogony the parasite enters the circulation and begins the disease- 
causing cycle of infection and re-infection of erythrocytes. The spleen is the main site for 
filtration and recognition of soluble antigens and initiation of T cell responses take place 
in the white pulp. Because erythrocytes are devoid of MHC molecules, generation of an 
immune response must proceed through antigen presenting cells, ie 
macrophages/monocytes, B lymphocytes or dendritic cells. These cells phagocytose 
whole infected cells as well as free parasites, resulting in processing and presentation of 
parasite-derived peptides to immune effector cells (Kuby, 1997).
The role of CD8  ^T cells in protection during blood stage infections is not clear but the 
regulatory and effector functions of different subsets of CD4^ T cells are relatively well 
established in both experimental and human malaria. In P. chabaudi infections, mice 
lacking or depleted of CD4^ T cells, and B cell knock out mice, are unable to clear blood
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Stage infections (Langhome et al., 1990). These animals were shown to retain a 
predominant CD4^ T helper (Th)l-like response throughout infection, unlike control mice 
where a switch in CD4^ cells to a Th2-type response resulted in recovery, demonstrating 
that B cells play an important role in the regulation of CD4^ T cell responses (Langhome 
et al., 1998). In humans, in vitro stimulation of CD4^ T lymphocytes with malaria 
antigens results in proliferation and/or secretion of IFN-y and interleukin (IL)-4, although 
correlation with protection is poor (Troye-Blomberg, 2002).
As described above, the course of a malaria infection is highly dependent on the balance 
of pro- and anti-inflammatory cytokines secreted by activated immune cells. Tumor 
necrosis factor (TNF)-a, induced in macrophages and monocytes by IFN-y, a Thl-type 
cytokine, plays a central role in both protection and pathology. In human malaria TNF-a 
levels are positively correlated with disease severity and malarial fever (Grau et al., 1989; 
Kwiatkowski et al., 1993). Although TNF-a does not kill parasites directly, it induces 
production of nitric oxide (NO) and reactive oxygen species (ROS) in other cell types 
such as leukocytes and endothelial cells (Burgner et al., 1999; Anstey et al., 1996). 
Production of NO is catalysed by nitric oxide synthase (NOS) and has been shown to be 
inhibitory to sporozoites and gametocytes (Mellouk et al., 1994; Naotunne et al., 1993). 
Two studies of children recovering from malaria showed higher levels of NOS in 
peripheral blood mononuclear cells from those with prior mild malaria than those with 
prior severe disease (Perkins et al., 1999; Chiwakata et al., 2000). However, several 
findings indicate involvement of NO in the pathogenesis of human cerebral malaria, and 
a recent report showed an association of elevated levels of NO with severe malarial 
anemia in African children (Taylor-Robinson and Smith, 1999; Troye-Blomberg, 2002; 
Gy an et al., 2002).
1.8.4 Anti-parasitic responses in the mosquito
Insect immune responses rely entirely on innate immunity since no adaptive immune 
system exists in invertebrates. Major components of the mosquito defense system include 
the hemocoel -  an open circulatory system filled with hemolymph, hemocytes -  
circulating immune cells involved in pathogen destruction through phagocytosis and 
encapsulation, and the fat body -  equivalent of the liver in vertebrates and main source of 
immune-related components secreted into the hemolymph (Figure 1.4).
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The specific interaction between Anopheles and Plasmodium has been extensively 
investigated and it has been shown that malaria infection induces a strong innate immune 
response in the mosquito. The parasite must survive for at least ten days inside the 
mosquito to complete its development, during which time it suffers significant losses, 
likely to be at least in part due to the inunune response of the mosquito (Dimopoulos et 
al., 2001). In vitro culture systems using P. falciparum and A. gambiae have shown 
between 40-fold and 300-fold reductions as the parasite develops from one stage to the 
next (gametocyte to ookinete, ookinete to oocyst, oocyst to sporozoite; Vaughan et al., 
1992; Vaughan et al., 1993; Beier, 1998; Ghosh et al., 2000). The response to a malaria 
infection results in activation of immune-related genes in a temporal and spatial pattern 
that follows the parasites life cycle in the mosquito, with a robust response around 24 
hours post-infection as the ookinete traverses the midgut epithelium, followed by a 
prolonged late phase between days 10 and 25 when sporozoites are released from the 
midgut (Dimopoulos et al., 1998).
1.8.4.1 Pathogen-recGgnition
The mosquito is capable of mounting a range of defense reactions, including both 
humoral and cellular responses. Triggering of these mechanisms requires a pathogen- 
specific recognition system. Several genes encoding proteins with domains known to be 
involved in microbial binding have been cloned in Anopheles, and are likely to function 
as pattem-recognition receptors (Figure 1.4, c). Lectins are molecules that bind various 
sugar residues and are widely used as innate immune receptors since the pattern of 
surface carbohydrate expression on microbes generally differs from that on higher 
organisms. IGALE20, a putative galactose binding lectin, is highly expressed in the 
mosquito midgut and has been shown to be up-regulated upon malaria infection 
(Dimopoulos et al., 1998). The gene coding for another potential carbohydrate-binding 
protein, gram-negative bacteria-binding protein (GNBP), is also activated upon malaria 
infection, systemically as well as locally in the mosquito midgut. Maximal transcription 
of this gene was seen around 24 hours post parasite infection, at the time when the 
ookinete traverses the gut epithelium (Section 1.3; Dimopoulos et al., 1997; Dimopoulos 
etal., 1998).
34
Chapter One Introduction
1.8.4.2 Serine proteases as immune response mediators
Recognition of a pathogen subsequently activates immune signaling pathways in the 
mosquito, many of which are initiated by the proteolytic activities of serine proteases. 
Serine proteases play a crucial role in invertebrate immunity by regulating a number of 
immune reactions leading to central anti-pathogenic defense mechanisms such as 
melanotic encapsulation, hemolymph coagulation and antimicrobial peptide synthesis 
(Figure 1.4, a and c; Gorman and Paskewitz, 2001). The proenzymes are usually 
monomers with a C-terminal catalytic domain, and one or more N-terminal domains. The 
enzymes are activated by cleavage at the amino-terminal end of the protease domain and 
the catalytic function of serine proteases is executed through the activity of a catalytic 
triad (reactive serine, histidine and aspartic acid). The type of substrate and degree of 
specificity is determined by the residues lining the binding-site (Perona and Craik, 1995). 
Although a number of serine proteases in A. gambie have been identified recently, few 
have a demonstrated function in anti-parasitic defenses. Transcriptional activation, 
systemically as well as locally in the midgut, of two serine protease genes, ISP 13 and 
ISPL5, occurs around 24 hours after infection with Plasmodium (Dimopoulos et al., 1997 
& 1998). Spl4A (Serine protease from chromosomal division 14A), another serine 
protease expressed in the mosquito midgut, showed specific up-regulation upon bacterial 
but not parasite challenge, with transcription also peaking 24 hours post Plasmodium 
infection. It has been suggested that Spl4A may activate prophenoloxidases, a family of 
proteins that upon proteolytic cleavage catalyses an enzymatic cascade resulting in 
melanotic encapsulation of invasive pathogens (Gorman and Paskewitz, 2001). 
Melanisation is the best-studied mosquito defense mechanism and is vital in mosquito 
strains refractory to parasite infection (Collins et al., 1986). A proteinacious layer of 
mainly melanin is deposited around the ookinete, killing it through either starvation or 
toxic by-products, such as free radicals, from the enzymatic reactions catalyzing capsule 
formation (Paskewitz et al., 1998). Another mechanism of refractoriness was recently 
observed in a selected strain of resistant Anopheles, based on lysis of ookinetes (Vemick 
et al., 1995).
Activation of serine proteases also triggers transient transcription of antimicrobial 
peptides. These act through a detergent-like mechanism, disrupting the integrity of the 
pathogen cell membrane. Four such peptides have been isolated from A. gambiae: one
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defensin, two cecropins and a novel molecule named gambicin. Defensin has been shown 
to have activity against sporozoites and enhanced transcription of the defensin gene takes 
place approximately 10 days post infection (Dimopoulos et al., 1997). Gambicin has been 
shown to cause a 2-fold increase in ookinete death in in vitro anti-parasitic assays (Vizioli 
et al., 2001).
1.8.4.3 Immunity-related serine proteases in other invertebrates
Serine proteases are widely used as immune activators in invertebrate immune defense 
against microbes. Hemolymph coagulation is a central mechanism of protection in many 
invertebrates. In insects this response is not well understood, however, horse shoe crab 
(Limulus) hemolymph coagulation is so far the most well-understood inunune response in 
invertebrates. The cascade that leads to pathogen destruction is initiated by Limulus 
Factor C, a protein with both a serine protease catalytic domain and a lipopolysaccharide 
(LPS)-binding region. Binding of bacterial LPS to Factor C induces a conformational 
change in the enzyme, resulting in autoactivation. Activated Factor C cleaves another 
serine protease. Factor B, which in turn cleaves proclotting enzyme (PCE), a third serine 
protease. PCE then catalyses the last step in the pathway, the processing of coagulogen to 
coagulin, which subsequently self aggregates and traps the pathogens in a gel-like clot 
(Iwanaga et al., 1998).
Another vital invertebrate mechanism of protection against pathogens is the production of 
antimicrobial peptides. Fungal infection in Drosophila melanogaster induces 
transcriptional activation of the gene encoding drosomycin, an anti-fungal agent. The 
pathway is induced by the activation of an extracellular serine protease, which 
subsequently cleaves the protein Spatzle. Spatzle dimerises and becomes a ligand for the 
membrane receptor Toll. Activation of Toll then results in a signal transduction cascade, 
ending with the up-regulation of the drosomycin gene (Hoffman et al., 1999; Levashina 
et al., 1999).
1.8.4.4 Nitric oxide m Anopheles immune defense
It was recently reported that nitric oxide production is used as an additional anti-parasitic 
defense mechanism in mosquitoes (Figure 1.4, b). Transcriptional induction of nitric 
oxide synthase (NOS) in the gut was shown to rise to twice the normal level at 24 hours
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post infection (Luckhart et al., 1998). NOS catalyses the production of the free radical 
nitric oxide (NO), demonstrated in mice and humans to inactivate sporozoites and 
gametocytes (Mellouk et al., 1994; Naotunne et al., 1993). Interestingly, a dietary NOS 
inhibitor increased oocyst formation whereas the NO precursor L-arginine depressed 
oocyst numbers (Luckhart et al., 1998). Enhanced NOS gene expression and enzyme 
activity has also been detected in the salivary glands on day ten post-infection, as has 
transcription of the anti-microbial peptide defensin (Figure 1.4, d; Dimopoulos et al., 
1997; Luckhart et al., 2003). This would be coinciding with the onset of sporozoite 
release into the hemolymph, suggesting that Anopheles NO may also interfere with the 
later stages of parasite development in the mosquito.
Immunity to malaria is complex, and very different from many viral and bacterial 
infections, where a single infection often results in protection to re-infection throughout 
life. The difference may be attributed to the more complex life cycle and genome of 
Plasmodium parasites. The parasite develops through several different stages and 
consequently expresses a number of different antigens. Many of these molecules have 
been shown to elicit strong immune responses, hence the parasite has evolved a number 
of evasion mechanisms to avoid and counteract these.
1.9 Avoiding the host immune response
1.9.1 Antigenic variation
In malaria, symptomatic disease is caused by development and expansion of the parasite 
population during the blood stages. Development of immunity to this part of the life cycle 
is thought to involve responses to parasite-encoded proteins expressed at the surface of 
infected erythrocytes. Because of their exposed location these proteins are targets for 
humoral host immune responses. To avoid these responses the parasite uses a strategy 
termed antigenic variation, whereby different variants of a protein is expressed at 
different times, allowing changes in antigenic identity at rates higher than random 
mutations. Variant antigens are encoded by multi-copy gene families. In P. falciparum 
three multi-gene families have been identified: the variant {yar) family, the repetitive 
interspersed family (rif) and the sub-telomeric variable open reading frame {stevor) 
family (Su et al, 1995; Kyes et al., 1997; Cheng et al, 1998). The genes within these
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families are expressed in a successive fashion, and the proteins they encode show little 
immunological cross-reactivity (Newbold et al., 1992; Bull et al., 1999). This enables the 
parasite to evade immune responses that are specifically targeting these proteins, thereby 
allowing it to persist in the host for longer. It also results in a prolonged acquisition of 
immunity in the host, and allows the parasite to re-infect previously exposed individuals. 
The most studied variant antigen is Plasmodium falciparum Erythrocyte Membrane 
Protein-1 (PfEMP-1), encoded by the var genes. These are, along with the other multi­
gene family genes, clustered towards the telomeres and in vitro studies have shown an 
antigen switching rate of approximately 2% per generation (Gardner et al., 2002; Biggs et 
al., 1992; Roberts et al., 1992). Even though there is some controversy as to what the 
primary function of PfEMP-1 is, it is well established that it mediates adhesion of 
infected erythrocytes to the host endothelium (Sections 1.4 and 1.7.1). PfEMP-1 is 
located on the surface of infected red blood cells and studies have shown that it is a target 
for the vertebrate host inunune response and, more importantly, that antibodies to it are 
associated with protection against disease. In an extensive study using sera from children 
in Kenya, Bull et al., showed that the PfEMP-1 variant expressed during clinical disease 
was less likely to be recognized by the corresponding child’s own antibodies, than by 
those from other children of the same age and in the same community (Bull et al., 1998). 
This suggests that responses against variant antigens are significant components of 
protective immunity in malaria, and that accumulation of variant-specific immunity 
against PfEMP-1 in particular, plays a key role in controlling P. falciparum infections.
1.9.2 Immunosuppression
Immunity to malaria involves activation of several different types of immune cells 
(Section 1.8). However, evidence is accumulating showing that Plasmodium parasites 
have the ability to extensively modulate the host response by suppressing and/or altering 
the functions of certain cells.
Macrophages and monocytes play crucial roles in both innate and acquired immune 
responses (Section 1.8). As phagocytic cells, they ingest hemozoin, the end product of 
parasite hemoglobin degradation, both as precipitates inside infected erythrocytes and as 
isolated pigment. However, recent reports have shown that hemozoin, causes inhibition 
of crucial immune functions. The crystals are insoluble and persist unmodified within the
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cells for long periods, suppressing normal monocyte functions such as MHC class II 
expression, IL-2 production and antigen processing (Schwarzer et al, 1998; Scorza et al, 
1999). Furthermore, other studies have shown that macrophage chemotaxis and 
generation of superoxide radicals for parasite killing, are perturbed in malaria infections 
(Nielsen et a l, 1986; Schwarzer and Arese, 1996).
For the acquired response antigen-presenting cells are crucial, perhaps most importantly 
dendritic cells (DC) because of their ability to activate both memory and naïve T 
lymphocytes, and hence initiate immune responses (Banchereau and Steinman, 1998; 
Aystyn, 1998). However, recently it was shown that P. falciparum-miQCiQÔ. erythrocytes 
are able to bind to the CD36 and CD51 surface receptors on myeloid DCs in vitro, 
inhibiting the normal upregulation of MHC class II molecules, co-stimulatory molecules 
and adhesion molecules. The DCs also had a profoundly reduced ability to stimulate 
antigen-specific primary and secondary T cell responses, as well as allogenic T cell 
responses (Urban et a l,  1999).
1.9.3 Molecular mimicry
In many micro-organisms, including bacteria {Salmonella spp.. Shigella spp. Listeria 
monocytogenes, reviewed in Stebbins and Galan, 2001), viruses (poxviruses, 
herpesviruses and retroviruses, reviewed in Bernet et a l, 2003) and parasites 
{Schistosoma mansonii, Damian, 1964; Capron et al, 1965; Trypanosoma cruzi, Hudson 
and Hindmarsh, 1985; Leishmania major, Handman and Goding, 1985) structural and 
functional mimicry is a common strategy for immune evasion. Mimicry is achieved either 
by acquisition of virulence factors from the host by horizontal gene transfer, or through 
convergent evolution that results in “re-modelling” of molecules from the pathogens own 
protein repertoire to perform a new function. The latter strategy can produce a protein 
that has a three-dimensional structure distinct from that of the molecule it mimics, but has 
evolved to imitate the chemical groups and characteristics of its functional homologue 
(Stebbins and Galan, 2001). Functional mimicry has previously been demonstrated in 
Plasmodium falciparum during the blood-stages in the human host: anti-sera against 
Plasmodium falciparum blood-stage antigen Pfll-1 was shown to cross-react with the 
human protein thymosin-alphal, and parasite GPI moieties have been shown to substitute 
for endogenous host GPI signal transduction pathways (Dubois et a l, 1988; Schofield
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and Hackett, 1993). Although not yet shown, it does not seem unlikely that the parasite 
also uses mimicry to avoid the immune response in the mosquito.
1.9.4 Avoiding the mosquito immune response
As the parasite leaves its vertebrate host and enters the mosquito it escapes from the 
erythrocyte, leaving it exposed to attack by the mosquito immune system. The parasite 
consequently suffer enormous losses, however, it still succeeds in establishing an 
infection. Very little is known about Plasmodium survival strategies in its insect vector 
and how it counteracts the mosquito immune response. A field study looking at resistance 
in A. gambiae to P. falciparum found a high frequency of naturally occurring resistance 
alleles in the mosquito, suggesting that the parasite exerts a significant selective pressure 
on its insect host in the form of adaptive responses, perhaps analogous to those found in 
asexual-stage parasites (Niaré et al., 2002).
1.10 Parasite and mosquito genome sequencing projects
1.10.1 The Plasmodium falciparum genome project
October 2002 saw the official release and publication of the complete sequence of the 
genome of Plasmodium falciparum (strain 3D7; Nature, 3 Oct 2002). The project was 
initiated in 1996 as a combined effort between the Sanger Center, Cambridge, UK, The 
Institute for Genomic Research (TIGR), Maryland, USA, and Stanford University, 
California, USA. Behind the program lay the overall objective to provide a foundation 
that would facilitate identification of new potential drug- and vaccine targets, and assist 
in gaining a better understanding of the unique biology of the Plasmodium parasite.
The sequencing project identified a total of 5,268 open reading frames distributed over 14 
chromosomes, with a total genome size of 22.8 megabases. The data revealed a number 
of unusual features of the parasite genome. Several genes coding for molecules that in 
other species are vital for energy metabolism appeared to be absent - two genes coding 
for components of the ATP synthase complex were missing, as well as all genes for the 
subunits of a conventional NADH dehydrogenase (Wirth et al., 2002). A comparison 
with free-living eukaryotic microbes showed that P. falciparum encodes fewer enzymes 
and transporter proteins, but a substantially larger repertoire of genes involved in 
immunity and host-parasite interactions. As much as 1.3% of the entire genome codes for
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molecules involved in cell adhesion or host cell invasion (Gardner et al., 2002). 
Interestingly, out of almost 5,300 predicted proteins, 60% (3,208 hypothetical proteins) 
have no as yet identified homologues in sequence databases of other organisms (Gardner 
et al., 2002). This may be due to the greater evolutionary distance between Plasmodium 
and other sequenced eukaryotes, and provides a substantial source of unique molecules 
that may have potential to be used as targets for medical intervention without harmful 
side effects to the human host.
In addition to the identification of the full repertoire of P. falciparum genes, the genome 
project also provided a basis for large-scale, comprehensive analysis of transcription and 
protein expression in relation to parasite development (Li et al., 2003, Mamoun et al., 
2001; Spielmann et al, 2003). Novel techniques, such as large-scale microarray analysis 
and high throughput mass spectrometry, as well as the development of more advanced 
computer algorithms (reviewed in Carucci, 2002, and Carucci et al., 2002) now allow a 
global approach to studying messenger RNA and protein expression profiles that cover 
the whole organism, rather than just individual genes or molecules. A high-accuracy mass 
spectrometric study of selected stages of P. falciparum examined 1,289 proteins in 
asexual and sexual-stage parasites. 714 of these were associated with asexual parasites, 
931 with gametocytes, and 645 were found in gametes. Between 15 and 30% of proteins 
expressed in each set were found to be unique to that particular developmental stage 
(Lasonder et al., 2002).
1.10.2 Rodent malaria sequencing projects
At the same time as the Plasmodium falciparum sequencing project was released, a five­
fold coverage of the genome of another malaria species was completed, the rodent 
species Plasmodium yoelii yoelii (17XNL strain; Carlton et al., 2002). Rodent malaria 
models reproduce many biological characteristics of the human malaria parasite and have 
been used widely to complement research on P. falciparum (Section 1.6). The P. yoelii 
genome was found to be slightly larger than the human parasite, with 5,878 predicted 
genes distributed over 23.1 megabases. A comparative analysis with the P. falciparum 
genome (5,268 predicted genes) identified 3,310 orthologs in P. yoelii. However, two 
gene families completely absent in P. falciparum  were also reported: the yir genes 
(Janssen et al., 2002), which have homologs in P. chabaudi {cir; Janssen et al., 2002) and
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P. vivax (vir; del Portillo et al., 2001), and the Py235 family (Preiser et al., 1999). These 
multi-gene families are thought to be involved in antigenic variation and erythrocyte 
invasion, respectively, and indicate a divergence between the rodent and human malaria 
species, with species-specific mechanisms for these particular processes.
Sequencing of the P. chabaudi genome is currently being undertaken by the Sanger 
Center in Cambridge, UK, with a three-fold coverage to be released “as soon as possible” 
from a partial genome shotgun library (Sanger website).
1.10.3 Anopheles gambie sequencing project
Concomitantly with the release of the sequence data from the Plasmodium projects, a ten­
fold shotgun sequence coverage of its mosquito vector. Anopheles gambiae (PEST 
strain), was also published (Science, October 2002). The project estimated a total of 
13,683 genes distributed over five chromosome arms, with almost half not previously 
reported (Holt et al., 2002). In order to relate the findings of the mosquito genome, a 
comparative analysis with Anopheles closest sequenced evolutionary neighbor. 
Drosophila melanogaster, was carried out (divergence estimated approximately 250 
million years ago). Over the entire genome, almost half of the genes identified in 
Anopheles have orthologs in Drosophila (Zdobnov et al., 2002). However, average 
sequence identity between these two species is approximately 56%, a number lower than 
that for the same comparison between human {Homo sapiens) and pufferfish {Fugu 
rubripes', diverged approximately 450 million years ago) orthologs. This indicates a 
divergence rate that is higher than in most vertebrates, and may reflect the specialized 
and intimate relationships of Anopheles with both vertebrates and parasites (Zdobnov et 
al., 2002).
As part of the analysis of the Anopheles genome, an extensive study was carried out 
focusing on genes involved in mosquito immunity. 242 Anopheles genes from 18 gene 
families were identified (Christophides et al., 2002). Comparisons with the fruitfiy 
showed prominent expansions of protein families involved in cell adhesion and immunity 
in the mosquito. Serine proteases, central mediators of invertebrate innate immunity and 
involved in processes such as hemolymph coagulation, melanin production and anti­
microbial peptide synthesis were well represented in both genomes. However, Anopheles
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has nearly 100 additional protease members. Again, this is probably, at least in part, due 
to the mosquito’s interactions with both parasites and vertebrates (Holt et al., 2002).
The identification of additional molecules involved in anti-parasitic responses and an 
improved overall understanding of Anopheles biology and immunity is essential in the 
fight against malaria, and it is now the hope of many that the availability of the genome 
sequence of Anopheles gambiae, in combination with the data from the fully sequenced 
genomes of Plasmodium falcipaum and man, will facilitate the development of new 
vaccines and drugs.
1.11 Disease intervention strategies
1.11.1 Vector control and drug development
It is believed that Plasmodium parasites originated in Africa and were brought across the 
Pacific to the New World by early travelers. It was not until the 17**" century, however, 
that treatment became available to the Western world in the form of “Jesuit powder”. 
This had been given to missionaries by native Peruvian Indians and was the bark of the 
cinchona tree, with the bitter substance quinine as the active ingredient. Chloroquine, a 
derivative of quinine was developed in the mid-1930ies and became a success, as it was 
both safe and very cheap.
In the 1940s the discovery of the insecticide DDT inspired a global eradication program 
aiming to completely eliminate malaria by reducing the level of mosquito transmission. 
The effort was initially successful, resulting in a dramatic decrease of the disease in many 
countries and almost eliminating the disease in the subtropics (Figure 1.1; Utzinger et al., 
2001). However, the program was problematic due to social and political barriers. In 
addition, mosquito resistance to DDT started appearing. This was soon followed by 
reports of emerging P. falciparum chloroquine resistance in South America and Southeast 
Asia, which by 1985 also had spread across the entire African continent (Bjorkman and 
Phillips-Howard, 1990; Wemsdorfer, 1991). By now, chloroquine resistance has been 
observed everywhere where malaria is endemic and the drug is considered ineffective 
unless coupled with antibiotics. Today it is agreed that the only realistic way to fight 
malaria is with the development of a vaccine.
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1.11.2 Vaccine development
The highly complex life cycle of Plasmodium includes several developmental stages that 
offer candidate proteins for vaccine and drug development. Antigens on the sporozoite, 
the asexual blood-stage parasite and the sexual stage parasite are all being considered as 
targets. However, the ability of Plasmodium to adapt to the human immune system and to 
misdirect and suppress it presents the main difficulty in developing a successful vaccine 
(Section 1.9; Wakelin, 1989).
Three main types of vaccines are currently being developed: pre-erythrocytic vaccines, 
vaccines against asexual blood-stage antigens, and transmission-blocking vaccines. A 
vaccine targeted at antigens expressed during the erythrocytic stages would mimic the 
natural, partial immunity acquired by persistent infection found in individuals living in 
endemic areas, and reduce the symptoms of the illness. Merozoite Surface Protein 1 
(MSP-1), a complex of polypeptides on the surface of the merozoite involved in 
erythrocyte invasion, is one of the main candidates considered for this type of vaccine. 
Immunisation experiments with recombinant polypeptide (MSP-119) and native protein in 
Aotus monkeys have been successful, making this antigen a promising candidate for a 
blood stage vaccine (Kumar et al., 1995). Other potential targets include Apical 
Membrane Antigen 1 (AMA-1) found in the micronemes and on the surface of the 
merozoite (Deans et al., 1988; Collins et al., 1994). A study using squirrel monkeys 
immunized with Plasmodium fragile AMA-1, and subsequently challenged with P. 
fragile trophozoites showed reduced levels of parasitemia, or delays in accumulated 
parasite counts in four out of five animals, suggesting some degree of protection (Collins 
et al., 1994). Further candidates include the microneme protein Erythrocyte-binding 
Antigen 175 (EBA-175) and Serine-rich Antigen (SERA), a molecule secreted into the 
parasitophorous vacuole (Jones et al., 2001).
Although a blood-stage vaccine would prevent serious disease and pathology, it would 
not protect a previously unexposed individual, such as a traveler, who would require 
protection aimed at the very early stages of infection, ie the sporozoite or liver-stage 
parasite in order not to fall ill (Phillips 2001). Following experiments showing that 
immunisation with whole, irradiated sporozoites induced complete protection against P. 
falciparum and P. vivax infections, Circumsporozoite Protein (CSP) was identified as the
44
Chapter One Introduction
main antigen on the sporozoite surface (Clyde, 1990; Nussenzweig and Nussenzweig, 
1989). More recently, in limited trials on malaria-naive volunteers, RTS,S, a hybrid of the 
C-terminal of CSP and the Hepatitis B surface antigen HbsAg, generated protection in six 
out of seven subjects (Stoute et al., 1997). Moreover, in a Phase I study with semi- 
immune individuals in The Gambia, RTS,S in combination with the adjuvant AS02 
generated strong T cell responses, and when preceeded by a PfCSP DNA vaccine in a 
sequential immunisation regime, also induced PfCSP-specific antibodies and Thl CD4  ^
T cells, and CDS  ^cytotoxic and Tel cells (Pinder et al., 2004, Wang et al., 2004).
Finally, in order to limit the spread of disease, the parasite life cycle would have to be 
interrupted. A vaccine targeting the parasite’s sexual reproduction within the mosquito 
would not protect against disease but would stop other individuals being infected by a 
mosquito carrying parasites, thereby reducing transmission. This type of immunity is 
mediated by antibodies against surface antigens on gametocytes and later developmental 
stages. Antibodies induced in the human host would be carried over to the mosquito, 
where they would act on parasites in the midgut. Antigens for these transmission- 
blocking vaccines fall into three groups depending on their time of expression: (i) 
prefertilisation antigens - expressed on gametocytes, (ii) postfertilisation antigens - from 
zygotes or ookinetes, and (iii) late-midgut-stage antigens - expressed in late ookinetes. 
One advantage of using pre-fertilisation antigens is that antibody responses may be 
boosted by natural infection, since these molecules are expressed by the parasite as it is 
developing within the vertebrate host. Post-fertilisation antigens, on the other hand, 
would not have been subjected to selection by immune evasion mechanisms, and may 
therefore be more immunogenic (Phillips, 2001).
Several prefertilisation antigens, including7^230, 7^48/45 and have been shown
to have transmission-blocking activity in vitro. Two postfertilisation antigens, Pfs25 and 
Pfs2S, have been considered as vaccine candidates. Pfs25 shows little antigenic diversity 
and has been shown to induce transmission-blocking antibodies in mice and monkeys 
following immunisation with recombinant protein (Barr et ah, 1991; Kaslow and 
Shiloach, 1994). Pfs25 has recently gone into Phase I trials (Kaslow, 1997). Of the late
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Table 1.1. Antigens considered for a malaria vaccine
Vaccine type Candidate antigen
Pre-erythrocytic Circumsporozoite Protein (CSP)
Blood-stage Merozoite Surface Protein 1 (MSP-1)
Apical Membrane Antigen 1 (AMA-1) 
Erythrocyte-binding Antigen 175 (EBA-175) 
Serine-rich Antigen (SERA)
Transmission-blocking Pfs230, Pfs4SIA5, P/11.1 (pre-fertilisation antigens) 
Pfs25, Pfs28 (post-fertilisation antigens)
Chitinase (late-midgut-stage antigen)
midgut-stage antigens chitinase has received some interest. As the parasite is ingested 
along with a blood meal, a layer of chitin, the peritrophic membrane matrix, forms 
around the mosquito midgut. This acts as a barrier as the ookinete tries to pass through 
the midgut wall, making penetration more difficult (Section 1.3). However, there is 
evidence suggesting that the parasite secretes a chitinase that breaks down the peritrophic 
membrane and chitinase inhibitors have been shown to block transmission (Huber et al., 
1991; Dnffy et al., 1993; Shahabuddin et al., 1993).
Major potential vaccine candidates are summarized in Table 1.1.
Because the expression of most parasite antigens is restricted to a certain stage of the life­
cycle, a fully effective vaccine would ideally include molecules from all developmental 
stages. Moreover, as most immunogenic blood-stage antigens are highly polymorphic it 
is also likely that inclusion of more than one allelic variant of an antigen would increase 
protection (Richie and Saul, 2002). These multi-stage, or combination vaccines, are 
currently being developed and some have gone into, or are awaiting, clinical trials. 
SPf66, a synthetic polyvalent vaccine comprised of P. falciparum sequences from three 
putative blood-stage antigens and the four amino acid repeat of the pre-erythrocytic CS 
protein has undergone the most extensive field testing of any malaria vaccine. Early trials 
in South America and Tanzania showed moderate efficacy, however, later testing in 
Thailand, Brazil and The Gambia showed no significant protection and at present no 
further trials are planned (Valero et al., 1993; Valero et al., 1996; Alonso et al., 1994; 
Nosten et al., 1996; Urdaneta et ah, 1998; D’Alessandro et al., 1995).
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DNA based vaccine technology may also provide a useful approach to induce protection 
against malaria. Animal studies have shown that both CD8^  T cell and Th 1 -type immune 
responses can be induced with DNA vaccines, something that has been difficult to 
achieve with protein-based methodology. The American Navy research group is currently 
working on a candidate vaccine, MuStDo, that will include sequences encoding chosen 
epitopes from five pre-erythrocytic and ten blood-stage antigens (Doolan and Hoffman, 
2002).
However, so far no malaria vaccine has gone into routine use.
1.12 Aims of project
One of the greatest obstacles in the development of a vaccine against malaria is the 
parasite’s ability to avoid the host immune response through antigenic variation. The 
variant proteins involved are encoded by large gene families in the parasite genome. A 
better understanding of how these genes are regulated and how the molecules they 
encode affect pathogenesis and survival of the parasite, is key in the progress towards a 
vaccine and more effective therapeutics. A rodent animal model would allow 
investigations into the molecular biology and immunology of this phenomenon that for 
ethical and practical reasons are impossible in infected humans or primates.
Previously in the division where the present work was carried out had identified a short 
sequence of an unknown gene that appeared to be a member of a multi-gene family in 
Plasmodium chabaudi chabaudi (AS). However, experiments performed early on in the 
present project demonstrated that this was not the case. Instead it was discovered that the 
gene encoded the first scavenger receptor-like protein in Plasmodium. Thus, the overall 
objective became to analyse this novel gene and protein, with the following aims:
i) To identify the full length sequence the P. c. chabaudi (AS) gene
ii) To analyse the protein sequence for structural and functional domains, as well
as other sequence motifs, such as targeting signals
iii) To determinate sub-cellular localisation of the protein and stage-specificity of 
expression
iv) To investigate protein function by targeted gene disruption
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Figure 1.1
Global distribution of areas with a high risk of malaria
Geographical map showing the changes in global distribution of areas with a high risk of 
malaria between the years of 1946 and 1994. The burden of disease is increasingly 
confined to the tropics.
Modified from Sachs and Malaney, 2002.
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Figure 1.2
The Plasmodium life cycle
The Plasmodium parasite has a complex life cycle that involves a series of developmental 
transitions in both the vertebrate host and the insect vector.
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Figure 1.3
A selection of P. falciparum proteins expressed in sexual- and sporogonie stages of 
parasite development
The sexual and sporogonie stages of the Plasmodium life cycle start with 
gametocytogenesis in the vertebrate host and are completed in Anopheles with the final 
maturation of sporozoites in the mosquito salivary glands. Differentiation through these 
stages involves a series of morphological changes, driven and defined by a 
developmentally regulated expression of specific antigens.
The diagram illustrates the expression of proteins at different life cycle stages, with 
continuous arrows signifying high levels of expression, and hatched lines low expression.
Modified from Sauerwein and Eling, 2002.
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Figure 1.4
Mosquito defense reactions against malaria parasites
The parasite’s development in the mosquito (yellow arrows) starts as ingested gametocytes 
fuse and produce a zygote, which soon develops into a motile ookinate. The ookinate 
traverses the epithelial cells and, once on the basal side, transforms into an oocyst. The 
oocyst matures and undergoes nuclear division, resulting in the production of thousands of 
sporozoites. The sporozoites are released into the mosquito hemocoel and travel to, and 
invade, the salivary gland.
Mosquito immune responses against the parasite (red arrows) have been documented in 
the midgut epithelium, the hemocoel and in the salivary glands. In the epithelium melanot­
ic encapsulation (a) and lysis have been observed as anti-parasitic defense mechanisms in 
two separate refractory mosquito strains. Nitric oxide (NO) has also been shown to restrict 
parasite development in the midgut (b). In the hemocoel, the insect’s circulatory system, 
the parasite is exposed to hemocytes, antimicrobial peptides and other humoral factors. 
Binding of soluble or surface-bound pattem-recognition factors (green) can trigger a cas­
cade of serine proteases, which in turn activate various immune-related molecules, such as 
the cleaving of PPG to PC, an enzyme involved in melanisation (c). Antimicrobial 
peptides and NO are also found in the salivary gland (d).
Serine protease Ookinete
Serpin (serine protease inhibitor) Sporozoite
Pattem-recognition receptor Oocyst with sporozoites
^  Anti-microbial peptide -{> Mosquito immune reactions
^  Hemocyte with pattern recognition receptors Parasite development
Figure modified from Dimopoulos et a l, (2001)
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Chapter Two 
Materials and methods
2.1 Media, solutions and buffers
All chemicals and reagents were of analytical grade and purchased from BDH Chemicals 
Ltd., Poole, UK, or Sigma, Poole, UK, unless otherwise stated. Compositions of media, 
solutions and buffers are given in the Appendix.
2.2 Bioinformatics
Alignments and editing of nucleotide and protein sequences were performed using the 
MegAlign®, EditSeq® and MapDraw® programmes (all DNASTAR Inc). BLAST® (Basic 
Local Alignment Search Tool) searches were carried out using the NCBI Genbank 
Database (http://www.ncbi.nlm.nih.gov/) and the PlasmoDB server (http://plasmodb.org). 
Searches for protein sequence motifs were carried out using the Simple Modular 
Architecture Research Tool (SMART) programme (http://smart.embl-heidelberg.de/). 
Post-translational modifications and localisation signals were predicted by running the 
PcSLAP sequence through the fo llow ing programmes: SignalP
(http://www.cbs.dtu.dk/services/SignalP/) for hydrophobic signal sequences, TargetP 
(http://www.cbs.dtu.dk/services/TargetP/) and PATS (Prediction of Apicoplast Targeted 
Sequences) programmes; http://gecco.org.chemie.uni-frankfurt.de/pats/pats-index.php) 
for localisation sequences in general and apicoplast transit peptides, respectively, and 
big-PI Predictor (http://mendel.imp.univie.ac.at/sat/gpi/gpi_server.html) for GPI 
modification sites.
2.3 Parasites and experimental animals
2.3.1 Parasites
Plasmodium chabaudi chabaudi (AS strain) was originally obtained from Dr K. N. 
Brown, National Institute for Medical Research (NIMR, London).
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Plasmodium berghei ANKA, originally isolated in Katanga, Congo, in 1965, was 
supplied by Professor D. Walliker (WHO Registry of Standard Strains of Malaria 
Parasites, Edinburgh University, Scotland) to Dr. W Jarra, (NIMR, London) as a cloned, 
mosquito transmitted, re-cloned and enzyme typed line (Beale et ah. Rodent Malaria). A 
frozen stabilate from this line was kindly given to us by Dr Jarra.
Cryopreserved stabilates (Section 2.3.2) of these two parasite lines, no more than six 
syringe passages from the original materials, were used for animal infections. Parasites 
were syringe passaged every 5-10 days, for a maximum of four times before the line was 
discarded.
2.3.2 Cryo preservation of parasites
Mice were culled by terminal anaesthesia, the blood collected into 50 pL heparin per 
mouse (5000 U/mL; Leo Laboratories Ltd., Aylesbury, UK) and centrifuged at 1000 x g, 
10 minutes at 4°C. The packed cell volume was estimated and two volumes of parasite 
freezing medium (Appendix) was added as follows: 1/5 of the volume to be added was 
mixed in gently and the parasites left for five minutes. The remaining 4/5 of freezing 
medium were then added drop wise with gentle mixing. Stocks were initially frozen at 
-80°C and then transferred to liquid nitrogen.
2.3.3 Experimental animals
6-10 week old female BALB/c mice were obtained from the NIMR Special Pathogen 
Free breeding unit and conventionally housed in sterilised cages, with sterile food and 
bedding.
6-10 week old female pMT mice, deficient in B cells due to a targeted mutation in the 
immunoglobulin (Ig) p-chain, were also used (Kitamura et al., 1991). These were bred 
and maintained at the breeding facilities of NIMR, and housed as described above.
Before any procedures were carried out, animals were left to acclimatise for seven days 
in the facilities subsequently used for the experiments.
49
Chapter Two Materials and Methods
2.3.3 Infection of experimental animals
Cryopreserved parasite stabilates were thawed on ice, 0.9% saline added to give a total 
volume of approximately 300 pL, and 100-150 pL injected intraperitoneally (ip) into two 
mice. Animals infected with Plasmodium chabaudi chabaudi (AS) were kept in an 
artificial, 12 hour reversed light cycle, so that parasite schizogony took place in the early 
afternoon (13.00 -16.00) rather than during the night. Parasitemia was monitored by light 
microscopy on methanol-fixed, Giemsa-stained thin blood films (10% Giemsa’s stain in 
phosphate buffer (Appendix), pH 7.4; Gamham, 1966), and determined as follows:
% Parasitemia = Total number of infected erythrocytes in n fields______  x 100
(Total number of erythrocytes in a representative field) x n
At parasitemias >1% 10 fields were counted, whereas below this percentage a total of 50 
fields were scanned.
To initiate new infections, infected blood containing 10 -^10  ^pRBC was diluted in 0.9% 
saline to a volume of 100 pL and syringe passaged into a naïve mouse.
2.3.4 Collection of blood & plasma preparation
Blood was collected into 0.1 mL heparin (5000 U/mL; Leo Laboratories Ltd., Aylesbury, 
UK) and centrifuged at 13000 x g, 4°C for 10 minutes. The plasma fraction was removed 
and used immediately or stored at -20°C.
2.4 DNA and RNA preparation and manipulation
2.4.1 Preparation of parasite genomic DNA
Plasmodium chabaudi chabaudi (AS)- or Plasmodium berghei ANKA-infected BALB/c 
mice were bled into heparin at 4°C, at approximately 20% parasitemia. The blood was 
washed twice in ice-cold phosphate buffered saline (PBS; Appendix) centrifuging for 5 
minutes at 400 x g, 4°C. The pelleted cells were resuspended in sterile ice-cold PBS (Life 
Technologies, UK; 30 mL PBS per mL pellet) and passed through a Plasmodipure filter 
(Euro-Diagnostica, The Netherlands) according to the manufacturer’s instructions, to 
remove mouse leukocytes. The cells were washed as above and extraction buffer
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(Appendix) and Proteinase K (lOmg/mL) were added to the pellet in the following 
volume proportions: pellet:extraction buffer: 10% SDS:Proteinase K -1:1:0.05:0.01. The 
mixture was incubated overnight at 50°C in a rotating Hybaid hybridisation oven. The 
following morning additional Proteinase K was added (same volume as before) and the 
incubation continued at 50°C until the evening. An equal volume of phenohchloroform 
(1:1, pH 10.5; Life Technologies) was added and the solution incubated overnight at 
room temperature in a rotating hybridisation oven.
The second morning the mixture was centrifuged for 10 minutes at 2000 x g, 4°C, and a 
second phenohchloroform extraction performed as above. 2.5 volumes of ice-cold 100% 
ethanol was subsequently added, resulting in the DNA falling out as a brown precipitate 
which was transferred to a clean Eppendorff tube. One mL of 70% ethanol was added, 
the tube inverted several times followed by centrifugation for five minutes at 13000 x g, 
room temperature. The DNA was then left to air-dry for ten minutes, re-dissolved in Tris- 
ethylenediaminetetraacetic acid (EDTA; TE) buffer (Appendix) and stored at 4°C.
2.4.2 Amplification of DNA by Polymerase Chain Reaction (FCR)
All primers used in standard PCR were synthesised by Oswel (Southampton, UK) and are 
listed in Tables 2.1 and 2.2. Reactions were carried out in a total volume of 50 pL and 
were performed using a Hybaid PCR Express machine.
2.4.2.1 PCR using Pfx DNA Polymerase
For amplification of sequences where accuracy was of great importance, the high-fidelity 
Pfx system (Life technologies) was used. Reactions included the following: 1 mM 
MgSO^, 50 pM of each dNTP (Pharmacia), 1 x Pfx amplification buffer, 250 nM of each 
primer, 100 ng template DNA and 1.2 units Pfx DNA Polymerase.
2.4.2.2 PCR using AmpIiTaq DNA Polymerase
For standard PCR AmpIiTaq (Roche) was used. Reactions included the following: 50 pM 
of each dNTP (Pharmacia), 1 x AmpIiTaq amplification buffer, 250 nM of each primer, 
100 ng template DNA and 1.2 units AmpIiTaq Polymerase.
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Reactions were run as follows:
Step 1 94°C 5 minutes Initial dénaturation
Step 2 94°C 30 seconds Dénaturation
Step 3 50°C 30 seconds Annealing
Step 4 72°C 1 minute Extension_______ , to Step 2 for 30 cycles
Step 5 72°C 10 minutes Final extension
2.4.3 Cloning of PCR products
PCR products that were to be sequenced were cloned straight into the pCR®4Blunt- 
TOPO® vector (Zero Blunt® TOPO® PCR Cloning Kit for sequencing, Invitrogen, 
Gottingen, FRG) according to the manufacturer’s instructions.
PCR products amplified from primers containing 5’ restriction sites were purified using 
PCR Clean Columns (Qiagen, Hilden, The Netherlands), digested with the appropriate 
restriction enzyme (Restriction enzyme digestion of DNA), purified again, and ligated 
with the vector at a 1:3 vector:insert ratio. Ligation products were transformed into 
TOP 10 One Shot chemically competent cells (Invitrogen) by heat shock and transformed 
bacteria selected for on agar plates (100 pg ampicillin /mL). Colonies were picked and 
overnight cultures set up in LB broth containing ampicillin (100 pg/mL). Plasmids were 
isolated as described in Section 2.4.4 and 2.4.5.
2.4.4 Small-scale preparation of plasmid DNA (minipreps)
Isolation of plasmid DNA was performed using the Qiagen Miniprep Kit (Qiagen), 
according to the manufacturer’s instructions.
2.4.5 Large-scale preparation of plasmid DNA (maxipreps)
Isolation of plasmid DNA was performed using the Qiagen Maxiprep Kit (Qiagen), 
according to the manufacturer’s instructions.
2.4.6 Restriction enzyme digestion of DNA
Digestion of genomic and plasmid DNA was performed as directed by the enzyme 
manufacturer.
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2.4.7 Sequencing of cloned PCR products
Positive clones were identified by restriction digestion of isolated plasmids (Sections
2.4.4 and 2.4.6), and sequenced by MWG Biotech (Milton Keynes, UK).
2.4.8 Bacterial cultures and stocks
Bacterial cultures were grown in standard LB Broth (Appendix), with shaking, at 37°C. 
The medium was supplemented with ampicillin at 100 pg/mL. Bacterial stocks were 
made from 85% bacterial culture and 15% glycerol and stored at -70°C.
2.4.9 The Vectorette II System
All work with the Vectorette System was carried out using the Vectorette II Starter Pack 
(Sigma Genosys, Cambridge, UK), according to the manufacturer’s instructions.
2.4.9.1 Construction oî Plasmodium chabaudi chabaudi (AS) gDNA Vectorette 
libraries
Plasmodium chabaudi chabaudi (AS) gDNA was isolated as described previously 
(Section 2.4.1) and aliquots of Ipg digested with Rsal (Roche, UK), Sau3AI (Promega, 
UK), SspI (Roche) or XhoII (Promega). Vectorette units were subsequently ligated onto 
the ends of the gDNA fragments to generate four Plasmodium chabaudi chabaudi (AS) 
gDNA libraries.
2.4.9.2 Vectorette PCR
Vectorette PCR was carried out as described (Section 2.4.2), but using the supplied 
Vectorette PCR primer and one of two primers based on the known PcSLAP gene 
sequence, either one for 5' extension, or one for 3' extension of the gene (Table 2.3). 
Reaction volumes included the following: 1 pL Vectorette library, 10 pL 10 x PCR 
amplification buffer, ImM MgSO^, 50 pM of each dNTP (Pharmacia), 250 nM
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Vectorette primer, 250nM PcSLAP primer, 1.2 units of Pfx DNA Polymerase and sterile 
dHzO to 100 pL. Reactions were performed using the following programme:
Step 1 94°C 5 minutes Initial dénaturation
Step 2 94°C 1 minute Dénaturation
Step 3 50“C 1 minute Annealing
Step 4 72°C 3 minutes Extension_______ , to Step 2 for 40 cycles
Step 5 72°C 10 minutes Final extension
PCR products were cloned into the pCR®4Blunt-T0P0® vector and sequenced as 
described (Figure 2.1; Sections 2.4.3 and 2.4.7).
2.4.10 Preparation of parasite total RNA
Infected BALB/c mice were bled into heparin at 4°C and the erythrocytes pelleted by 
centrifugation at 1000 x g, 4°C, for five minutes. Ten pellet volumes of Trizol® (pre­
warmed to 37°C, Invitrogen), was added to the cells and the tube shaken vigorously until 
all clumps were dissolved. At this stage the preparation was either frozen at -80°C, or left 
for five minutes (RT). Two pellet volumes of chloroform were added to the Trizol®-mix 
followed by shaking for 15 seconds. The mixture was left to separate at RT for three 
minutes, then centrifuged for 30 minutes at 3000 x g, 4°C. The supernatant was 
transferred to clean tubes, mixed with isopropanol in the following proportions: 0.6 pellet 
volumes supernatant + 0.5 pellet volumes isopropanol, and left on ice for 60 minutes. 
Samples were centrifuged for 25 minutes at 13000 x g, 4°C, in a microfuge, each pellet 
washed with 1 mL 70% ethanol (13000 x g, 10 minutes, 4°C) and the tubes inverted and 
air-dried for five minutes. Pellets were resuspended in 10-50 pL of formamide (volume 
depending on pellet size), heated to 60°C for 10 minutes then placed on ice. Samples 
were transferred to new tubes excluding any drops on the side of the old tubes. RNA 
concentrations were estimated by measuring optical density at 260 nm. Samples were 
stored at -80°C.
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2.4.11 Preparation of total RNA from mouse (BALB/c) blood
Isolation of RNA from mouse blood was performed as parasite RNA isolation, but using 
blood from uninfected, female BALB/c mice.
2.5 DNA and RNA electrophoresis
2.5.1 Gel electrophoresis of DNA
Electrophoresis of DNA was performed as described in Current Protocols of Molecular 
Biology using Multi Purpose Agarose (Roche) at concentrations between 0.8% and 3%, 
in TBE buffer (Appendix).
2.5.2 Gel electrophoresis of RNA
Total RNA from P. c. chabaudi (AS), P. berghei ANKA or BALB/c peripheral blood 
mononuclear cells was resolved in 1% agarose gels containing five mM guanidine 
thiocyanate, in TBE running buffer. Each sample contained 10-20 mg of RNA in 10 mL 
formamide and a very small amount of ethidium bromide (a pipette tip was dipped in a 10 
mg/mL solution of ethidium bromide and then into the sample) Samples were incubated 
at 60°C for 10 minutes, chilled on ice and loaded. Loading dye alone was added to the 
final well, with unused wells in between to avoid contamination. Gels were run for an 
initial 10-15 minutes at 110 volts, after which the voltage was decreased to 70 volts. 
Electrophoresis was continued until the bromphenol blue dye was approximately 10 cm 
from the wells.
2.5.3 Extraction of DNA from agarose gels
DNA was extracted from agarose gels using the QIAquick Gel Extraction Kit (Qiagen), 
according to the manufacturer’s instructions.
2.6 Southern and Northern blotting
2.6.1 Southern blotting
0.5 pg of DNA per sample was digested and electrophoresed as described (Sections 2.4.6 
and 2.5.1). The gel was incubated in depurination buffer for 15 mins (Appendix), washed 
in transfer buffer for 30 minutes (Appendix) and the DNA blotted onto a positively
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charged nylon membrane (Hybond N+, Amersham) by capillary action overnight (all 
incubations on a rotating platform). The membrane was rinsed in 2xSSC (Appendix) and 
cross-linked at 120 mJoules (Auto-crosslink setting) using a Stratalinker® UV 
Crosslinker.
2.6.2 Northern blotting
Electrophoresed RNA was transferred by capillary action over night onto a positively 
charged nylon membrane (Hybond N+, Amersham) after washing with rotation in RNA 
transfer buffer for 30 minutes (Sambrook 1977). The membrane was rinsed in 2xSSC and 
cross-linked under UV-light as above.
2.6.3 Radio-labelling of DNA probes
Radio-labelleling was performed using >25 ng of probe and P^P]-dATP (Amersham), 
using the Prime-It® II Random Primer Labelling Kit (Stratagene, La Jolla, USA) 
according to the manufacturer's instructions.
2.6.4 Hybridisation with radio-labelled probes
Membranes were pre-hybridised for at least 1 hour in PerfectHyb™ hybridisation 
solution prior to probe addition. After probe addition DNA membranes were hybridised 
at 60°C, for 6 hours or longer. RNA membranes were hybridised with probe at 42°C, over 
night. Membranes were then washed in 0.1% SDS and reducing concentrations of SSPE 
(Appendix; from 2x to 0.5x) for 15 minutes per wash, rinsed in 2xSSC (no SDS) and 
exposed to Kodak Biomax MR Single emulsion film at -70“C.
2.7 Gametocyte purification
BALB/c mice were inoculated with 10^  parasitised erythrocytes. On 4 successive days, 
starting 24 hours post inoculation, pyrimethamine was administered by intraperitoneal 
injection (10 mg kg‘^  bodyweight). At the end of drug treatment blood was collected for 
gametocyte isolation. All steps were performed at 37°C, except centrifugations. Animals 
were bled into heparin, the blood diluted in RPMI 1640/10% ECS (Invitrogen; 
Globepharm, UK) and run through a Plasmodipure filter to remove leukocytes. This was
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followed by centrifugation seven minutes at 200 x g, the pellet resuspended in 
RPMI/10% FCS and overlaid onto a 48% Nycodenz/(RPMI/10% FCS) gradient (Robins 
Scientific, UK; 35 mL culture over 10 mL Nycodenz). The gradient was centrifuged for 
15 minutes at 350 x g with slow acceleration and no brake. The interface was isolated and 
washed with RPMI for seven minutes at 300 x g. The purified gametocytes were used for 
RNA isolation or for making thin blood smears for indirect immunofluorescence assays 
(Sections 2.4.10 and 2.13).
2.8 Analysis of protein
2.8.1 Expression of recombinant PcSLAP protein
A bacterial stock containing a 270 bp cDNA fragment of pcslap was provided by Maria 
Mota and Anthony Holder (Division of Parasitology, NIMR). The fragment had been 
cloned into the Pstl and HinàWl restriction sites of the pTrcHisC expression vector 
(Invitrogen), creating the pTrcHisC-pc5/a/727o construct, and subsequently transformed 
into E. coli DHIOB cells. The vector contained an N-terminal hexa-histidine tag (Hisg) 
for purification on nickel-matrices.
Five mL of an overnight culture with the above transformed bacteria was inoculated into 
500 mL of LB broth and incubated with shaking (250 rpm) at 37°C. Expression was 
induced when the ODgoonm of the bacterial culture reached 0.6, by addition of isopropyl-P- 
D-thiogalactopyranoside (IPTG) to a final concentration of ImM, and incubation 
continued as described above. A preliminary assay showed that maximal expression was 
achieved at five hours post-induction. These conditions were used to prepare a large 
scale, 40 liter culture (Margaret Goggin, NIMR) for subsequent purification.
2.8.2 Purification of recombinant PcSLAP protein
Frozen bacterial extracts were thawed and solubilised overnight in lysis buffer 
(Appendix). Samples were then centrifuged at 15000 x g at 4°C for 1 hour, 
ultracentrifuged at 30000 x g, 4°C for an additional hour and applied to a nickel- 
nitrilotriacetic acid (Ni-NTA) affinity chromatography column (Qiagen) pre-equilibrated 
with lysis buffer. The column was washed with lysis buffer and the bound protein eluted 
with 200 mM imidazole in lysis buffer. A second step of purification was performed
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using an FPLC gel filtration column with Superdex 200 prep grade matrix (Amersham 
Pharmacia Biotech, Uppsala, Sweden). The column was washed and the protein eluted 
with lysis buffer. The fractions containing the protein were then pooled and slowly 
dialysed against PBS to remove the urea, by dilution of the urea by a factor of two each 
time the dialysis solution was changed. The protein was then concentrated under pressure 
in an Amicon concentrator (Sartorius, Epsom, UK) with a lOkD cut-off membrane 
(Sartorius), before use in immunisations of mice and rabbits.
2.8.3 Protein separation by SDS-PAGE
Proteins were separated over gels consisting of a 4% acrylamide stacking gel and a 10% 
acrylamide resolving gel (both Appendix). 10 pL sample was mixed with 10 pL SDS 
sample buffer (Appendix), boiled for five minutes, transferred to ice and loaded. 
Electrophoresis was carried out at 25mA in SDS running buffer (Appendix). Gels were 
stained in Coomassie blue stain (Appendix) for approximately one hour and incubated in 
de-stain (Appendix) until the protein bands were clearly visible.
2.9 Immunisations
2.9.1 Protein immunisations for antibody production - mice
Groups of five female BALB/c mice received intraperitoneal injections of 100 pL RIBI 
adjuvant -antigen emulsion containing 25 pg of P cSLAPgg antigen per injection 
(adjuvant-antigen ratio according to the manufacturer’s instructions). Four booster 
injections were subsequently administered with the same amount of antigen, at two to 
three week intervals and plasma collected one week after every boosts as described in 
Section 2.3.4. Antibody responses in each animal were monitored by enzyme-linked 
immunosorbent assay (ELISA).
2.9.2 Protein immunisations for antibody production - rabbits
Rabbit immunisations were carried out at Abbott Murex Biotech Ltd. (Dartford, UK). 
Briefly, two rabbits received subcutaneous injections of 200 pL Freund's complete 
adjuvant-antigen emulsion, containing 0.5 mg of fcSLAPgg antigen per injection. Booster 
injections were administered at two-week intervals, at a total of four times, with the same
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amount of antigen in Freund’s incomplete adjuvant. Sera were collected one week after 
the boosts and antibody responses monitored by ELISA. Before the start of the 
immunisations, samples of pre-immune serum had been collected from each rabbit to be 
as negative controls.
2.9.3 Preparation of murine hyperimmune plasma
Mice were repeatedly infected with 10^  P. c. chabaudi (AS) infected erythrocytes up to a 
total of seven times. Blood was collected and plasma prepared as described as described 
in Section 2.9.1.
2.10 ELISA
2.10.1 Preparation of P. c. chabaudi (AS) parasite lysate for ELISA and Western 
analysis
Trophozoite- and schizont stage parasite-infected blood was collected into heparin, on 
ice, from P. chabaudi-mnoc\x\àiQà BALB/c mice. Mouse leukocytes were removed by 
passing the blood through Plasmodipure filters according to the manufcturer’s 
instructions, the remaining erythrocytes washed three times in 50 mL ice-cold PBS at 800 
X g, 8 minutes at 4°C, and resuspended in 5 mL PBS. Drops of 10% saponin (in PBS) 
were slowly added until the solution started turning brown (erythrocyte lysis), at which 
point 30 mL PBS was immediately added and the cells centrifuged as before. The wash 
was repeated twice, the supernatant carefully discarded and the parasite pellet 
resuspended in 1 mL PBS with 100 pg of Aprotinin protease inhibitor added. For 
Western analysis the preparation was used immediately whereas for ELISA, aliquots 
were frozen and stored at -20°C (Sections 2.11 and 2.10.4, respectively). When needed, 
an aliquot was thawed, carefully resuspended in parasite lysis buffer (Appendix) until 
parasite lysis occurred (clear light brown colour), and optical density measured at 280 nm
59
Chapter Two Materials and Methods
to determine protein concentration. The preparation was used at OD2go=1.5 for both 
ELISA and Western analysis.
2.10.3 PcSLAP-specifîc ELISA assays to determine antibody levels to the PcSLAP 
fusion protein
2.10.3.1 a-PcSLAP antibody levels in immunised mice and rabbits
50 pL of coating solution containing 2.5 pg/mL purified PcSLAP fusion protein in 
carbonate buffer (Appendix), was added to 96-well Polysorp plates (Nalge Nunc 
International) and incubated over night. Non-specific binding sites were blocked with 200 
pL blocking buffer (Appendix) at 37°C for 1 hour. Plasma from immunised animals was 
added, starting at a dilution of 1:100 and then two-fold serially diluted 12 times in 
blocking buffer. Hyper-immune mouse plasma (Section 2.9.3) was used as a 
standard/positive control and normal mouse plasma (Section 2.3.4) or pre-immune rabbit 
serum (Section 2.9.2) as a negative control. The samples were incubated at 37°C for 1 
hour. To detect bound antibodies, alkaline phosphatase (AP)-conjugated- goat a-mouse 
IgG (1:1000 dilution in PBS; Bio-Rad) or goat a-rabbit IgG (1:15,000 dilution in PBS; 
Bio-Rad) was added and the plate incubated 1 hour at 37°C. p-Nitrophenylphosphate- 
sodium (PNPP) salt in diethanolamine buffer (Appendix) was used as a substrate to 
produce a colour reaction. Fully developed plates were read at OD^ osnm when the sample 
from the lowest serial dilution of standard was 1 or greater, using Revelation software 
and an MRX TCII microplate reader (Dynex Technologies, Billinghurst, UK)
2.10.3.2 a-PcSLAP antibody levels in hyperimmune plasma
Coating of plates and blocking were performed as in Section 2.10.3.1. Test samples 
containing BALB/c and C57B1/6 hyperimmune plasma (Section 2.9.3) were serially 
diluted as above but starting at a 1:10 dilution. Immune plasma from PcSLAP 
immunisations was used as a standard/positive control and normal mouse plasma from 
BALB/c and C57B1/6 as negative controls. Incubations, detection, development and 
reading of the plate were performed as described in Section 2.10.3.1.
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2.10.4 Malaria specific ELISA assay to determine whether a-PcSLAP antibodies 
recognise antigens in a parasite preparation
50 pL of parasite lysate preparation (Section 2.10.1) in PBS (final OD2go=0.075) was 
used to coat 96-well Polysorp plates (Nalge Nunc International). Blocking was performed 
as in Section 2.10.3.1. Test samples containing a-PcSLAP plasma, starting at a dilution 
of 1:10 and then two-fold serially diluted 12 times in blocking buffer were added along 
with hyper-immune plasma as a standard/positive control and normal mouse plasma as a 
negative control, and incubated at 37“C for 1 hour. Incubations, detection, development 
and reading of the plate were performed as in Section 2.10.3.1.
2.11 Western analysis of a P. chabaudi lysate using a semi-dry blotting system
10 pL samples (prepared as described in Section 2.10.1) were mixed with 2 x reducing or 
non-reducing loading buffer (Appendix) and boiled for five minutes. The samples were 
resolved by SDS-PAGE on a 10% gel along with a protein marker, by running at 120 V 
until the dye front reached the bottom of the gel. The separated proteins were 
subsequently transferred onto a nitrocellulose membrane using a horizontal transfer unit 
at 0.8 mA/cm^ for approximately 45 minutes. A transfer unit is defined as a stack of 
(starting from the bottom) filter paper (Whatman) soaked in cathode buffer, gel, 
membrane, filter paper soaked in anode buffer 1, and filter paper soaked in anode buffer 
2 (anode and cathode buffers in Appendix). Following transfer, the membrane was 
washed in PBS on a shaker for 10 minutes at RT, and incubated with blocking buffer 
(Appendix) overnight at room temperature to block free, non-specific binding sites. The 
following morning it was washed in wash buffer (Appendix) twice for five minutes, at 
RT, and probed with primary antibody (in Antibody dilution buffer. Appendix) for one 
hour at 37°. Plasma or antibodies varied between experiments and are referred to in 
Chapter Four. The membrane was again washed twice for five minutes in wash buffer 
(Appendix), before incubated with the secondary antibody, horseradish peroxidase- 
conjugated goat anti-mouse IgG, at 1/1000 dilution (in Antibody dilution buffer), for one 
hour at room temperature. After washing again as above, labeled proteins were visualised 
using the Supersignal® West Pico Chemiluminescence system (Pierce, Rockford, IL, 
USA).
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2.12 Indirect immunofluorescence assay (IFA)
Blood was collected from malaria-infected female |MT mice at 15-25% parasitemia, 
centrifuged at 13000 rpm, five minutes at 4°C, and the pellet mixed with three pellet 
volumes FCS. Thin blood smears were prepared on glass slides, left to dry at RT, and 
fixed in acetone (BDH), acetone-methanol (1:1) or left unfixed. If fixed, slides were left 
to dry for a further 30 minutes at RT, wrapped in aluminium foil and frozen at -20°C.
On the day of the assay, slides were removed from the freezer, immediately fixed in 
acetone or acetone-methanol (1:1) and left to dry at room temperature before incubated 
with primary antibodies, plasma or sera (Table 2.4) for 1 hour at 37°C in a humid 
chamber. The slides were washed 2 x 5  minutes in PBS + 1% (w/v) bovine serum 
albumin and incubated as before with fluorochrome-conjugated secondary antibodies 
(Table 2.5). At the end of the assay, slides were submerged briefly in a solution of 4,6- 
diamidino-2-phenylindole (DAPI, Ipg/mL) to stain nuclear material. Slides were 
mounted in Citifluor and viewed under a Zeiss microscope or an Olympus DeltaVision 
fluorescence microscope, both with a 100 x magnification objective with oil.
For co-localisation studies, antibodies were added in the following order: anti-PcSLAP 
plasma -  anti-mouse secondary antibody - 85RF.45.3 rat monoclonal antibody - anti-rat 
secondary antibody.
2.13 Transfection of Plasmodium berghei ANKA parasites
All transfection and selection procedures in Section 2.13 follow the protocol outlined by 
Waters et al. (1997).
2.13.1 Construction of pbslap transfection vectors
The transfection vectors pSLAPInt and pSLAPRep were constructed by cloning 
sequences from the P. berghei ANKA slap gene into the pBSK-dhfr-ts vector (a gift from 
R. Tewari, Imperial College, London; Fig 5.3). The pBSK-dhfr-ts vector was made from 
the pBluescript II SK (+) phagemid vector backbone (Stratagene), with the DHFR-TS 
transcription unit (5.2 kilobases) inserted between the Hindlll and the EcoRI restriction 
sites in the pBluescript II SK multiple cloning site (MCS; Figure 2.2). The DHFR-TS 
transcription unit comprises the pyrimethamine resistant form of the Toxoplasma gondii
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dihydrofolate reductase-thymidilate synthase (dhfr-ts) gene, flanked by the Plasmodium 
berghei 5’- and 3’ dhfr-ts UTR sequences.
The pbslap gene fragments were amplified from Plasmodium berghei ANKA genomic 
DNA (isolated as described in Section 2.4.1) by PCR, using the high fidelity Platinum 
Pfx system (Life Technologies) and the primers listed in Table 2.6. All primers were 
designed using Mac Vector software. The following was included in each 50 pL PCR 
reaction: 1 mM MgSO^, 50 pM of each dNTP (Pharmacia), 1 x amplification buffer, 250 
nM of each primer, 100 ng Plasmodium berghei ANKA gDNA and 1.2 units Pfx DNA 
Polymerase. PCRs were performed on a Hybaid PCR Express machine using the 
following program:
Step 1 94°C 5 minutes Initial dénaturation
Step 2 94°C 1 minute Denaturing
Step 3 50°C 1 minute Annealing
Step 4 72°C 3 minutes Extension________, to Step 2 for 30 cycles
Step 5 72°C 10 minutes Final extension
Products were analysed by gel electrophoresis, followed by cloning into the pBSK-dhfr-ts 
transfection vector (described in Sections 2.13.2 and 2.13.3).
2.13.2 Construction of the pSLAPIns insertion construct
The 911 bp pbslap gene fragment was amplified by PCR with the SLAPInsForw and 
SLAPInsRev primers and blunt-ligated into the pCR®4Blunt-T0P0® vector, using the 
Zero Blunt® TOPO® PCR Cloning Kit for sequencing (Invitrogen), according to the 
manufacturer’s instructions. The vector was propagated and purified (Sections 2.4.8 and 
2.4.4), the cloned fragment excised from the vector using the EcoRI restriction sites 
flanking the cloning site, gel purified (Section 2.5.3) and re-cloned into pBSK-dhfr-ts at 
the EcoRI site. Cloning and selection procedures were performed as described (Section
2.4.3).
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2.13.3 Construction of the pSLAPRep replacement construct
Fragment 2 was digested with EcoRI and Xbal restriction enzymes and directionally 
cloned into the pBSK-dhfr-ts vector between the EcoRI and Xbal restriction sites. The 
vector was propagated and purified (Sections 2.4.8 and 2.4.4), and Fragment 1, digested 
with Apal and Hindlll, was cloned in between the Apal and Hindlll restriction sites in 
the vector. Cloning and selection procedures were performed as described (Section
2.4.3).
2.13.4 Preparation of Plasmodium berghei ANKA donor culture
Female BALB/c mice were infected by intraperitoneal injection with 10^  or 10^  
parasitised BALB/c-derived erythrocytes. At 15-20% parasitemia the animals were 
culled, the blood collected into heparin, transferred into RPMI 1640 and centrifuged for 8 
minutes at 450 x g, RT. The rbc pellet was equally divided between two 500 mL 
Erlenmeyer flasks each containing 60 mL of COz-saturated RPMI 1640 with 20% heat 
inactivated FCS. The culture was saturated with gas mixture of 10% O2, 5% CO2, 85% 
N2, sealed and incubated on a shaker at 38°C for approximately 20 hours (overnight).
2.13.5 Schizont isolation for electroporation
When the majority of parasites were at the late schizont stage (as examined by Giemsa- 
stained thin blood smears), the culture was overlaid on a 55% Nycodenz/PBS gradient 
(Robins Scientific; 35 mL culture over 10 mL Nycodenz) and centrifuged without a brake 
at 300 X g, 25 mins, RT. The interphase was collected and washed at 800 x g for 10 
minutes, RT. This yielded approximately 10^  schizonts, which were subsequently mixed 
with cytomix (Appendix) to a total volume of 100 pL.
2.13.6 Preparation of transfection vectors for electroporation
50 pg of each transfection vector was digested with the appropriate restriction enzyme(s) 
and buffer in a total volume of 50 pL, at 37°C over night. Digested vectors were 
subsequently purified, either over PCR Purification columns (Qiagen), or by phenol- 
chloroform extraction followed by ethanol precipitation. Each vector was made up with 
cytomix to a final volume of 300 pL.
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2.13.7 Electroporation
The parasite- and vector preparations were mixed, transferred to a 0.4 cm electroporation 
cuvette and subjected to a single pulse of 1.1 kV and 25 pF (time constant between 0.6 
and 1 ms), using a Bio-Rad electroporator. Cuvettes were immediately transferred to ice 
and 0.2 mL of the mixture injected intravenously into the tail vein or intraperitoneally 
into each mouse.
2.13.8 Pyrimethamine injections
A stock solution of 2.5 mg mL'* pyrimethamine (Appendix) was diluted with saline to 
prepare injection volumes of 0.1 mL, to give a final dose of 10 mg kg'* bodyweight, 
injected intraperitoneally.
2.13.9 PCR screening of transfected parasites
PCR analysis for screening of transfected parasites was performed as described (Section 
2.4.2.2), using the primer combinations described in Section 5.3.4.1. All primer 
sequences are listed in Table 2.2.
2.13.10 Southern analysis screening of transfected parasites
Southern analysis for screening of transfected parasites was performed as described 
(Section 2.6), with the exception of using two pg of DNA per lane rather than 0.5pg. The 
blotted membrane was probed with a radio-labeled 1202 basepair fragment corresponding 
to the sequence between nucleotides 439 and 1640 of the pbslap gene. The probe was 
amplified by PCR, using primers SLAPRepFl and SLAPRepR2, gel purified and radio- 
labeled, as described (Sections 2.5.3 and 2.6.3).
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Table 2.1 Primers used in conventional PCR to identify the 5’- and 3’ ends of the pcslap 
gene
Primer Sequence
5’ end oî pcslap gene: 
PSLAPext.Fl (forward) 
PSLAPext.F2 (forward) 
PSLAP5’:1 (reverse) 
PSLAP 5’:2 (reverse)
GACGTGATTGTATTAGTTCATG
CTAGCTGTTCAGAAGATTGTGC
TTAACCACATACTAGTGCAAG
TGTGTGCAATAAATTATTAACAGGG
3’ end of pcslap gene: 
PSLAP 3’:1 (forward) 
PSLAP 3’:2 (forward) 
PSLAPext.Rl (reverse) 
PSLAPext.R2 (reverse)
TTTCAGTATATTTTTTAGCTAC
CTAATTTGTATTGGTTGAATAG
CACGTATATGACAATCTATGTC
ATAGCTGCAGCACATATAGAGG
Table 2.2 Primers used for PCR screening of transfected parasites
Primer Sequen ce
SLAPRepFl / I* (forward) 
SLAPRepRl / 5* (reverse) 
SLAPRepF2 / 6* (forward) 
SLAPRepR2 / 4* (reverse) 
DHFR2 / 3* (forward) 
DHFR3 / 2* (reverse)
CCCCCGGGCCCGAAGAAAAACGAGAAGCAAC
CCGGAAGCTTCCCCATTTATTATTTACACGG
GGCCGAATTCGCTGTTTGTAAAAAAGGTCC
CCGGTCTAGACCATTAGATGTAGGTGAACC
AATAATAACTTATAAATATGAG
GTGGAAATAAAATAACATATAA
For clarity, instead of using their names, these primers were given numbers in Section 5.3.4.2.
Table 2.3 Primers used in Vectorette PCR
Primer Sequence
Forward primers
(for 3’ extension):
Forwl
Forw2
Forw3
Forw4:l
Forw4:2
CCACATGAAACATCTGAAGATATTTACTGTTCTC
AGCAGCTATACATGCAGGTGTTCTATCGAG
CCAAGTAGTAAAGGGAAAAATACATGG
ACAAGCAACTGATTACTTTATAGGGG
TGTTCAGATAATTTACTCAGTGAGCG
Reverse primers
(for 5’ extension):
Revl
Rev2
Rev3:l
Rev3:2
GCTTC ATCTCCTTTACATCTAAAATTCGTTG 
GAATGGTTCCGTTTTCTATCGAATCGTTAC 
AACTATGACAGTTTTGTGGGCATCGAAC 
CGGAACTATGACAGTTTTGTGGGCATCGAAC
Table 2.4 Primary antibodies, plasmas and sera used in IFA
Antibody
Working
dilution Source
a-PcSLAP mouse immune plasma (BALB/c)
a-PcSLAP rabbit immune plasma 
a-PJSLAP mouse immune sera (BALB/c)
85RF.45.3 (a-/^48/45), rat monoclonal IgG
NIMP23-FITC, mouse monoclonal IgG
1:40
1:40
1:40
lOpg/mL
1:50
Cecilia Waller, Langhome laboratory, 
NIMR
Abbott Murex Biotech Ltd.
Isabelle Delrieu, Holder laboratory, 
NIMR
Dr. R. Sauerwein, University Hospital 
Nijmegen, The Netherlands 
Ching Li/Latifu Sanni, Langhome 
laboratory, NIMR
Normal mouse plasma (BALB/c)
Pre-immune rabbit sera 
Rat IgG, purified 
Mouse IgG, purified
Hyperimmune a  -P. c. chabaudi (AS) plasma
1:40
1:40
lOpg/mL
30|ig/mL
1:100
Langhome laboratory, NIMR 
Abbott Murex Biotech Ltd. 
Sigma 
Sigma
Langhome laboratory, NIMR
Table 2.5 Secondary antibodies used in IFA
Antibody
Working
dilution Source
Goat a-mouse IgG-FITC (green)
Goat a-mouse IgG-FITC (green)
Goat a-mouse IgG-Alexa Fluor® 594 (red) 
Goat a-rat IgG-FITC (green)
Goat a-rat IgG-Alexa Fluor® 488 (green) 
Goat a-rat IgG-Alexa Fluor® 594 (red)
1:160
1:1500
1:400
1:200
1:200
1:500
Sigma
BD Pharmingen 
Molecular Probes 
Sigma
Molecular Probes 
Molecular Probes
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Figure 2.1
pCR4Blunt-TOPO (Invitrogen)
Vector map for pCR4Blunt-T0P0, used for cloning of PCR products for subsequent 
sequencing.
201
261
311
LacZa initiation codon 
M 13 Reverse priming site |
I I I
CACACAGGAA ACAGCTATGA CCATGATTAC GCCAAGCTCA 
GTGTGTCCTT TGTCGATACT GGTACTAATG CGGTTCGAGT
T3  priming site
|S p e l P st  I P m e  I £coR  I
GACTAGTCCT GCAGGTTTAA ACGAATTCGC CCTT 
CTGATCAGGA CGTCCAAATT TGCTTAAGCG GGAa I
Blunt PCR 
Product
GAATTAACCC TCACTAAAGG 
CTTAATTGGG AGTGATTTCC
EcoR I N ot I
I I
lAAGGGC GAATTCGCGG 
It t c c c g  CTTAAGCGCC
T7 priming site
CCGCTAAATT CAATTcdcCC TATAGTGAGT CCTATT^GAA 
GGCGATTTAA GTTAAGCGGG ATATCACTCA GCATAATGTT
M 13 Forward (-20) priming site
TTcdcTGGCC GTCGTTTTAc' 
AAGTGACCGG CAGCAAAATG
pC R "4Blunt-T 0P0
3954 bp
Comments for pCR®4Blunt-T0P0®
3954 nucleotides
lac promoter region: bases 2-216 
CAP binding site: bases 95-132 
RNA polymerase binding site: bases 133-178 
Lac repressor binding site: bases 179-199 
Start of transcription: base 179 
M l 3 Reverse priming site: bases 205-221 
LacZa-ccdB gene fusion: bases 217-810 
LacZa portion of fusion: bases 217-497 
ccûB portion of fusion: bases 508-810 
T3 priming site: bases 243-262 
TOPO® Cloning site: bases 294-295 
T7 priming site: bases 328-347 
M l3 Forward (-20) priming site: bases 355-370 
Kanamycin promoter: bases 1021-1070 
Kanamycin resistance gene: bases 1159-1953 
Ampicillin {bla) resistance gene: bases 2309-3061 (c) 
Ampicillin {bla) promoter: bases 3062-3158 (c) 
pUC origin: bases 3159-3832
(c) = complementary strand
Figure 2.2
pBluescript IIS K  (Stratagene)
Vector map for pBluescript II SK, used for construction of the pSLAPIns and pSLAPRep 
transfection vectors for disruption of the pbslap gene.
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Chapter Three
PcSLAP -  Identification and analysis of a novel Plasmodium chabaudi 
chabaudi (AS) gene and protein
3.1 Introduction
The Apicomplexa is an ancient phylum made up entirely of parasitic species. 
Phylogenetic reconstruction based on comparisons of small subunit ribosomal RNA 
sequences and conserved protein sequences predict that Apicomplexa has diverged 
extensively from the other eykaryotic kingdoms of animals, plants and fungi (Gajadhar et 
al., 1991; Escalante and Ayala, 1994; Baldauf et al, 2000). It is therefore likely that a 
number of genes will be unique to this phylum. Indeed, the Plasmodium falciparum 
sequencing project found that of 5,268 predicted proteins, over 60% (3,208) did not have 
homologues in any other organisms. These species-specific molecules are of particular 
interest as their study will allow a better and more complete understanding of the unique 
biology of the parasite, as well as the opportunity to discover new drug targets and 
vaccine candidates. Proteins that are restricted to a pathogen are especially well suited as 
therapeutic targets as they pose less of a risk of unwanted side effects if used for medical 
intervention.
This chapter describes the identification of a novel gene in Plasmodium chabaudi 
chabaudi (AS). In previous studies a small fragment of a gene (270 nucleotides) had been 
identified (Maria M Mota, PhD thesis, 1998). Examination of preliminary sequences on 
the TIGR website revealed un-annotated homologues to this sequence in both 
Plasmodium falciparum and Plasmodium yoelii. These were single exon genes of 
approximately 3.8 {P. falciparum) and 3.9 (P. yoelii) kilobases. Alignments of the open 
reading frames (ORFs) of these genes showed a 75% identity at the nucleotide level and 
63% at the protein level (data not shown), suggesting a well conserved, novel Plasmodial 
protein. Thorough searches through sequence databases from other organisms, including 
the NCBI non-redundant database, failed to detect any orthologues, indicating that this 
could be a gene unique to Apicomplexa. Work by us on the P. falciparum homologue 
revealed a multi-domain protein with several types of adhesive motifs, including
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revealed a multi-domain protein with several types of adhesive motifs, including 
Scavenger Receptor Cysteine-Rich (SRCR) domains and Limulus factor C, Coch-5b2 and 
Lgll (LCCL) modules, and was subsequently named Plasmodium SRCR LCCL 
Adhesive-like Protein (PSLAP; Delrieu et al., 2000).
At the start of this study very little sequence data was available from the P. chabaudi 
genome and thus BLAST searches with the 270 nucleotide sequence did not produce any 
hits. In order to identify the full sequence of the P. chabaudi slap (pcslap) gene two 
experimental approaches were used: Vectorette PCR and conventional PCR. As more 
data was being made available in the P. chabaudi sequence database towards the end of 
the study, the 5' end of the gene that still remained to be identified was obtained from a 
sequence database search.
This chapter describes the cloning of the full sequence of the P. chabaudi gene, as well as 
structural and functional analysis of secondary structural motifs within the protein.
67
Chapter Three VcSLAP -  Analysis o f a novel gene and protein
3.2 Results
3.2.1 Cloning of the pcslap gene
3.2.1.1 Identification of pcslap gene sequence using Vectorette PCR
In order to extend the original pcslap sequence of 270 base pairs the Vectorette II System 
(Sigma Genosys) was used. This is a method that allows amplification of unidentified 
nucleotide sequences upstream and downstream of known DNA.
First a “Vectorette library” is created by digesting DNA with a restriction enzyme and 
adding on short DNA adaptor sequences, Vectorettes (Fig 3.1), to the fragment ends. The 
Vectorette library is then used as template DNA in a PCR. Vectorette PCR is a “one­
sided” reaction performed with one primer based on the known gene sequence and the 
other primer binding to the Vectorette adapter sequence (Fig 3.2). Amplification from 
DNA fragments lacking the known sequence is avoided by the fact that the Vectorette 
primer sequence is complementary only to the strand that is created by extension from the 
known primer. This is because the sequence of the Vectorette primer is identical to one of 
the strands in the mismatched portion of the Vectorette unit, and so will only anneal once 
a complementary strand of this portion has been produced.
In order to avoid a situation where further amplification would be difficult and time 
consuming due to too many restriction sites of the chosen enzyme(s) being present within 
the pcslap gene sequence, it was decided to construct four Vectorette libraries. 
Plasmodium chabaudi chabaudi (AS) genomic DNA was digested with the restriction 
enzymes Rsal, Sau3AI, SspI and XhoII. The first three enzymes cut frequently in 
Plasmodium DNA: Rsal and Sau3Al have short, 4-base recognition sequences (GT'*'AC 
and '*'GATC, respectively) whereas SspI recognises a six-base sequence, but one made up 
of only adenine and thymine nucleobases (AAT'^ATT), both of which are abundant in 
Plasmodium DNA. XhoII, on the other hand, cuts infrequently as it has a six-base 
recognition sequence that includes at least one guanine and one cytosine nucleobase 
(R'*'GATCY, (R=either purine and Y=either pyrimidine)). The Vectorette Kit contains 
adapters with five different ends: four sticky end adapters and one blunt end adapter. For 
the present project, the Rsal- and Sspl-digested genomic DNA samples were ligated to 
the blunt Vectorette adapters, and the Sau3AI- and XhoII-digested genomic DNA with 
the BamHI adapter.
68
Chapter Three PcSLAP -  Analysis o f a novel gene and protein
Primers based on the 270 bp original pcslap sequence were subsequently designed, one 
for amplification in the S' direction, Revl, to obtain sequence upstream of the known 
pcslap sequence, and one for 3' amplification, Forwl, for downstream sequence 
identification (Figures 3.3, 3.4 and Tables 3.1 and 2.3). All four Vectorette libraries were 
screened with both of the above primers, and the results analysed by gel electrophoresis. 
This first screen generated products from upstream as well as and downstream 
amplification of pcslap2 7 0, both approximately 1100 nucleotides long, and from the SspI 
and Sau3AI libraries, respectively (Figure 3.5A). The products, designated 5':SeqI for 
the product extending pcslap in the 5' direction, and 3':SeqI for the extension in the 3' 
direction, were cloned into the pCR®4Blunt-T0P0® sequencing vector (Invitrogen) and 
sequenced (Figure 3.5B). Both sequences were confirmed as being derived from the 
pcslap gene as they were identical to pcslap 270 at the gene specific primer ends. The new 
sequences also displayed a high degree of identity with the slap gene in P. falciparum 
(data not shown).
The addition of the 5':Seql and 3':Seql products, 1045 and 1065 nucleotides long, 
respectively, onto pcslap 2 1 0 resulted in a 2126 nucleotide long sequence (Figure 3.6). 
This translated into an open reading frame without a stop codon at the 3' end (data not 
shown). This, in conjunction with the size of the P. falciparum slap gene (3816 
nucleotides), indicated that the full P. chabaudi homologue had not yet been identified.
3.2.1.1.2 The Second Vectorette Screen
The 5':SeqI and 3':SeqI sequences were thus used to design a second set of primers, 
Rev2 and Forw2, to "walk" further up and down the gene (primers I and 3, respectively, 
in Figure 3.5B, and Tables 3.1 and 2.3). Again, all Vectorette libraries were screened in 
the PCR. This second screen generated an approximately 700 nucleotide product using 
the Forw2 primer and the Rsal library (Figure 3.7A), but no upstream amplification with 
the Rev2 primer. The 700 base pair product, designated 3':Seq2, was cloned and 
sequenced as before (Section 3.2.1.1.1), and produced a sequence of 621 base pairs 
(Figure 3.7B). Again, as there was a significant overlap (282 nucleotides) of complete 
identity between 3':Seq2 and the previously obtained pcslap sequence, the product was 
considered to be a true continuation of the gene. In order to try and generate more 5'
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Table 3.1 Experimental strategies used to clone pcslap.
PCR Forward primer(s)* Reverse primer(s)* Product
Vectorette PCR, P‘ screen 
5' amplification 
3' amplification
Vectorette primer 
Forwl (pcslap specific)
Revl (pcslap specific) 
Vectorette primer
5':Seql
3':Seql
Vectorette PCR, 2”^ screen 
5' amplification 
3' amplification
Vectorette primer 
Forw2 (pcslap specific)
Rev2, Rev2:l (pcslap specific) 
Vectorette primer 3':Seq2
Conventional PCR 
5' amplification 
3' amplification
pslap.5':l, pslap.5':2 
Forw3:l, Forw3:2
Rev3:l, Rev3:2 
pslap.3':l, pslap.3':2 3':Seq3
*Primer sequences are listed in Chapter 2, Tables 2.1 and 2.3. 
- No product obtained
sequence, a second primer, Rev2:l (primer 2 in Figure 3.5B), was designed and run in a 
Vectorette PCR. However, again no product was obtained.
The 3':Seq2 product added 367 nucleotides to the existing slap sequence (Figure 3.8). 
However, when translated, the amino acid sequence was still lacking a 3' stop codon, 
again suggesting that the end of the gene had not yet been cloned (data not shown).
3.2.1.2 Conventional PCR for cloning of the 5' and 3' ends of pcslap 
At the start of this project no rodent slap sequences had yet been identified and so they 
were not available in public data bases. However, during the Vectorette sequencing, both 
the P. yoelii slap and the P. berghei slap (pyslap and pbslap, respectively) sequences 
were entered into the PlasmoDB database. This made it possible to use a different 
strategy that could recover the remaining sequence at the 5' and the 3' ends of P. 
chabaudi slap in a single attempt. This approach relied on conventional PCR with 
primers based on the up- and downstream un-translated regions (UTRs) of pyslap and 
pbslap. This would most likely be a faster method, as with the Vectorette approach it 
could potentially be necessary to do several more screenings to clone the full gene, if
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there were several Rsal, Sau3AI, SspI and XhoII restriction sites present in the missing 
sequence.
The P. yoelii and P. berghei slap 5' and 3' UTRs were aligned and shown to share 93% 
identity over 183 nucleotides for the 5' UTR and 89% identity over 209 nucleotides for 
the 3' UTR (Figure 3.9 A and B, respectively). This high degree of identity, in addition to 
an 86% identity between the 2.5 kilobases of P. chabaudi slap sequence identified so far 
and the corresponding sequence in these other two rodent malarias (data not shown), 
indicated that the slap gene itself and the sequence surrounding it are well conserved and 
that the P. chabaudi UTRs would most likely be similar enough to bind primers based on 
these regions. Thus primers were designed from regions in the alignment with no or one 
differing nucleotide. Primers pslap.5':l and pslap.5':2 were based on the P. yoelii/P. 
berghei 5' UTR, and pslap.3':I and pslap.3':2 on the P. yoelii/P. berghei 3' UTR (Figure 
3.9A and B, respectively. Tables 3.1 and 2.1). These were run together with primers 
designed from the previously obtained pcslap sequence: Rev3:I and Rev3:2 were used 
for 5' amplification (new primers were made as primers Rev2:l and Rev2:2 had not 
worked in the Vectorette PCR), and Forw3:I and Forw3:2 for 3' amplification (Figures 
3.5B, 3.7B, 3.8, and Table 3.1). P. chabaudi genomic DNA, as well as the four 
Vectorette libraries, were used as templates. An approximately 750 base pair long 
product was produced in the 3' amplification with primers Forw3:2 and pslap.3':2 from 
P. chabaudi genomic DNA (Figure 3.I0A), and was subsequently cloned and sequenced 
(Figure 3.1GB). Because the product, designated 3':Seq3, had sequence overlapping with 
the identified pcslap sequence it was considered part of the gene and added to the 
existing sequence (Figure 3.11). It translated into an ORF terminated by a stop codon 
towards the C-terminal, marking the end of the gene.
3.2.3 Identification of the 5' end of pcslap by BLAST
Because no products had been generated in the 5' sequencing attempt, the beginning of 
pcslap was still missing. However, at this time more sequence had been made available in 
the Sanger Center P. chabaudi database. A BLAST search using the known pcslap 
sequence as the query for searching P. chabaudi sequence data produced a hit with a 
2053 base pair long sequence (P score 3.7 Figure 3.12) in the genomic contigs
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database. The contig was aligned with the pcslap sequence (data not shown), adding 1205 
base pairs of new sequence to the 5' end of the gene (Figure 3.13). A translation showed 
that the ORF was initiated by a start codon 460 bases into the contig sequence 
(underlined in Figure 3.12).
The complete coding pcslap sequence proved to be 3897 nucleotides long and translating 
into a 1298 residue protein (Figure 3.14).
3.2.2 Determination of pcslap copy number in P. c. chabaudi (AS)
To investigate the copy number of pcslap in the P. chabaudi genome. Southern blot 
analysis was performed. Parasites were harvested from P. chabaudi infected mice, 
genomic DNA isolated and aliquots digested with Rsal, Sau3AI, SspI and XhoII 
restriction enzymes. A restriction map for pcslap, along with the relative position of the 
probe within the sequence, is shown in Figure 3.15. The fragments were resolved on an 
agarose gel (Figure 3.I6A) and probed with radio-labelled pcslap2 7 0 (the 270 bp original 
sequence). Hybridisation was carried out at 65°C and resulted in single bands of the 
expected sizes in all four digests (Table 3.2 and Figure 3.I6B).
However, hybridisation was subsequently also performed at 55°C with the pcslap2 7 0  
probe. This resulted in a second, smaller band appearing in each digest, of the following 
approximate sizes: Rsal - 400 nucleotides, Sau3AI -  350 nucleotides, SspI -  650 
nucleotides and XhoII - 5000 nucleotides (Figure 3.I6C). This suggested that there is 
another gene in the P. chabaudi genome with sequence similarity to the probe sequence.
Table 3.2. Expected band sizes from restriction digests of P. chabaudi genomic DNA 
probed with pcslap27o-
Restriction enzyme No of sites in probe 
sequence
Sizes of fragments (nucleotides)
Rsal 0 2661
Sau3AI 0 1417
SspI 0 1883
XhoII 0 >4014
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In order to try and identify this potentially related gene, the pcslap2 jo sequence was 
BLASTed through the P. chabaudi genomic contigs database and the P. chabaudi 
shotgun reads database and the highest scoring sequences in each of these analysed. As 
there is still redundancy in the data within these databases, the sequences in each set were 
aligned and any identical sequences removed, so that six unique sequences from each 
database remained. The highest scoring sequence in these searches was a part of the P. 
chabaudi slap gene itself - a 615 nucleotide long sequence in the shotgun reads database 
with a P value of 4.8 x e'^  ^and 100% identity. The rest of the hits had P scores between 
0.00011 and 0.00038, and identities ranging from 59% to 65% (data not shown). In order 
to investigate whether any of these sequences could represent the second band seen in the 
Southern analysis, the Rsal, Sau3AI, SspI and XhoII restriction sites were mapped out for 
each sequence (data not shown) and the sizes of fragments compared with the size of the 
second band. However, none of the sequences obtained in the BLAST searches had a 
restriction map that would produce the fragments seen in the Southern analysis.
Southern analysis was subsequently repeated using pcslap2 i3o, a 2.1 kilobases long probe 
comprising pcslap2 7o and the sequences identified in the first Vectorette screen (5':SeqI 
and 3':Seql). pcslap2 j3o carried restriction sites of the enzymes used to digest the DNA 
and would therefore bind more than one fragment, resulting in more than one band in 
each digest (Figure 3.15 and Table 3.3). The smallest fragments produced in the Rsal and 
Sau3AI digests (64 and 18 nucleotides, respectively), were however unlikely to generate 
bands as they would have been lost into the running buffer during electrophoresis of the 
DNA. Likewise, the 606 base pair long fragment generated in the Sau3AI digest only 
contained 6 nucleotides of the pcslap2 j3o probe sequence, and would therefore not be 
expected to bind the probe. As shown in Figure 3.18, the expected bands are all present 
on the autoradiograph. In addition, the extra bands seen previously with the pcslap2 7o 
probe are also visible, although very faintly. This was expected as pcslap2 7o is contained 
within the pcslap2 i3o sequence (Figure 3.15).
These results indicate that pcslap is a single copy gene in the P. chabaudi genome.
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Table 3.3. Expected band sizes from restriction digests of P. chabaudi genomic DNA probed 
with pcslap2i3o-
Restriction enzyme No of sites in 
probe sequence
Sizes of fragments (nucleotides)
Rsal 2 393, (64), 2661
Sau3AI 3 822, (18), 1417, (606)
SspI 1 1883,952
XhoII 0 >4014
Fragments in brackets are unlikely to be visible on the blot (see further Section 3.2.2 and Figure 
3.15).
3.2.3 pslap copy number in Plasmodium yoelii and Plasmodium berghei 
In order to investigate the number of genes in other rodent malarias, a second Southern 
analysis was subsequently performed, using genomic DNA from Plasmodium yoelii 
yoelii (I7X strain) and Plasmodium berghei ANKA as well as from P. chabaudi. To 
control for hybridisation to contaminating, co-purified mouse DNA from leukocytes and 
reticulocytes, BALB/c genomic DNA from an un-infected mouse was included as a 
negative control to ensure that the generated bands were from hybridisations to parasite, 
and not murine DNA. This sample was prepared alongside the parasite preparations. 
Because of the high level of conservation of the slap gene it was possible to use pcslap2 jo 
as a probe for all genomic DNAs. Alignments with the homologous sequences in these 
rodent species showed 91% identity with the P. berghei ANKA sequence and 90% 
identity with the P. yoelii sequence (Figure 3.18).
The genomic DNAs were digested with either Sau3AI or SspI restriction enzymes, the 
fragments separated by gel electrophoresis and probed with pcslap2 7 0  at 55°C (Figure
3.19). Expected hybridisation patterns are shown in Table 3.4. No binding to the negative 
control, BALB/c genomic DNA, was detected, demonstrating that the generated bands 
were not from contaminating mouse DNA. As before (Section 3.2.2) two bands appeared 
in the digested P. chabaudi genomic DNA. Interestingly, the P. berghei digests also
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Table 3.4. Expected band sizes from restriction digests of P. berghei and P. yoelii genomic 
DNA probed with pcslapiro-
Parasite Restriction enzyme No of sites in 
probe sequence
Sizes of band (nucleotides)
P. chabaudi Sau3AI 0 1417
Ssp 0 1883
P. berghei Sau3AI 0 683
SspI 0 1475
P. yoelii Sau3AI 0 1364
SspI 0 1475
showed a second weaker band. Only one band was detected in the P. yoelii digested 
DNA. A BLAST search was thus carried out to search the P. berghei assembled contigs 
and genome shotgun reads databases to try and identify the second gene, in the same way 
the P. chabaudi database had been screened previously (Section 3.2.2). However, again 
no sequence was detected that would have given the restriction pattern that was observed.
3.2.4 Summary of results - the pslap gene in Plasmodium chabaudi chabaudi (AS)
Starting with a 270 basepair fragment, most of the pcslap gene was identified using 
Vectorette PCR, but the 3' end obtained through conventional PCR and the 5' end from a 
sequence in the Sanger P. chabaudi database. The identification and analysis of pcslap 
showed that the full coding sequence of the gene is 3897 basepairs, with an AT-content 
of 73%, a typical high value for Plasmodial sequences, pcslap consists of a single exon 
and southern analysis showed that it exists as a single copy gene in the P. chabaudi 
chabaudi (AS) genome. The gene was also detected as a single copy in P. yoelii and P. 
berghei using southern analysis.
3.2.5 Analysis of the PcSLAP protein
The 3897 nucleotide long pcslap gene translates into an open reading frame of 1298 
amino acids, with a calculated molecular weight of 146,785 Daltons. In order to identify
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sequences related to PSLAP, protein data bank searches were performed using PSI- 
BLAST. Significant hits with E values less than le'^ included a number of proteins 
containing Scavenger Receptor Cysteine-Rich (SRCR) domains. To further analyse the 
sequence, motif and pattern prediction programs were used. Analysis of the PcSLAP 
protein using the Simple Modular Architecture Research Tool (SMART) revealed two 
centrally located Scavenger Receptor Cysteine-Rich (SRCR) domains, flanked by two 
Limulus factor C, Coch-5b2 and Lgll (LCCL) modules (Figure 3.20). A third LCCL 
motif is present at the C-terminal of the protein and a Lipoxygenase Homology 
2/Polycystin-l, Lipoxygenase and a-Toxin (LH2/PLAT) domain towards the N-terminal. 
The protein also carries an N-terminal signal sequence.
3.2.5.1 Scavenger Receptor Cysteine-Rich (SRCR) domains
SRCR domains belong to an ancient, highly conserved super family of proteins that was 
first recognised during the analysis of the type 1 macrophage scavenger receptor (Aruffo 
et al, 1997; Resnick et al, 1994; Freeman et al, 1990). The domain is around 110 amino 
acids in length and contains six or eight conserved cysteine residues, predicted to 
participate in intra-domain disulphide bonds to produce a structural domain. SRCR 
domains are most commonly located in the ecto-domains of membrane bound proteins, 
but are also found in secreted molecules. Many of the proteins in this family are involved 
in the development of the immune system or in regulation of immune responses (Aruffo 
et al, 1997).
The SRCR family can be further divided into two sub families. Group A and B, based on 
the number of cysteines present in the domains, and the spacing between these residues. 
Both groups have six conserved cysteines (denoted by stars in Figure 3.21) in common, 
predicted to form three disulphide bridges, but Group B also has an additional pair, 
forming a fourth disulphide bond. In addition, in Group A each SRCR domain is coded 
for by an individual exon (Aruffo et al., 1997).
Two SRCR domains were identified in the PcSLAP protein, and subsequently designated 
SRCR-1 and SRCR-2 (expectation values 5.16 x e*^  and I.9I x e'^ , respectively; Figure
3.20). SRCR-1 is 113 residues long and SRCR-2 115 residues, with both domains 
containing eight cysteine residues. Since the full pcslap gene is coded for by an single 
exon, the above classification groups the PcSLAP SRCR domains into the Group B sub
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family. Group B modules build up the extra-cellular domains of several lymphocyte cell 
surface proteins, most importantly CD5 and CD6 (Aruffo et al., 1997).
PSI-BLAST and multiple sequence alignment show that PcSLAP SRCR-1 and -2 share 
up to 35% identity and 51% similarity with other SRCR domains (Fig 3.21). Excluding 
PSLAP in other Plasmodium spp., PcSLAP SRCR-1 is most similar to mouse {Mus 
musculus) Sp-alpha (mSpa), a secreted protein containing three SRCR domains (Gebe et 
al., 2000; Fig 3.22). mSpa has been suggested to play a role in development and/or 
maintenance of the lymphoid compartment. The gene is transcribed in most lymphoid 
tissues and knock-out mice have a reduction in numbers of double positive thymocytes, 
suggesting that mSpa may be an inhibitor of apoptosis of maturing thymocytes 
(Miyazaki et al., 1999). PcSLAP SRCR-2 most closely resembles Scavenger Receptor 
Cysteine-Rich Protein Variant 1 (SpSRCRl), a protein found in the purple sea urchin 
Strongylocentrotus purpuratus. SpSRCRl belongs to a large family of SRCR genes 
specifically expressed in coelomocytes, the immune effector cells in these organisms 
(Pancer et al., 1997; Pancer, 2000). The primary function of these cells is to protect 
against invasive marine pathogens.
3.2.S.2 Limulus factor C, Coch-5b2 and Lgll (LCCL) domains
The LCCL module was named after Limulus factor C, the cochlear protein Coch-5b2 and 
Late gestation lung protein-1 (Lgll), the best characterised proteins it was first 
discovered in. The module is typically 100 residues long and forms a structural domain 
due to the presence of disulphide bridges. Alignments of known LCCL sequences have 
shown eight potential cysteine locations within the module, four of which are highly 
conserved and found in the majority of LCCL proteins (Fig 3.23). The C-terminal end is 
the most conserved part of the domain and believed to be the core of the module. A 
highly conserved histidine within a conserved m otif in this region, 
YxxxSxxCxAAVHxGVI (underlined in Figure 3.23), is present in nearly all LCCL 
domains identified so far (Trexler et al., 2000).
The three LCCL domains identified in PcSLAP, LCCL-1, -2 and -3 (expectation values
1.84 X e'^ 8.49 x e'^  and 2.47 x e-17) are 101, 91 and 86 amino acids long respectively, 
and contain four cysteines each. The conserved region is clearly present in LCCL-2 and 
LCCL-3, but not in LCCL-1, which most importantly lacks the histidine (Fig 3.23).
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LCCL domains have been identified previously in both Plasmodium  and other 
Apicomplexa. CCP2, a protein present in several Plasmodium spp., including P. 
falciparum and the rodent species P. yoelii and P. berghei (GenBank accession number 
AF491294) contains one LCCL and one Ricin B domain (Figure 3.24). Putative 
orthologues to CCP2 were also found in other Apicomplexa, including a complete gene 
in Cryptosporidium parvum (Cpal35, GenBank accession number AJ006593.2), and a 
partial sequence in Toxoplasma gondii (cDNA, GenBank accession number BM131310; 
Tosini et al., 1999; Tang et al (Toxoplasma EST project), 2001). Furthermore, a mass 
spectrometric proteomic analysis of different developmental stages of P. falciparum 
parasites revealed the presence of four LCCL-containing proteins, including PSLAP, 
CCP2 and two previously unidentified molecules, PFA0445w and PF14_0532 (Figure 
3.24; Lasonder et al., 2002).
3.2.5.3 The Lipoxygenase homology 2/FoIycystin-l, lipoxygenase and a-toxin 
(LH2/PLAT) domain
LH-2/PLAT domains are found in a variety of membrane and lipid associated proteins. 
The domain is a p-sandwich composed of two sheets with four strands each. It is about 
90 residues in length, with most of the conservation found in the p-strands (Bateman and 
Sandford 1999). LH2 domains are present in several membrane or lipid-associated 
proteins, and thus appear to be involved in either protein-lipid, or protein-protein 
interactions. In PcSLAP a region with some similarity to this domain type was 
discovered, although with a rather high expectation value (2.24 x e' )^. The LH-2/PLAT 
domain is the most N-terminal motif identified in the PcSLAP sequence (Fig 3.20).
3.2.5.4 Further sequence analysis - Signal peptides and localisation signals
Newly synthesized proteins have intrinsic signal sequences that function as "address 
tags" and are necessary for efficient and effective translocation to their respective 
destinations. Eukaryotic proteins that are destined for organelles, membranes or for 
secretion out of the cell carry an N-terminal hydrophobic signal sequence. This sequence 
directs them to the rough endoplasmic reticulum and allows translation immediately into
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the lumen of this compartment (Lodish et al., 1995). Additional sequence motifs 
subsequently determine the final destination of the proteins.
The N-terminal of PcSLAP consists of a sequence that potentially is a signal peptide for 
translocation into the endoplasmic reticulum. The methionine start codon is immediately 
followed by a positively charged arginine, after which there is a twenty residue stretch of 
mainly (eleven out of twenty) hydrophobic amino acids (Figure 3.20). The PcSLAP 
protein sequence was therefore run through SignalP (Nielsen et al., 1997). The program 
predicted a signal peptide from residues 1-22, followed by a von Heijne-type cleavage 
motif between amino acids 22 and 23: AYG-KE (Figure 3.20).
To further investigate the destination/localisation of PcSLAP the TargetP Vl.O and PATS 
(Prediction of Apicoplast Targeted Sequences) prediction programs were used. Both 
programs use neural networks to predict subcellular locations of proteins based on N- 
terminal sequence information. TargetP discriminates between eukaryotic proteins 
destined for the mitochondrion, the chloroplast and the secretory pathway. The program 
screens the 120 most N-terminal residues and detected a secretory peptide in PcSLAP but 
no mitochondrial pre-sequence (chloroplast prediction was turned off) and thus classified 
it as a secreted protein.
PATS was specifically designed to analyse Plasmodium sequences for apicoplast 
targeting signals. The program analyses the first 80 amino acids of the query and gives 
the sequence a score between 0 and 1, where values close to 1 signify proteins likely to 
be apicoplast targeted and values near 0 denote unlikely apicoplast candidates (Zuegge et 
al., 2001). PcSLAP was scored 0.026 and thus categorised as a non-apicoplast protein. 
Furthermore, no trans-membrane sequence was identified in the PcSLAP protein 
sequence. These results strongly indicate that PcSLAP is a secreted protein.
3.2.6 PSLAP is highly conserved among Plasmodium species
As previously mentioned, homologues of the pcslap gene are present in several other 
Plasmodium genomes, including P. falciparum, P. knowlesi, P. yoelii and P. berghei. An 
alignment between the three rodent parasites using the coding part of the gene showed an 
82% identity at the nucleotide level (Figure 3.25) and 79% identity at the protein level 
(Figure 3.26). The same alignment with PcSLAP and the P. falciparum homologue
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displayed 73% identity between the genes (Figure 3.27), and 63% identity between the 
compared proteins (Figure 3.28).
In contrast to the high degree of conservation of PSLAP among Plasmodium species, 
until recently no significant homology was found with genes from other apicomplexan 
parasites, other metazoans, protists or bacteria. However, a recent BLAST search 
identified an orthologue in another member of Apicomplexa, Toxoplasma gondii. This 
protein. Toxoplasma gondii Scavenger receptor 1 (TgSRl; accession no AAN74967), is 
1247 residues long and is made up of an identical set of domains, apart from having an 
extra C-terminal LCCL module (Figures 3.22 and 3.23). An alignment of the protein 
sequences of TgSRl and P. falciparum SLAP showed that the molecules share 30% 
identity (data not shown). Furthermore, when looking for sequence similarities within 
Plasmodia, the SRCR and PLAT motifs were not present in any other available 
sequences, including the fully sequenced P. falciparum genome, whereas the LCCL motif 
was found in other genes. However, as more genomic sequence data is retrieved from 
other organisms, homologues to PSLAP may be found in other Apicomplexan parasites.
80
Chapter Three PcSLAP -  Analysis o f a novel gene and protein
3.3 Discussion
We have identified and analysed a novel gene and protein in Plasmodium chabaudi 
chabaudi (AS). Using the Vectorette system and standard method PCR, a 270 base pair 
fragment of a gene was extended in the 3' and 5' directions, and a 3897 nucleotide 
sequence, translating into a 1298 residue ORF, was obtained.
We have identified and analysed a novel gene and protein in Plasmodium chabaudi 
chabaudi (AS). Using the Vectorette system and standard method PCR, a 270 base pair 
fragment of a gene was extended in the 3' and 5' directions, producing 2692 base pairs of 
open reading frame of the gene. The remaining sequence at the 5' end was obtained from 
a BLAST search of the Sanger Center P. chabaudi database. The full gene sequence of 
3897 nucleotide sequence had thus been identified, translating into a 1298 residue ORF. 
As expected from a Plasmodium gene the sequence has a typical AT-bias, with 73% 
(adenosine+thymine) nucleotides (the fully sequenced P. falciparum  genome has an 
80.6% (A+T) content (Gardner et al, 2002). Southern analysis using high stringency 
conditions showed that pcslap is present as a single copy gene in the P. chabaudi 
genome. This agrees with the data from work on P. falciparum (3D7 strain) slap, which 
has been shown to be a single copy gene on chromosome 14, as reported previously by 
us, as well as confirmed by the presence of only one slap gene within the sequence data 
from the completed P. falciparum genome sequencing project (Delrieu et ah, 2002; 
Lasonder et ah, 2002). However, lowering of the stringency revealed hybridisation to a 
second fragment in the digests, indicating the existence of a sequence with a high degree 
of similarity to pcslap. Interestingly, analysis of pslap copy numbers in other rodent 
parasites also showed hybridisation to a second fragment in P. berghei, but not in P. 
yoelii. However, searches through P. chabaudi and P. berghei sequence databases failed 
to identify this potential related gene, as they did not generate any sequences with a high 
degree of identity. However, the genomes of these two rodent species have been 
sequenced to a coverage of 2x and 3x, respectively, and it is possible that this second 
hybridising sequence has simply not been cloned and sequenced yet, and therefore not 
entered into the public sequence databases. The other possibility is that the second 
sequence only has a weak similarity to pcslap2iQ but still enough to support hybridisation. 
Clearly, it would be interesting to identify this second gene, as so far no other genes have 
been observed in Plasmodium with any primary structure similarity to pslap, or with a
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similar domain composition (at least one copy of each domain found in the query 
sequence). As more sequence data is made available it may be possible to identify the 
sequence in silico. Alternatively, the gene could be isolated by screening a genomic 
library using pcslap2iQ as a probe.
Analysis of the PSLAP secondary structure revealed a mosaic protein composed of 
several types of domains, including two SRCR domains, three LCCL modules and one 
LH2/PLAT domain. A 22 residue signal peptide is present at the N-terminal end of the 
protein but no further translocation signals were identified, suggesting that the protein is 
secreted rather than retained within the parasite.
SRCR domain proteins make up an ancient and highly conserved super family, present in 
species from several phyla (Aruffo et al., 1997). The SRCR domains themselves are well 
conserved across species boundaries and were first recognised during the analysis of type 
1 Macrophage scavenger receptor, a membrane-bound cell surface molecule on 
mammalian macrophages (Kodama et al., 1990). They have since been found in a wide 
range of proteins such as CD5 and CD6 on mammalian T cells (and some B cells), WCl 
on yô T cells in pigs, sheep and cattle, Mac-2 Binding Protein in human and murine 
carcinoma cells, 18-B in chicken serum. Complement factor 1 in mammalian and 
amphibian plasma, Sp22D in Anopheles gamble mosquito hemocytes, and the Speract 
receptor on sperm cells and SpSRCRl and SpSRCR5 on coelomocytes (invertebrate 
immune cells) in sea urchins (Jones et al., 1986; Aruffo et al., 1991; Wijngaard et a l, 
1992; Koths et al., 1993; Chicheportiche and Vassalli, 1994; Iwasaki et al., 2001). 
Although in some proteins, SRCR domains are present as one of several secondary 
structures, such as PSLAP, they are in many instances the only identifiable motif, as is 
the case with among others CD5 and CD6. This proves that SRCR domains play 
important functional roles and do not only serve as structural elements in molecules.
So far, all identified Group B SRCR domain proteins have functions relating to 
immunity, such as the mammalian antigens CD5, CD6 and CD163. However, the role of 
the SRCR domain itself is still unclear but it appears to be involved in receptor-ligand 
interactions. To date only a few Group B SRCR interactions have been characterised in 
detail at a molecular level. The best documented interaction is that between CD6 on T
82
Chapter Three PcSLAP -  Analysis o f a novel gene and protein
cells and Activated Leukocyte Cell Adhesion Molecule (ALCAM) on lymphocytes 
(Bowen et a l, 2000). CD6 contains three SRCR domains, of which the most membrane 
proximal binds one of the V-like immunoglobulin domains of ALCAM. This interaction 
is believed to modulate T cell receptor signalling. Recently it was shown that the bacteria 
binding and agglutinating properties of salivary agglutinin can be attributed to its SRCR 
domains. A sixteen residue synthetic peptide, based on a consensus sequence of the 
salivary agglutinin SRCR domains, showed binding to a wide range of gram positive and 
-negative bacteria, including Esherichia colt, Staphylococcus aureus, Streptococcus 
mutans, Heliobacter pylori and Prevotella intermedia, as well as mediated the 
agglutination of S. mutans (Bikker et ah, 2002).
Interestingly, SRCR domains are also present in proteins in Anopheles gamble, the 
invertebrate vector of Plasmodium parasites. Sp22D (Serine protease from chromosomal 
division 22D) is a multi-domain serine protease that contains two SRCR domains (Figure 
3.22). It is constitutively expressed in mosquito hemocytes, fat body and midgut 
epithelial cells -  all tissues involved in inununity (Section 1.8.4). Infection experiments 
have shown that Sp22D mRNA is upregulated upon bacterial challenge, indicating a role 
in host defense against invading pathogens (Danielli et a l, 2000). It has been suggested 
that Sp22D may have an immune recognition function similar to that of Limulus factor C 
in the horseshoe crab (Gorman et al, 2000). A putative homologue to Sp22D named 
GRAAL, coded for by the gene tequila, was recently identified in Drosophila 
melanogaster (accession number AJ251803; Adams et al., 2000). GRAAL shares all 
domains of Sp22D, except for having one rather than two N-terminal chitin binding 
domains. An alignment between the protein sequences of the two molecules showed a 
29% identity (data not shown). The function of GRAAL is also unknown.
A BLAST search using PcSLAP SRCR-1 as the query sequence also identified a novel 
gene from the Anopheles gamble sequencing project. A large open reading frame coding 
for a 3069 residue protein labeled agCP4856 (accession number EAA15063.1) included 
two SRCR domains and 11 parallel P-helix repeats (Fig 3.22). This sequence has not 
been curated by experts and no publication on the gene or protein is yet available.
Unlike the SRCR domain, which is frequently the only identifiable motif in a protein (Sp- 
a, CD5, CD6), the LCCL domain has so far always been found alongside other modular
83
Chapter Three VcSLAP -  Analysis o f a novel gene and protein
domains such as epidermal growth factor (EGF)-like domains, serine protease motifs and 
von Willebrand type A domains. It has therefore not been clear whether it has a purely 
structural function or if it is involved in interactions with other molecules. However, 
studies of the human deafness disorder DFNA9 showed that the mutations that cause it 
are all located in the LCCL part of the Coch-5b2 protein (reviewed in Trexler et al., 
2000). More importantly, one of these mutations, Trp91Arg, did not affect the overall 
structure of the protein, indicating that the progressive loss of hearing that is a result of 
the disease is not due to a structural change in the protein, but most likely caused by a 
failing ligand interaction between the LCCL domain and a yet unknown binding partner 
(Liepinsh et al, 2001).
In the horse shoe crab, the LCCL-containing Limulus clotting factor C protein is part of 
an antibody-independent host defense system against invading pathogens. It has been 
shown that the N-terminal part of the protein is involved in binding of LPS but it has not 
yet been proven that the LCCL domain mediates this interaction. Similarly, the 
mammalian late gestation lung protein-1 (lgll) is expressed at the same time during 
development as a number of anti-microbial proteins, raising the possibility that it has a 
similar function to these molecules.
A follow-up study to the P. falciparum sequencing project, using high-accuracy mass 
spectrometry, analysed the expression of developmentally regulated proteins in the 
parasite. Among proteins expressed during the sexual stages, four molecules containing 
LCCL domains, including P/SLAP, were identified (Lasonder et al., 2002; P/SLAP, 
PF14_0732, PF14_0732 and PFA07445w in Figure 3.24). Interestingly, all of these also 
carried lectin-like domains: Ricin B domains, found on CCP2, have been shown to bind 
simple sugars such as galactose and lactose, discoidin domains on PF14_0732 bind cell 
surface carbohydrates, a galactose-binding motif was identified on PFA07445w, and 
SRCR domains, found in PSLAP, have been suggested to bind carbohydrate surface 
molecules on bacteria (Bikker et al., 2002). Thus, binding of carbohydrates appear to be 
an important characteristic of sexual-stage parasites, perhaps playing a role in 
fertilization, evasion of host or vector immune responses, or in development within the 
mosquito. Indeed, it has been shown that lectins with specificities for N-acetyl-D- 
glucoseamine (GlcNAc) and N-acetyl-D-galactoseamine (GalNAc) residues bind to
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midgut sections from Aedes aegypti and Anopheles stephensi, respectively (Rudin and 
Hecker, 1989). The authors suggested that carbohydrates play a role in parasite 
recognition of, and migration within, the vector, stating that “If the parasite’s recognition 
of the vector tissue and subsequent penetration of the midgut epithelium depends on 
surface-exposed sugars, stage-specific lectin-like proteins should be on the parasite 
surface.”
Up until recently, extensive searches throughout available databases failed to identify any 
homologues of SLAP, or any molecules with similar domain composition (ie at least one 
copy of each domain in the query sequence). However, a recent search using BLAST 
identified an orthologue to Plasmodium  SLAP in another apicomplexan parasite. 
Toxoplasma gondii. This protein. Toxoplasma gondii Scavenger receptor 1 (TgSRl; 
accession no AAN74967), is 1247 residues long, shares 30% identity with P. falciparum 
SLAP and is made up of an identical set of domains, but with an additional C-terminal 
LCCL module (Figure 3.22). As in Plasmodium, this is the first SRCR-containing protein 
that has been identified in T. gondii, and nothing is yet known about its function. 
Extensive searches through a number of sequence databases, including the NCBI non- 
redundant database, failed to detect any other genes homologous to pslap.
Clearly, PSLAP is an interesting novel protein, not previously seen in any other species. 
Its high conservation within Plasmodium spp. indicates that PSLAP has an important 
biological function in the parasite. The multi-domain composition with several adhesive 
motifs suggests that PSLAP is involved in some type of interaction with other molecules. 
The finding that the SRCR-containing mosquito protein Sp22D responds to invading 
pathogens raises the possibility that PcSLAP might be used in molecular mimicry. It is 
known that Plasmodium infections cause up-regulation of mosquito genes involved in 
insect immune responses (Dimopoulos et al., 1997; 1998). A molecule with the ability to 
act in a similar way to Sp22D could potentially divert the host immune response away 
from pathogen destruction and thereby increase the parasite’s chances of survival.
The LCCL domain also has potential for ligand-binding. Multiple alignment showed that 
LCCL-1 has diverged more from the domain consensus sequence than LCCL-2 and -3.
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This could indicate an adaptation to a species-specific ligand interaction, whereas the 
other two modules may serve as structural elements within the PSLAP protein.
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Figure 3.1
Structure of the Vectorette adapter
The Vectorette adapter is a short DNA sequence with a sticky end that allows it to be 
ligated onto DNA digested with the appropriate restriction enzyme. The adapter is double 
stranded with a central mis-matched region where the DNA strands are non- 
complementary. The Vectorette primer, (hatched line underneath the Vectorette) has a 
sequence identical to one of these strands (hatched bottom strand), and therefore cannot 
anneal in the PCR until a complementary region has been amplified, initiated from the 
gene-specific, known primer.
Comptentao- Mis-matched paît Complementary
<  X --------------------------> < ’’^ >
Top strand  
3’
Sticky end 
3’ - r  -  -  5 ’
. Bottom  stran d
3’ ■  ■  ■  ■  5’
V ectorette P rim er
Figure 3.2
The Vectorette II System
The Vectorette II System allows identification and amplification of unknown DNA
sequences upstream and downstream of a known sequence. The method includes three
steps:
I .  Target DNA is digested with a restriction enzyme (R), generating fragments 
containing the known sequence (red) and fragments without this sequence.
I I . Vectorette adapters (blue), with a central mismatched region, are ligated onto the 
ends of the DNA fragments.
I I I . In the Vectorette PCR, the first round of amplification is from the gene-specific, 
known primer (KP) only. Since fragments without the known sequence cannot 
bind this primer, no amplification is initiated. In the second round, amplification 
takes place from both primers. The Vectorette primer (VP) has the same sequence 
as the mismatched portion of the bottom strand of the Vectorette, and can 
therefore anneal to the new strand produced in the first round of amplification.
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II. Ligation of Vectorette i 
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> >
I
Clone products 
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Figure 3.3
Primers used in the first Vectorette screen
Primers for the first Vectorette screen were based on the original pcslap2-jQ sequence. One 
reverse primer, Revl (red), for amplification of sequence upstream of pcslap2 2 o, and one 
forward primer, Forwl (blue), for downstream amplification, were designed. These were 
run in separate PCR reactions together with the Vectorette primer (not shown).
pcslap2nfs
AATGGATTTTCTAAACAACTATGTAGTGATATAGCAGGTGAAAATTTATGTGGTCATGAT
^ -----------------------------------------------------
ACAGAAAGAATTAATGCAACGAATTTTAGATGTAAAGGAGATGAAGCTAATTTAAAAAAT 1 2 0
TGCCCACATGAAACATCTGAAGATATTTACTGTTCTCACGAAGAAGATATAATTATTGGT 
TGTGCAAATGCAGAAGAAGATGGAGATGCTTCGACCAGTTCAACTAGCATTTCTAAATAT 2 4 0  
GGATTAAACAAACATATAATGTCAATGGA
Figure 3.4
Schematic representation of the position of pcslap2iQ in relation to the expected size 
of the full pcslap gene
Based on the sizes of the P. yoelii and P. falciparum slap genes (3816 and 3900 
basepairs, respectively) the full length of P. chabaudi slap was estimated to 
approximately 4000 basepairs. The schematic shows the predicted position of pcslap2 -jq 
(red) within the gene, based on sequence alignments between pcslap2 -io and the other two 
genes (data not shown). Primers Revl and Forwl, used for upstream and downstream 
amplification, respectively, are shown as half-head arrows.
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Figure 3.5
PCR products obtained in the first Vectorette screen
(A) Gel electrophoresis of PCR products from the first Vectorette screen. Ten pL of each 
product was loaded onto a 1% agarose gel. Shown on the left is the result from the 5' 
amplification, showing a band of approximately 1100 nucleotides (5':Seql, arrow) using 
the Revl primer and the SspI library. On the right is the result from the 3' amplification 
with primer Forwl and the SauAI library. An approximately 1100 basepair product was 
generated and designated 3':Seql (arrow). M = Marker VI, Roche. NT = negative control 
containing sterile water instead of template DNA.
(B) Products 5':Seql and 3':Seql were sequenced and their authenticity as extensions of 
pcslap verified. Primers for further gene identification were subsequently based on these 
sequences.
1 = Primer Rev2
2 = Primer Rev2:1 L Used in Second Vectorette screen
3 = Primer Forw2
4 = Primer Rev3:1 1 Used in conventional PCR for identification of 5' and 3'
5 = Primer Rev3:2 J &nds of pcslap
cr0O)
If)
2176
1230
1033
653
m
bp
2176-
1230-
1033-
653-
D"0cp
CO
H
B
5 ' : Seql
ATGGAAATGCAAAAGACATAGATTGTCATATACGTGCTAATGATTTAATAGATACAACTAAATCATTAAATAATAGTTTT
GTTTTACAAAATAAGGTACATATATTTAAAGTTCGATGCCCACAAAACTGTCATAGTTCCGATTTTTCTATCATAGAAGG 1 6 0
TACTTCTATACATCCTGCATCTACCTCTATATGTGCTGCAGCTATTTATGATGGTTCATTAACAGAAAGTGGAGGCGAAA 
TTATTGTTACTATAACAAAAGGATTAAATTATTATTATGCAATGGATGGCACATATAATAATTTAAAAGCAATTGAATTT 3 2 0  
TCTACCAAAGGTGATGAAAGTGATGAAAATAATTTCTCTTTTTATACATATCATTTGACATCTATTGATGATATAAAAAG 
TAATGTTAGAATCGTTGATTCTTTTGGAAAATTATCTTCTTTAGGAAGATTAGAAATTCGTGTAAATAATAAATGGGGAG 4 80 
CTGTTTGTAAAAAAGGTCCAAACTTTGAATTTTCAGAAGAGGCAGCAAAAAGAGCTTGTAAAGATTTAGGTTTTCCAAAT 
GGTATATATATTAGAGATACTTGCTCAAATATCAATGAACAAAATTATTGTGCTGGGTATAAATATCCATTTAATGCTTC 6 4 0  
TGGTATTTTATGTTCTGGAAATGAACAGAATTTATTATCCTGTAATACTGACGATCCTTCATATTGTATAGATCATCATG 
ATGATGTTATAATACAATGTGTTAATCAATTAGGTAACGATTCGATAGAAAACGGAACCATTCGACTTTTAGACAGCACT 8 0 0  
GGTGCACCTACATCTAATGGAATAGGAAGATTACAAATATATTACAATGGGGTATTCGGTTCTGTTTGTTCAGAAGGATG 
GACAAAAGAAACAGAAAAAATTGCATGTTTAGAATTAGGTTATCATAATGTAAAAGCA
3 ' :Seql
AAAAAAACAATTTCATCCCAAAATCGAATTAAGTTGCTTTGAGAAAATAAGTTCTAAAGCTGAATTGAGTAAAGGAAATG
TTGGAGATATATTTTTAGTCAGCTGCCCAGAAAAATGTGATGAAGATAGTGGTGTAATAAAAGGAACTTTTGTATACACA 1 6 0
TTCGATTCTTATATATGTAAAGCAGCTATACATGCAGGTGTTCTATCGAGTAATGTTGCTGATGATGTAGTTCTTATCAT
TACCCATAGTAGAAATAAATTTATAGGAACCAAAAGAAATAATGTAGAATCAAAAGAATTTAATGGTGAATCGAAAAGTT 3 2 0
T TAGC T TAAGTATACCAACAAAT TATAT CATAAT GGAAGAAAGACAAAATAAT T CAAAATAT GAAGAT GAAAT T T TAAAA
GATGATAATGATTTTTATTATGAACATATATTTAATAAACAAAATAATAATGAAAAAGGAAAAAATAAAACGTTTTTTGA 4 80
ACATAATATGCATCTAGAACCCACTTTTCAATGGATAGCTCCATCCTCTTTTACTGGATTCAATGGAAATGAAAATGAAT
3 -----
ATATAAATGCTAGTAATCTTCCTAATGAAAAATATATTAGAACTCTTTCTAATTTTACTTTTATTACACACTTCATTCCA 64 0
________________________kk.
AGTAGTAAAGGGAAAAATACATGGAGAACAATATTATCTCATAGTTTATGTGAAGGTATATCTATATCTATTGATGAAGA 
AAATGAATTAGTAATAGAACAAAATTGTAACCCTCATTTAATAAAAACTAAATTTATCCCAAAATTTGAACACCCTTATC 8 0 0  
ATCTGGTTCTAATTTATAACAAGCCAAATAAATCAATTTCTTTATATATTAATCAGAAAAAAATTAACCTTGAAAATATG 
AAAATCGATTTTACCCTAAATGGAGATTTAACTATTGGTAGATC
Figure 3.6
Schematic representation of sequences obtained in the first Vectorette screen 
relative to pcslap2iq and the full length gene
Product 5':Seql extended the known sequence of pcslap  938 nucleotides in the 5' 
direction, and 3':Seql identified 924 nucleotides in the 3' direction (both products shown 
in blue). Primers Rev2, Rev2:l and Forw2 designed for further sequence identification 
up- and downstream of the known sequence are shown as half-head arrows by the 
5':Seql and 3':Seql sequences.
The original gene sequence, pcslap2 io, is shown in red and sequences obtained by 
Vectorette PCR are shown in blue.
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Figure 3.7
PCR product obtained in the second Vectorette screen
(A) Gel electrophoresis of PCR reactions from the second Vectorette screen. Ten |iL of 
each product was loaded onto a 1% agarose gel. A 700 basepair product, designated 
3':Seq2, was generated in the 3' amplification attempt using the Rsal library (arrow). M = 
Marker VI, Roche. NT = negative control containing sterile water instead of template 
DNA.
(B) Product 3':Seq2 was sequenced and subsequently used to design primers for further 
sequence identification:
1 = Forw3:l
2 = Forw3:2
B3 ' : Seq2
bp
2 1 7 6 -
1230-
1033-
653-
517-
CCAAGTAGTAAAGGGAAAAATACATGGAGAACAATATTATCTCATAGTTTATGTGAAGGT 
AT AT CT AT AT C T AT T GATGAAGAAAAT GAAT TAG T AAT AGAAC AAAAT T GT AACC C TC AT 1 2 0
TTA A TA A A A A C TA A A TTTA TC C C A A A A TTTG A A C A C C C TTA TC A TC TG G TTC TA A TTTA T 
AACAAGC CAAATAAAT GAAT T T C T T TATA TA T TAAT CAGAAAAAAAT TAAC C T T GAAAAT 2 4  0 
ATGAAAATCGATTTTACCCTAAATGGAGATTTAACTATTGGTAGATCAAACAAACAAGCA 
A C TG A TTA C TTTA TA G G G G A TA TTA A TTTTG TTA A A A TTTA TA A A TA TA TA TTA A C A G A A  3 6 0  
CAAGAAAT TAAAGAGT C C T T T GAT T GAG T T G T T T GAAATAAT TAT T TAAAT GAT GGGATG 
T G T G GAAAT G GAAAGATAAATAGTAGAAAAATAGAAAATAAAAAAAGAAAAAAT CAAG GA 4 8 0
1 .
AAAAGTATAGATGGAGGTGATTGTATTAGTTCATGTAAATGGAAAAGGAATGTAAATAAA 
AA TATAGAAATTAATAGGGAAGAATTTTAGGTGAAGTGTTGAGATAATTTAGTGAGTGAG 6 0 0
GG ATTTAGTGGAAAAATTGGAAGTCAGTTTTTGGGTAGGTGTTCAGAAGATTGTGGTAGC
TGAAAATATATAGTAAAAGGGTGTAAGAATTAGTAGAGAGGAGAT
Figure 3.8
Schematic representation of sequences obtained in the second Vectorette screen 
relative to previously obtained sequence and the full length pcslap gene
Product 3':Seq2 (short blue bar) added 367 nucleotides to the known sequence of pcslap 
in the 3' direction. Primers Rev3:l, Rev3:2, Forw3:l and Forw3:2, subsequently used for 
conventional PCR for further sequence identification, are shown as half-head arrows.
The original gene sequence, pcslapjjQ, is shown in red and sequences obtained by 
Vectorette PCR are shown in blue.
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Figure 3.9
Alignment of 5'- and 3' un translated regions (UTRs) from the P. yoelii and P. 
berghei slap genes
The 5'- and 3' UTRs from P. yoelii and P. berghei slap were aligned in order to find 
regions of high conservation that could be used for designing degenerate primers to be 
used in the identification of the 5'- and 3' ends of P. chabaudi slap. Primers are shown as 
black half-head arrows in the figure.
(A) Alignment of the 5' UTRs from P. yoelii and P. berghei slap. Primer pslap.5':l was 
based on nucleotides 34-55 and pslap.5':2 on nucleotides 77-101. Both of these 
sequences shared complete identity between P. yoelii and P. berghei.
(B) Alignment of the 3' UTRs from P. yoelii and P. berghei slap. Primer pslap.3':l was 
based on nucleotides 61-82 in the alignment and pslap.3':2 on nucleotides 136-157. 
These two sequences each had one nucleotide differing between the P. yoelii and P. 
berghei sequences.
Red colour denotes identity between nucleotides, blue colour denotes difference between 
nucleotides.
The alignment was generated with the MegAlign sequence alignment program using the 
ClustalW algorithm.
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Figure 3.10
PCR product obtained from conventional PCR
(A) Gel electrophoresis of products from a conventional PCR using pcslap-spQcific 
primers and degenerate primers based on the 5'- and 3' pslap UTRs of P. yoelii and P. 
berghei. A  product of approximately 750 nucleotides was generated and designated 
3':Seq3.
M = Marker VI, Roche. NT = negative control containing sterile water instead of 
template DNA.
(B) Sequence of product 3':Seq3. Translation of 3':Seq3 revealed a C-terminal stop 
codon at position 597 (underlined) marking the end of the ORF.
Hbp
2000 -
1 6 0 0 -
1000 -
5 0 0 -
B
3 ' :S eq3
CTAGCTGTTCAGAAGATTGTGCTAGCTCAAAATATATAGTAAAAGGGTCTAACAATTACT 
ACACACCAGATACGTCAATATGTAAAGCAGTTATGCATTCAGGAATAATGCGTAAAAATA 1 2 0  
AT GAGC A TGATAAGGAT GATAAC GAAAATAATAAAAAT TC G TTTA TTA TA A A A A T T GT T G 
AA GGCTTAACAGAATATAAATCATCTAGAGGTCATTTTGGAATCATTTCAAAAGCAGAAA 2 4 0 
A A C A A TG A G A A TTA A G A TC C TTTTC TC TTTTTTC A A A A A A TG A A G A TG A TA TTTTTA C A T 
GTTTTA CA G A TG G A TC A TTTTTA TTTG A A TTA C C TA TTG G A A G TA C A A A A A A TA TTA TTT 3 6 0  
GTCCCGAGAATTGCCATAAAATCGATAAACAAATATACGGAACTAATACATATAGTCCTT 
TA TC TTC TG TTTG TA A A G CAG CTA TA CATGCAG GTGTTA TTTCA ATAAA GGG AGG TCA AA 4 8 0  
TACAAGT T GTT GT T GGGAAAGGT CAACAAGAATTTAAACCATCCACACAAAATAAT GT T C 
AA TCA TA TA TA G CA G A A A A A CA A G A TCG TTCA TTCA CCTTTTTCA A G CG CTTA TA TTA G T 6 0 0  
TA TG C A A AATATGTATACTTA CATAATGTGTAA TTACATTAGTCTAACCA AAA GTAAG TA 
A A A A A TA G A A TG A TA TTTTTTTTTA TTA A G TTC A A A TTA A A A C A A TTTTG TG TTTG TTTC  7 2 0  
TATTCAACCAATACAAATTAG
Figure 3.11
Schematic representation of product obtained from conventional PCR relative to 
previously obtained sequence and the full length pcslap gene
The 741 nucleotides long product 3':Seq3 (green) translated into an ORF terminated by a 
C-terminal stop codon at position 597 in the sequence. The position of the end of the 
gene was predicted from alignments with the P. yoelii slap gene.
The original gene sequence, pcslap2 iQ, is shown in red, sequences obtained by Vectorette 
PCR are shown in blue and sequence generated by conventional PCR is shown in green.
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Figure 3.12
Contig from the P. chabaudi genomic contigs sequence database
Reverse complement sequence of a P. chabaudi 2053 nucleotide long contig, identified in 
a BLAST search through the genomic contigs database. The 3' end of the contig aligned 
with the identified pcslap sequence. The ATG start codon initiating the pcslap ORF at 
position 460 in the sequence is underlined.
> 1 2 0 2 8 6 8 . C 0 0 0 7 0 3 2 9 5.Contlgl (reverse complement)
TTCATATATCATTTAAAATGGGATGTGCATAAATGTACAGAAACATATGAAATTTTGTTA 
TTGAACATTTAGTAATAAGAAAAGCATTTGCTTAATTTGGTGAATTTGTTGAACAGATTC 1 2 0  
GTGATAAATAACAACAATAGTTACTTGGGTTATTAAATTCTCGCACACACACATACTGTG 
TATATATATATTCATAAGTTTATTTTCATATTATAGTTTTTTTATACATTGTAAGTTTTT 2 4 0  
TTTTTCAGACTAGCATAGTGCGCCTTTTTAACCTATAAATTTTTGTCTAAAAGGTATTTT 
TAGTGTCCAATATTTTTAAGCATATTACTTGTGCAGGTTTTTTTTTTTAGCTAGCTATTT 3 6 0  
GTGTGCAAAAAATTATTAACAGGACATAAAAAAAAATAGTTATATAATAAAGTTGAGATA 
CACCCTTCCATATATTTTTTCATATTTTTAGTGAAGAAAATGAGAATCTATAACTGGGTT 4 80  
AGTTGTGGATTTATATTTTTGCAATTTTTTCTGAGCGCATATGGAAAGGAATGGTGCAAA 
GCAAAATTTGAATATGGAATGTCTGATTATGCAGAGTGCCAAAAAGAAGGAGATAATCTA 6 00  
ACGAAATATATGATTGAAATAATTCCTGCTAAAGCAAATAATATAGATTTATATAGTGAT 
GTTTCAATAGTTTTATCGAATTCTCAAGGTATTAATACTAAAGAAATAATTATTGGTAGT 7 2 0  
GAAAAAGAAGGACTATTTAGAAAAATATATTCGGTTAGAAAAGATATAGATAATCCAGAA 
TATATTCATGTAAAATTAAATTCGAAAATAAATAATAATAGAAATTGGAAATGTAAAAAA 8 4 0  
ATAAAAGTTTGGAAAGAATATAAGTATTGGACTTTTGAttgTATAGGTATATTAAATGAA 
GAAAAACAAGAAGCAACATATTTCTTGTCTGGTAATAAATTATATACTGCTTATGTTCAA 9 6 0  
ACAGGAAAAGATATAGAAGCAGGTACTACTGGAATTATAGATATAATATTACTAGGTAAT 
AACAACAAAAGAAGTAATACA7VAAATGCTACATGAAGGATTTACATCTGGCGGATTAAAA 1 0 8  0 
AAAATAAAATTTCAAGCATCAGATGTAGGAAATTTAGAAAATATAATATTAATAAACAAT 
TCTTATAATGATCCATGGTATTGTGATTTTGTTAAAATAAAAGGTGATGATAACAAAGTT 1 2 0 0  
TATGTTTTCAATGTAAAAAGTTGGATTGGTTATCCATATAATAATAAAATAAAAATAAAT 
ATAAATACAAATAATATTGATGGAAATGCAAAAGACATAGATTGTCATATACGTGCTAAT 1 3 2 0  
GATTTAATAGATACAACTAAATCATTAAATAATAGTTTTGTTTTACAAAATAAGGTACAT 
ATATTTAAAGTTCGATGCCCACAAAACTGTCATAGTTCCGATTTTTCTATCATAGAAGGT 1 4 4 0  
ACTTCTATACATCCTGCATCTACCTCTATATGTGCTGCAGCTATTTATGATGGTTCATTA 
ACAGAAAGTGGAGGCGAAATTATTGTTACTATAACAAAAGGATTAAATTATTATTATGCA 1 5 6 0  
ATGGATGGCACATATAATAATTTAAAAGCAATTGAATTTTCTACCAAAGGTGATGAAAGT 
GATGAAAATAATTTCTCTTTTTATACATATCATTTGACATCTATTGATGATATAAAAAGT 1 6 8  0 
AATGTTAGAATCGTTGATTCTTTTGGAAAATTATCTTCTTTAGGAAGATTAGAAATTCGT 
GTAAATAATAAATGGGGAGCTGTTTGTAAAAAAGGTCCAAACTTTGAATTTTCAGAAGAG 1 8 0 0  
GCAGCAAAAAGAGCTTGTAAAGATTTAGGTTTTCCAAATGGTATATATATTAAAGATAAT 
TGCTCAAATATCAATGAACAAAATTATTGTGCTGGGTATAAATATC CATTTAATGCTt c T  1 9 2  0 
GGTATTTTATGTTCTGGAAATGAACAGAATTTATTATCCTGTAATACTGACGATCCTTCA 
TATTGTATAGATCATCATGATGATGTTATAATACAATGTGTTAATCAATTAGGTAACGAT 2 0 4  0 
TCGATAGAAAACG
Figure 3.13
Schematic representation of position of the P. chabaudi contig relative to the 
identified pcslap gene sequence
The P. chabaudi contig was translated and an ORF with a start codon 460 nucleotides 
into the sequence was identified. This sequence (orange) was added to the already 
obtained sequence of pcslap and completed the gene. The ORF of the gene was shown to 
be a total of 3897 base pairs.
The original gene sequence, pcslap2 iQ, is shown in red, sequences obtained by Vectorette 
PCR are shown in blue, the sequence generated by conventional PCR is green and the 
sequence from the contig is shown in orange.
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Figure 3.14
Sequence of the full-length coding sequence of pcslap
The identified sequence of P. chabaudi slap was shown to be 3897 nucleotides long, 
translating into a continuous ORF of 1298 amino acids without introns.
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Restriction map of pcslap
Sites of cleavage by each of the four restriction enzymes Rsal, SauSAI, SspI and XhoII 
are shown as black lines across grey bars representing the pcslap gene. The numbers 
above the restriction sites denote the exact position of cleavage in the nucleotide 
sequence of pcslap. The positions of pcslap2-jo ^^d pcslap2 iso, used as probes in Southern 
analysis, within pcslap are shown in red and orange, respectively.
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Southern analysis of P. chabaudi genomic DNA using pcslap2qQ as a probe
P. chabaudi genomic DNA was isolated and aliquots digested with Rsal (lanes denoted 
1), SauBAI (lanes denoted 2), SspI (lanes denoted 3) and XhoII (lanes denoted 4). 
Expected bands are listed in Table 3.2.
(A) The digested DNA was resolved on a I % agarose gel along with À/HindIII marker 
(M) and transferred to a nylon membrane.
(B) Hybridisation was performed over night with [a-32P]-dATP-labelled pcslap2 -jo, Sit 
65°C. A single band can be seen in each restriction digest.
(C) Hybridisation was performed over night with [a-32P]-dATP-labelled pcslap2 -]o, at 
55°C. Two bands appear in each restriction digest.
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Southern analysis of P. chabaudi genomic DNA using p c s l a p as a probe
P. chabaudi gDNA, digested with Rsal (lane 1), SauSAI (lane 2), SspI (lane 3) and XhoII 
(lane 4) was blotted as in Figure 3.19, and probed over night with [a-32P]-dATP-labelled 
pcslap2 i2 o at 55°C. As the restriction enzymes used to digest the DNA cut within the 
probe sequence, several bands are expected in each digest (Table 3.3).
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Figure 3.18
Alignment of P, chabaudi pcslap2^  and the homologous sequences in P. berghei and 
P. yoelii
Alignments of pcslap2jo from P. chabaudi with the homologous sequences in P. berghei 
and P. yoelii. The comparison was carried out in order to ensure that there was sufficient 
identity between the sequences for Southern analysis hybridisation of pcslap2 jo to P. 
berghei and P. yoelii genomic DNA.
(A) Alignment of pcslap2iQ nucleotide sequence in P. chabaudi with the homologous 
sequence in P. berghei ANKA. The overall identity was 91%.
(B) Alignment of pcslap2-jo nucleotide sequence in P. chabaudi with the homologous 
sequence in P. yoelii. The overall identity was 90%.
Red colour denotes identity between the residues in all sequences, green colour denotes 
residue dissimilarity in one sequence and blue colour denotes dissimilarity between 
residues in all three sequences.
The alignment was generated with the MegAlign sequence alignment program using the 
ClustalW algorithm.
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Figure 3.19
Southern analysis of P. yoelii and P. berghei slap using pcslap2-jQ as a probe
Genomic DNA from P. chabaudi, P. yoelii and P. berghei was digested with SauSAI and 
SspI, resolved on a 1% agarose gel and probed with [a-32P]-dATP-labelled pcslap2-,oBt 
55°C. Expected bands are listed in Table 3.4
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PcSLAP secondary structure
Analysis of the PcSLAP protein showed three types of sequence motifs: two Scavenger 
Receptor Cysteine-Rich (SRCR) domains (green), three Limulus factor C, Coch-5b2 and 
Lgll (LCCL) modules (blue) and one Lipoxygenase Homology 2/Polycystin-l, 
Lipoxygenase and a-Toxin (LH2/PLAT) domain (red). A signal sequence (dark red) is 
located at the N-terminal of the protein.
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Multiple alignment of Scavenger Receptor Cystein-Rich (SRCR) domain sequences
PcSLAP SRCR-1 and SRCR-2 were aligned with SRCR domains from other proteins 
from the SRCR superfamily. Similar residues are aligned and shown in the same colour. 
Gaps in the sequences signify positions that represent deletions within one sequence 
relative to another. The stars mark the six conserved cysteine residues shared by all 
members of the family.
The alignment was generated using the SMART database and Hmmalign with the
ClustalW algorithm.
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Proteins with Scavenger Receptor Cysteine-Rich domains
Domain key
I SRCR domain 
C D  LCCL module
LH2/PLAT domain
von Willebrand factor repeats 
C Z )  Extracellular matrix-like domain 
°  Signal peptide
H Transmembrane domain
Chitin-binding type 2 domain
t
Low-density lipoprotein receptor class A domain i Parallel p-helix repeats
Trypsin-like serine protease domain
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Figure 3.23
Multiple alignment of LCCL domain sequences
PcSLAP LCCL-1, LCCL-2 and LCCL-3 were aligned with other LCCL-containing 
proteins from the SMART sequence database. LCCL domains contain up to eight 
cysteine residues (potential positions marked by stars), four of which are highly 
conserved. A seventeen residue conserved motif is located near the C-terminal end 
(underlined in the consensus sequence) and is believed to be the core of the module.
The alignment was generated using the SMART database and Hmmalign with the
ClustalW algorithm.
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Proteins with Limulus factor C, Coch-5b2 and Lgll (LCCL) domains
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I I SRCR domain 
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Figure 3.25
Multiple sequence alignment of the nucleotide sequence of the slap gene in P. 
chabaudi, P. yoelii and P. berghei
Alignment of the open reading frames of P. chabaudi (3897 nucleotides), P. yoelii (3900 
nucleotides), and P. berghei (3915 nucleotides).
Red colour denotes identity between nucleotides of all sequences, green colour denotes 
nucleotide dissimilarity in one sequence and blue colour denotes nucleotide 
dissimilarities between all three sequences.
The alignment was generated with the MegAlign sequence alignment program using the 
ClustalW algorithm.
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Figure 3.26
Multiple sequence alignment of the PSLAP protein sequences in P. chabaudi, P. 
yoelii and P. berghei
Alignment of PSLAP coding sequence from P. chabaudi (1298 residues), P. yoelii (1300 
residues), and P. berghei (1305 residues).
Red colour denotes identity between residues in all sequences, green colour denotes 
residue dissimilarity in one sequence and blue colour denotes dissimilarities between 
residues of all three sequences.
The alignment was generated with the MegAlign sequence alignment program using the 
ClustalW algorithm.
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Figure 3.27
Alignment of the nucleotide sequences of Plasmodium slap in P. chabaudi and P. 
falciparum
Alignment of the open reading frames of P. chabaudi (3897 nucleotides) and P. 
falciparumi (3816 nucleotides).
Red colour denotes identity between nucleotides in all sequences, green colour denotes 
nucleotide dissimilarity in one sequence and blue colour denotes nucleotide 
dissimilarities between all three sequences.
The alignment was generated with the MegAlign sequence alignment program using the 
ClustalW algorithm.
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Figure 3.28
Alignment of the PSLAP protein sequences of P. chabaudi and P. falciparum
Alignment of the PSLAP coding sequence from P. chabaudi (1298 residues) and P. 
falciparum (1269 residues).
Red colour denotes identity between the residues in all sequences, green colour denotes 
residue dissimilarity in one sequence and blue colour denotes dissimilarity between 
residues in all three sequences.
The alignment was generated with the MegAlign sequence alignment program using the
ClustalW algorithm.
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Chapter Four
PSLAP transcription, expression and localisation
4.1 Introduction
Chapter Three identified PSLAP as a novel molecule with a complex domain 
composition not previously reported in biology. The analysis showed that PSLAP carries 
two SRCR domains, two LCCL rnodules and an LH2/PLAT domain, all motifs 
implicated in receptor-ligand interactions. Recent studies suggest that SRCR domains 
bind surface carbohydrates, whereas the LH2 motif is associated with membrane or lipid 
interactions (Bikker et al., 2002). Although no precise function or ligand has yet been 
proposed for the LCCL module, recent studies suggest that it is involved in binding to 
other molecules (Liepinsh et al, 2001).
As a parasite Plasmodium is highly dependent on molecular interactions with its hosts in 
order to survive and develop. Critical events such as evasion of host immune responses, 
host cell invasion and migration are all reliant on receptor-ligand interactions between 
parasite and host. The importance is clearly reflected in the parasite’s genome, where a 
very small part consists of genes encoding enzymes and transporter proteins, and as much 
as 1.3% of identified genes code for molecules involved in either adhesion or immune 
evasion (Section 1.9; Gardner et al., 2002).
A number of different adhesive domains have been identified in Plasmodium. Some of 
these motifs are present in several molecules, making up families of proteins with similar 
characteristics, such as the cysteine-rich Duffy Binding-Like (DBL) domain in the 
Erythrocyte Binding Protein (EBP) family. The DBL motif determines ligand-specific 
recognition and binding of vertebrate erythrocytes, and the family includes the P. 
falciparum protein Erythrocyte-Binding Antigen-175 (EBA-175) and the P. vivax Duffy 
Binding Protein (DBP), both involved in erythrocyte invasion, but also the variant surface 
antigen P/EMP-1, responsible for cytoadhesion to the vertebrate endothelium (Section 
1.7.1). Because of a relatively high sequence variation, the DBL domains of different
87
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EBP proteins interact with a diverse set of erythrocyte receptors, including ICAM-1, 
complement receptor-1 and heparan sulphate (P/EMP-1), Glycophorin A (EBA-175) and 
Duffy blood group antigen (DBP; Smith et al., 2000; Rowe et al., 1997; Chen et al., 
1998; Orlandi et al., 1992; Miller et al., 1976).
The expression profiles of Plasmodial proteins that carry adhesive domains are specific 
both in time and space, and reflect the different functions of the molecules. An 
understanding of the timing of transcription of the genes encoding these proteins, as well 
as their location, is crucial for identifying a function. For example, the var genes that 
encode P/EMP-1 are transcribed during the erythrocytic blood stages in asexual parasites. 
This is significant since, as mentioned above, P/EMP-1 functions as a sequestration 
receptor that allows the infected erythrocyte to adhere to various ligands on the 
endothelium in the vertebrate host. Cytoadhesion prevents destruction of parasitised 
erythrocytes in the spleen, which filters the cells in the blood by recognizing subtle 
changes in the rigidity of the red blood cell membrane. Adhering to the host blood vessels 
allows the parasite population to survive and expand, thereby establishing an infection.
At present, the molecular parasite-host interactions that take place during the vertebrate 
stages are known in more detail than the mosquito phases of parasite development. This 
may be, at least in part, due to the greater difficulty in obtaining pure and large enough 
quantities of parasite material from mosquito stage parasites (Ghosh et al., 2003). 
However, the complex series of developmental transitions inside the mosquito involves 
numerous interactions of parasite proteins with host cell molecules. One such event is the 
involvement of the ookinete protein CSP- and TRAP-related protein (CTRP) in mosquito 
midgut invasion. Sequence analysis of P. falciparum  CTRP had shown a predicted 
structure of several domains with adhesive properties, including six von Willebrand 
factor type-A related domains and seven human thrombospondin type-1 domains. 
Transcription studies of the P. berghei homologue using Northern analysis demonstrated 
that the ctrp gene was active in ookinetes but not in erythrocytic stage parasites. Indirect 
immunofluorescence confirmed the presence of the protein in mosquito-stage parasites, 
showing expression throughout ookinete development, mainly located to the micronemes 
(Yuda et al., 1999). The micronemes, together with the rhoptries and dense granules.
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make up the apical complex, a collection of secretory organelles whose contents are 
thought to be involved in host cell recognition and attachment (Dubremetz et al., 1993). 
Consequently, a theory that CTRP played a role in midgut invasion was formed, and later 
verified by ctrp gene disruption in P. berghei. It was shown in dissections of parasite- 
infected mosquitoes that CTRP-deficient ookinetes were unable to enter the midgut 
epithelium, as well as to migrate through the epithelium to the hemocoelomic side of the 
midgut (Dessens et al., 1999).
In a similar way, the function of the parasite protein MAEBL was suggested by its 
location. Immunofluorescence analysis showed expression of MAEBL in the micronemes 
of mosquito-stage sporozoites. However, closer examination revealed that the protein was 
present in midgut sporozoites collected from oocysts, but not in salivary gland 
sporozoites. This indicated that MAEBL played a role during the stages between late 
oocyst development and sporozoite translocation to the salivary glands, but not later for 
maturation within the glands or subsequent development inside the vertebrate host. This 
was confirmed when disruption of the P. berghei maebl gene resulted in an accumulation 
of sporozoites in the mosquito hemolymph, but none were found inside, or associated 
with, the salivary glands, suggesting that MAEBL functions as a sporozoite binding 
ligand for the initial attachment to the surface of mosquito salivary glands prior to 
invasion (Kariu et al., 2002).
Chapter Three discussed the nucleotide sequence and protein structure of PSLAP. The 
present chapter continues the examination of the PSLAP gene and protein in blood-stage 
parasites. Analysis of pslap transcription, as well as the generation of anti-PcSLAP 
antibodies, and their use in determining the stage-specificity of expression of the PSLAP 
protein and its sub-cellular localization is described.
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4.2 Results
4.2.1 Expression and purification of PcSLAP for generation of antibodies
In order to study PcSLAP, antibodies were raised against part of the molecule in mice 
and rabbits. A 270 base pair nucleotide sequence of the pcslap gene, cloned into the 
pTrcHisC expression vector (Invitrogen), was translated and expressed in Escherichia 
coli DHIOB cells as a hexa-histidine-tagged fusion protein. The expressed sequence, 
designated PcSLAPgo, was 90 residues long and included the C-terminal half of SRCR-2 
and 28 residues of the sequence between SRCR-2 and LCCL-2 (Figure 4.1).
Expression was induced by addition of IPTG (one mM final concentration) and a small- 
scale test-run was performed with culture samples collected at one hour intervals for 
seven hours (Section 2.8.1). The samples were solubilised and centrifuged, and pellets 
and supernatants analysed separately by SDS-PAGE (Figure 4.2 A). The expressed 
protein was identified in the pellet fractions, demonstrating that it is not soluble. 
Maximum expression was found to take place at five hours post-induction, thus this time 
point was used for subsequent expression and purification of PcSLAPgo on a larger scale.
Purification was performed by capture on a nickel-nitrilotriacetic (Ni-NTA) matrix, and 
the protein was eluted with 200 mM imidazole. A second purification step was carried 
out over an FPLC gel filtration column (Superdex 200 prep grade matrix, Amersham 
Pharmacia Biotech; Section 2.8.2). Eluted fractions that corresponded to high OD280- 
values were analysed by SDS-PAGE in order to identify the peak corresponding to 
PcSLAPgo (data not shown). The correct fractions were pooled and concentrated under 
pressure in an Amicon concentrator. The concentrated sample was run on a 
polyacrylamide gel, followed by Coomassie-staining to ensure that no major 
contaminants were present in the preparation (Figure 4.2 B). Lastly, the protein was re­
folded in order for it to be used in mouse and rabbit immunisations, by removal of the 
high level of urea (eight molar) through slow dialysis against PBS. Recovery in the final 
preparation was determined spectrophotometrically by absorption at 280 nm and by 
comparison with a quantitative protein marker in SDS-PAGE, and found to be 
approximately 11 mg (data not shown).
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4.2.2 Immunisation with PcSLAPpo and characterisation of anti-PcSLAP plasma by 
ELISA
Four female BALB/c mice were immunised and boosted with the purified PcSLAPgo 
protein and subsequently bled for plasma, which was tested for anti-PcSLAP reactivity 
using a PcSLAP-specific ELISA (Sections 2.9.1 and 2.10.3.1). The assay showed high 
levels of PcSLAPgo-specific antibodies, with plasmas from all mice having titers over 
100,000 (Figure 4.3). To control for non-specific binding to PcSLAPgo by naturally 
occurring antibodies present in normal plasma, the assay also included plasma from un­
treated mice as a background control (NP control in Figure 4.3). These results were 
negative, confirming that normal BALB/c plasma did not react with the expressed portion 
ofPcSLAP.
Polyclonal anti-sera to PcSLAPgq were also raised in rabbits (Section 2.9.2). Reactivity of 
the sera with PcSLAPpo was tested for as with the mouse plasmas above, and again 
showed titers of above 100,000 (419 and 431 in Figure 4.4). Pre-immune sera from the 
rabbits were used as negative controls and displayed no binding to the PcSLAPpo protein, 
demonstrating that the reactivities seen with the immune sera were due to the presence of 
induced anti-PcSLAP^o antibodies (Figure 4.4).
All plates in both assays also included duplicate wells of diluent in place of plasma or 
serum, so called “blanks”. An average of the two blank values was subtracted from the 
OD^Qg-readings obtained from immune and normal plasma/serum on the same plate and 
then used for plotting the graph, and therefore no separate blank readings are shown in 
the figures.
The readings from the blank wells were in all cases below OD405=0.1.
4.2.3 Anti-PcSLAP plasma recognises P. chabaudi blood stage parasites
To test whether the generated anti-PcSLAP antibodies recognised the native PcSLAP 
protein, and whether this is expressed during the blood stages of the parasite life cycle, an 
ELISA was performed using a lysate made from predominantly late trophozoite- and 
schizont stage P. chabaudi parasites (Section 2.10.4).
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Negative controls using plasma from un-treated animals showed that there was no non­
specific binding of components in normal mouse plasma to the parasite preparation (NP 
control in Figure 4.5). To ensure that the assay itself worked, plasma from mice 
repeatedly infected with P. chabaudi, referred to as “hyperimmune plasma” (HIP; 
Section 2.9.3), was included. A strong reactivity with the parasite lysate confirmed that 
this was the case (HIP control in Figure 4.5).
Although low, all anti-PcSLAP plasmas showed reactivity with the parasite preparation. 
End point titers ranged between 500 (Mouse 2) and 2000 (Mice 3 and 4; Figure 4.5). 
Repeats of the experiment produced similar results, confirming that the polyclonal anti- 
PcSLAP antibodies recognised the PcSLAP protein, but that the levels of the protein 
present in the blood-stage lysate were low.
4.2.4 Western analysis of PcSLAP
The results from the ELISA suggested that PcSLAP was present in the P. chabaudi 
blood-stage parasite lysate, however, the reactivity was low and this prompted 
examination of the expression of PcSLAP by Western analysis (Section 4.2.4). Western 
analysis also gives an experimental estimation of protein size. The theoretical molecular 
weight of PcSLAP had been determined to 147 kilodaltons (EditSeq sequence analysis 
program).
The first parasite preparation tested was a lysate of P. chabaudi (mainly trophozoites and 
schizonts) similar to that previously recognized by the PcSLAP antibodies in ELISA 
(Section 4.2.4). The lysate was resolved by SDS-PAGE (10% gel) under both reducing 
and non-reducing conditions, blotted onto nitrocellulose and tested for immunoreactivity 
with the four individual PcSLAP^Q-specific plasmas. Hyperinunune plasma was used as a 
positive control in the assay and normal mouse plasma from un-infected mice was 
included as a negative control. Hyperimmune plasma reacted strongly with proteins of a 
wide range of sizes, demonstrating that the assay worked. However, no reactivity was 
observed with the anti-PcSLAP antibodies (data not shown). Despite repeats of the 
experiment no bands were produced.
It was subsequently reasoned that the PSLAP protein may have been lost in the process 
of lysate preparation. As it was shown in Chapter Three that PcSLAP has a signal
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sequence, the protein could be secreted into the erythrocyte and would thus be lost when 
the cells were lysed and centrifuged. The protein could also be sensitive to freezing and 
may have degraded since the lysate was made. It was therefore decided to use whole 
infected erythrocytes, prepared without discarding any material. Fresh, parasitised blood 
was obtained from a P. chabaudi-infQciQd mouse (Table 4.1), mouse leukocytes removed 
by Plasmodipure filtration and the contents of the lysed cells resolved under reducing and 
non-reducing conditions by SDS-PAGE. The assay included the same controls as above, 
as well as samples of non-infected blood, prepared identically to the parasitised blood and 
incubated with the same antibodies. Three out of four of the anti-PcSLAP plasmas 
reacted with the lysate and produced some bands, however these were also seen with the 
normal mouse plasma. Two bands at approximately 45 kDa and 80 kDa appeared to be 
specific to the plasma from Mouse 3, and could represent breakdown products of 
PcSLAP. However, this result was not reproducible despite numerous attempts, and 
therefore no conclusions can be drawn from this record (data not shown). The Western 
analysis was repeated several times with amendments to the protocol, including longer 
incubations and more concentrated plasma samples, but without success (data not 
shown).
4.2.5 Anti-PcSLAP plasmas react with fixed P. chabaudi parasites 
In order to further analyse the expression of the PSLAP protein in blood-stage parasites, 
and to investigate its subcellular location, indirect immunofluorescence assays (IFA) 
were performed. Thin blood films were made from P. chabaudi-mfQciQd mice bled at 
parasitemias of 15-25 %, fixed with acetone and stored at -20°C (Section 2.12). Giemsa- 
staining of the slides and analysis by light microscopy was carried out in order to 
determine the relative proportion of different developmental stages in the preparation 
(Table 4.2). To avoid binding of the secondary antibody used in the assay, goat anti­
mouse IgG-FITC, to antibody present in the collected blood, P. chabaudi-ixdQcXQÔ. B cell- 
and antibody-deficient pMT mice were used as a source of infected erythrocytes 
(Kitamura et al, 1991).
The four plasmas from the PcSLAPgo-immunized mice were tested individually on the 
fixed blood smears. The slides were also stained with 4,6-diamidino-2-phenylindole
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(DAPI) to distinguish infected erythrocytes from un-infected ones (mature erythrocytes 
lack nuclear material). A previously characterized monoclonal antibody against P. 
chabaudi MSP-1, NIMP23, was used as a positive control and produced a distinct 
circular pattern of staining, demonstrating that the assay worked (McKean et al., 1993; 
Figure 4.6 C). A negative control using plasma from un-treated BALB/c mice, included 
to ensure that there was no binding of antibodies present in normal plasma, did not show 
any fluorescence (Figure 4.6 E). A control for non-specific binding of the fiuorochrome- 
conjugated secondary antibody (anti-mouse IgG-FITC) to the cells was also negative 
(Figure 4.6 F).
When testing the anti-PcSLAP plasmas, specific staining was observed with antibodies 
from Mouse 1 and Mouse 3, producing a similar pattern of staining. The fluorescence had 
a punctate appearance with a more intense staining at the center of the fluorescent area 
and somewhat blurred edges, suggesting cytosolic, rather than surface labeling (Figure
4.6 A). The close proximity to the parasite nucleus suggested that the plasmas were 
recognizing a component of the parasite and not the erythrocyte. A manual increase in the 
fluorescence intensity visualised the outline of the host cell membranes, and revealed that 
the staining ranged from occupying a small area immediately surrounding the nucleus, to 
extending throughout the entire cell. It also showed that the boundaries of fluorescence 
were well-defined, suggesting that the labeled molecule is expressed and contained 
within the parasite cytosol, and not exported into the erythrocyte cytoplasm (Figure 4.6 
B). Figure 4.7 show further examples of the observed PcSLAP staining patterns. These 
experiments were repeated at least five times with the same result.
As compared with the total number of infected cells, identified by DAPI-stained nuclei, 
very few were also labeled with the anti-PcSLAP plasmas (Figure 4.8). Several repeats of 
the assay, as well as the fact that the positive control worked, confirmed that the 
scarceness of labeled cells was not due to an experimental artifact. Approximately 0.3% 
of the total number of parasitised erythrocytes were positive for PcSLAP. This small 
proportion of labeled cells suggested that the antibodies recognized a specific subset of 
blood stage parasites, and suggested that the expression of PSLAP is carefully controlled 
in space and/or time. Interestingly, the percentage matched the small numbers of
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gametocytes normally present in P. chabaudi blood stage infections, and prompted a 
careful examination of the numbers of parasites at different developmental stages on the 
slides used in this experiment. Table 4.2 shows the differential counts, with a percentage 
of gametocytes at approximately 0.4%, a number that compared well with the proportion 
of PcSLAP-positive cells (0.3%). Alternatively, the protein may be expressed only during 
a very short window of time during another stage of development.
The two PcSLAPço anti-sera raised in rabbits were also tested in indirect 
immunofluorescence assays. Pre-immune sera from each respective rabbit were included 
as negative controls. However, a high level of background fluorescence was observed in 
these controls. In addition, the PcSLAP-specific sera stained infected as well as 
uninfected erythrocytes (data not shown). The secondary antibody (goat anti-rabbit IgG- 
TRITC) had been used previously and so was known not to cross-react with mouse 
preparations. However, non-specific reactivity is not an uncommon problem with 
polyclonal rabbit sera and is probably due to naturally occurring anti-mouse antibodies in 
rabbits. To overcome these difficulties and remove the pre-existing anti-mouse 
antibodies, the rabbit sera (immune and pre-immune) were adsorbed onto fresh 
uninfected mouse erythrocytes. Staining with lower concentrations of sera and secondary 
anti-rabbit antibody was also tried. However, the sera kept reacting with uninfected 
erythrocytes on the fixed blood preparations. It was therefore decided to use the mouse- 
derived plasmas instead of the rabbit sera in subsequent assays.
4.2.6 Northern analysis of pslap transcription
The ELISAs and immunofluorescence assays had shown that PcSLAP is present during 
the erythrocytic stages of the P. chabaudi life cycle, with an indication towards specific 
expression in gametocytes (Sections 4.2.3 and 4.2.5). In order to investigate the time and 
stage of transcription of the pslap gene. Northern analysis was performed using all 
developmental forms present in a blood-stage infection.
During the blood-stages the majority of parasites are asexual. However, the only intra- 
erythrocytic form that can survive transmission to a mosquito is the gametocyte, and 
therefore a small number of asexual parasites transform into sexual forms (Section 1.3).
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The number of gametocytes generated in an infection varies between parasite species. P. 
chabaudi produces relatively few gametocytes, which makes isolation difficult (Figure 
4.9 top graph). However, other species, such as P. berghei, generate a higher proportion 
of sexual parasites, and it was therefore decided to include a sample of P. berghei 
purified gametocytes, as well as a sample of mixed asexual P. berghei parasites in the 
assay (Figure 4.9, bottom graph). This was possible due to the high degree of 
conservation of the slap gene within rodent Plasmodia, as verified by an alignment of the 
probe sequence used for the hybridization from the two species, which showed 93% 
identity (Figure 4.10). The probe had been specifically chosen to corresponded to a 
region of pcslap that did not code for any secondary motifs, as some of these (the LCCL 
modules) are known to be present in other proteins in Plasmodium, and could potentially 
bind the probe and produce a false positive result (Figure 4.12). The 252 base pair long 
srequence, named pcslap2si, was part of the 3':F1 Vectorette PCR fragment that was 
produced when the full sequence of the pcslap gene was being identified (Chapter Three, 
Section 3.2.1.1).
To control for hybridization to contaminating, co-purified mouse RNA from leukocytes 
and reticulocytes, a sample of blood from an un-infected mouse was prepared alongside 
the parasite preparations (Section 2.4.11). In order to avoid contamination with asexual 
parasites within the P. berghei gametocyte preparation, the infected mice were treated 
with pyrimethamine prior to parasite collection (Section 2.13.8). Pyrimethamine is a 
folate antagonist that interferes with DNA synthesis (Section 5.1). In a blood stage 
malaria infection, treatment with pyrimethamine kills replicating asexual parasites, 
whereas non-replicating gametocytes survive (Ferone et al, 1969).
Parasitised blood was collected from a highly synchronous infection of P. chabaudi at 
specific time points in order to obtain as high as possible a proportion of ring-, 
trophozoite- and schizont stage parasites, respectively. The P. berghei ANKA infection is 
inherently asynchronous and all developmental stages are present at all times of the day, 
thus collection at any hour will result in a mixed-stage parasite population. P. chabaudi- 
infected mice were kept in a reverse light cycle, resulting in schizogony taking place in
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the early afternoon, whereas animals infected with P. berghei ANKA were kept under 
normal light conditions (Section 2.3.3).
For each preparation, blood was collected from two or three mice, pooled and total RNA 
extracted (Section 2.4.10). A thin blood film was prepared from each pooled blood 
sample, Giemsa-stained and examined by light microscopy, in order to determine the 
proportion of parasites at different developmental stages (Table 4.3). The purity of the 
preparations ranged between 94 and 99%. No attempt was made to remove mouse RNA, 
such as using Plasmodipure filters to collect mouse leukocytes, as it was reasoned to be 
safer to extract a larger amount of RNA per sample to minimise losses of parasite RNA 
during the preparation process. The extracted RNA was separated on a 1% agarose gel, 
with ribosomal RNA bands of both parasite and mouse origin being clearly visible 
(Figure 4.11 A; Section 2.5.2). Although care had been taken to use similar quantities of 
RNA from all samples, the electrophoresis showed obvious differences in loaded 
amounts, something that had to be taken into consideration when interpreting the results 
of the hybridisation analysis. The immobilized RNA was transferred to a nylon 
membrane and subsequently hybridised with the 252 basepair probe sequence (Section 
2.6.2). To make the probe, the plasmid carrying the 3':F1 sequence was propagated, 
restriction digested and the pcslap2S2 fragment gel purified and radioactively labeled 
(Sections 2.4, 2.5 and 2.6).
A signal at approximately six kilobases was detected in preparations of P. chabaudi ring- 
and trophozoite-stage parasites, as well as in P. berghei asexual and gametocyte RNA, 
but not in the BALB/c preparation (Figure 4.11 B). Taking into account the differing 
amounts of RNA loaded into each lane, the strongest relative signal was generated by 
probe hybridization to the P. berghei gametocyte sample, followed by the P. berghei 
mixed asexual preparation, and a weaker signal in the P. chabaudi ring- and trophozoite 
samples. This suggested that peak transcription of pcslap takes place in gametocytes, but 
that the gene may also be active in early- and mid-stage asexual parasites. Alternatively, 
because the asexual P. chabaudi preparations contained contaminating gametocytes, it 
may be that the signal originated from pslap transcripts within these parasites (Table 4.3).
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The bands on the blot were approximately six kilobases in size, although the coding 
regions of pcslap and pbslap are about four kilobases. This is not an abberant result as it 
is not uncommon to have both 5' and 3' untranslated regions (UTRs), as well as a poly(A) 
tail of up to 200 base pairs for mRNA to be translated (Lewin et al., 1997).
The radiograph also shows a weaker signal in all samples at approximately four 
kilobases. This is the size of the largest rRNA band on the agarose gel shown in Figure 
4.11 A, indicating that the high amounts of RNA collected at this level caused non­
specific hybridisation of the probe due to quantity rather than sequence complementarity.
The Northern analysis was repeated with a second set of RNA samples (prepared as 
before) and produced similar results to those described above (data not shown).
4.2.7 Immunofluorescence staining of P. chabaudi gametocytes
The results from the ELISA and the immunofluorescence assays had shown that PcSLAP 
is expressed in P. chabaudi blood stage parasites, while the Northern analysis indicated a 
strong gene expression in gametocytes (Sections 4.2.3, 4.2.5 and 4.2.6). It was therefore 
necessary to investigate whether the parasites that had been reacting with the PcSLAP 
antibodies in the previous immunofluorescence assays were gametocytes or asexual 
forms.
In P. falciparum, gametocytes are easily identifiable due to the crescent-like shape of the 
host erythrocyte (apart from very young, stage I gametocytes which are round). In rodent 
Plasmodia, on the other hand, gametocytes and their host cells retain the circular shape of 
the asexual parasite, making them more difficult to distinguish from other developmental 
stages (Wemsdorfer and McGregor, 1988). To overcome this problem in assays such as 
IFA, dual staining can be performed, using antibodies against the molecule of interest in 
combination with antibodies against a known sexual-stage antigen. A previously 
characterized rat monoclonal antibody, 85RF.45.3, raised against the P48/45 gametocyte- 
specific antigen in P. falciparum was used in the present studies (Roeffen et al., 2001; 
Section 1.7.2). A homologue to P/s48/45 had recently been reported in P. yoelii, 
suggesting that this protein could be conserved within Plasmodium, and also present in 
other rodent parasite species (Carlton et al., 2002). Indeed, a BLAST search through the
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PlasmoDB rodent Plasmodia sequence database identified partial sequences of both P. 
chabaudi and P. berghei P/s48/45 homologues (data not shown).
The 85RF.45.3 antibody was used in the immunofluorescence assays following the same 
protocol as before and P. chabaudi fixed blood films from the same batch as for the 
staining with the anti-PcSLAP plasmas (Section 4.2.5). However, although intense 
fluorescence was observed with the positive control, the NIMP23 monoclonal antibody, 
no staining could be detected with 85RF.45.3 (data not shown). The assay was repeated 
with amendments to the protocol, including different fixatives, different lengths of 
fixation and variations in primary and secondary antibody concentrations, but without 
success (data not shown).
4.2.8 Immunofluorescence staining of P. berghei gametocytes
Because the immunofluorescent staining of P. chabaudi gametocytes was unsuccessful it 
was decided to investigate whether 85RF.45.3, as well as the plasmas against P. chabaudi 
SLAP, could be used in the same assay but with parasites of another rodent species. P. 
berghei ANKA had been used previously for isolation of gametocyte RNA for Northern 
analysis and was therefore the obvious second choice after P. chabaudi (Section 4.2.1).
Thin blood films of mixed-stage blood stage parasites were made from P. berghei ANKA 
infected blood and differential counts of the maturation stages present in the preparation 
obtained from Giemsa-stained blood films examined by light microscopy (Table 4.2). 
The slides were stained with the 85RF.45.3 antibody and appropriate controls, followed 
by goat anti-rat IgG-Alexa®488 (green). Examination of the stained slides showed 
fluorescence with a somewhat punctate appearance throughout positively stained cells. 
Quantitative analysis revealed that approximately 2% of the total number of parasitised 
cells stained with the 85RF.45.3 antibody (Figure 4.13 A). However, light microscopy of 
Giemsa-stained parasites from the same preparation had shown gametocyte numbers of 
almost 6%, indicating that not all sexual stage parasites were labeled in the fluorescence 
assay (Table 4.2).
99
Chapter Four PSLAP transcription, expression and localisation
Staining with NIMP23, used as a positive control, confirmed that the assay worked (data 
not shown). No fluorescence was observed with the negative controls, which included 
purified rat IgG (for 85RF.45.3) and diluent in place of plasma (for non-specific binding 
of the secondary antibody; Figure 4.13 B and C, respectively).
4.2.9 Anti-PcSLAP plasmas react with fixed P. berghei blood-stage parasites
Before co-localisation of P48/45 and SLAP could be carried out, the P. berghei blood 
films also had to be tested for reactivity with the plasma raised against the PSLAP 
protein. Although the plasma had been raised against P. chabaudi SLAP, it was likely 
that it would also bind the P. berghei homologue, due to the high level of conservation 
between the two species. An alignment of P. chabaudi PcSLAPçq, the part of the protein 
used in the immunisations, and the homologous sequence in P. berghei, had an overall 
identity of 88%, with a 41 residue central stretch of complete identity (Figure 4.14). With 
this high degree of similarity it seemed highly probable that the immunisations would 
have generated antibodies to identical sequences, which would be able to react with 
SLAP from both species.
The reactivity of the anti-PcSLAP plasmas with P. berghei ANKA blood-stage parasites 
was assessed using the same blood films as for the staining with 85RF.45.3 (Section 4.2.7 
and Table 4.2). The fluorescence showed the pattern previously seen in staining of P. 
chabaudi with anti-PcSLAP plasma: a punctate fluorescence surrounding the parasite 
nucleus, the extent of which ranged from a small area around the nucleus to the entire cell 
(Section 4.2.5; Figure 4.15 A). Between three and four percent of the parasitised cells 
stained positive with the plasmas. As with the labeling of P. chabaudi with the PcSLAP- 
specific plasma, this number is close to the proportion of gametocytes present in the 
preparation, another indication that PSLAP may be a sexual-stage protein (Section 4.2.5).
No staining was observed using normal plasma from un-treated mice, or with the 
conjugated secondary antibody (anti-mouse IgG-Alexa® 594) on its own (Figure 4.15 C 
and D, respectively).
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4.2.10 P. berghei PSLAP co-localises with the gametocyte-specific antigen F48/45
To test whether PSLAP was expressed in gametocytes, blood films were made from P. 
berghei ANKA-infected mice treated with pyrimethamine (Section 2.13.8). 
Pyrimethamine eliminates asexual parasites but does not affect the viability of sexual 
stages (Section 4.2.1). The animals were treated with a dose of 10 mg pyrimethamine per 
kilo bodyweight on four consecutive days and the parasite counts followed by 
microscopic examination of Giemsa-stained blood smears from the mice. On day four of 
treatment only sexual parasites were detected on the smears. P. berghei gametocytes have 
distinctive morphological characteristics that are visualized by the stain. Macro­
gamétocytes (female) have compact nuclei and a blue staining cytoplasm due to a basic 
pH caused by an abundance of ribosomes (Figure 4.16 A). Micro-gametocytes (male) are 
pink due to acidic cytoplasms and have large nuclei (Figure 4.16 B). Both sexes contain 
scattered pigment granules and entirely fill up the host erythrocyte, making them clearly 
distinguishable from asexual parasites.
After finished treatment, blood was collected and thin blood films made. Although the 
films had a very low percentage of infected cells (approximately 0.5%) due to the small 
proportion of gametocyte-infected cells in a blood-stage infection, the purity of the 
preparation was very high (Figure 4.16 A and B, Table 4.2).
Co-localisation studies were subsequently performed using the anti-PcSLAP plasmas, 
anti-iys48/45 monoclonal antibody 85RF.45.3 and the P. berghei gametocyte thin blood 
films. Analysis of the slides by single colours showed the previously observed 
fluorescence patterns for the PSLAP-specific plasmas (Alexa®594 -  red) and 85RF.45.3 
(Alexa®488 green). Moreover, double colour analysis showed the same cells staining for 
both PSLAP and P48/45 (Figure 4.17). However, not all parasitised cells were labeled 
with the antibodies. Approximately 93% of DAPl-staining cells were positive for PSLAP 
and 35% also labeled with the anti-P48/45 antibody.
The fluorescence produced by the two antibodies in dual-stained cells in some cases 
displayed very similar patterns, with a punctate staining throughout the infected cells. 
However, merging of the images revealed small regions stained only with one of the two 
antibodies, as well as a variation in the fluorescence intensity over different areas of the
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cells, verifying that the similarity in pattern was not due to cross-reacting secondary 
antibodies. These results strongly indicate that P. berghei ANKA PSLAP is a sexual 
stage protein present in gametocytes.
4.2.11 P. falciparum SLAP is expressed in gametocytes
The results obtained by Northern analysis and IFA suggested that rodent (P. berghei and 
P. chabaudi) PSLAP is expressed in both asexual and sexual stage parasites. Due to the 
high degree of conservation between the rodent slap and the homolog in P. falciparum 
(Section 3.4), they would be expected to share similar patterns of expression. However, a 
parallel project in the division where the present work was carried out, investigating the 
P. falciparum homolog of PcSLAP, had showed transcription of the slap gene in P. 
falciparum gametocytes but not in asexual parasites. To investigate the expression profile 
of the PySLAP protein, immunofluorescence assays were performed, following the same 
protocol as for the rodent parasites (Section 2.12).
In vitro systems for culturing of P. falciparum  are well established and specific 
techniques allow enrichment for gametocytes within parasite populations. By restricting 
the addition of fresh erythrocytes and new medium to a culture, the parasites start 
preparing for transmission (to a new host) by developing into sexual forms. Parasites 
were thus grown under such conditions, purified and thin blood films were made. The 
smears were stained with polyclonal sera against three different regions of the P/SLAP 
protein: the LCCL-1, LCCL-2 and SRCR-1 motifs (Figure 4.18). As before, the 
85RF.45.3 antibody was used for dual labeling, to identify sexual stage parasites, and 
DAPI to distinguish infected cells.
Analysis of the staining showed that PSLAP was expressed on the same cells as the 
gametocyte-specific protein P48/45. No fluorescence was detected in cells that did not 
stain with the 85RF.45.3 antibody. The appearance and pattern of the P/SLAP staining 
was similar to that of PSLAP in P. chabaudi and P. berghei, with a punctate fluorescence 
distributed throughout or part of the parasite cytosol (Figure 4.19 A; Sections 4.2.5 and 
4.2.7). However, a punctate pattern following the outline of the erythrocyte membrane 
was also observed (Figure 4.19 B). This was not present in the staining of parasitised 
rodent cells. P/SLAP appeared to be expressed in a stage-specific fashion during
1 0 2
Chapter Four PSLAP transcription, expression and localisation
gametocytogenesis: it could not be detected in early gametocytes (stages I-II) but became 
abundant in more mature stages (stages III-V).
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4.3 Discussion
The previous chapter (Chapter Three) demonstrated that PcSLAP has a complex and 
unique domain composition, not reported anywhere outside of Apicomplexa. However, 
its high degree of conservation across different species of Plasmodium suggests it would 
possess an important function. Determining the location and time of expression of 
PSLAP is essential in trying to understand its role in the parasite.
In order to characterise PcSLAP, antibodies against a 90-residue portion of the protein 
were raised in mice and rabbits for use in expression- and localization studies. It is 
notable that, to reduce the risk of non-specific reactivity, this sequence of PcSLAP did 
not include any domains, or parts of domains, that have been identified in other 
Plasmodial proteins. The plasmas obtained from the immunised animals were first used 
in ELISAs that showed binding to a lysate made from P. chabaudi blood-stage parasites. 
However, the reactivity was low. There are several plausible explanations for this: (i) low 
levels of PcSLAP expression, (ii) loss of PcSLAP during the preparation of the lysate 
due to its location, (iii) loss of PcSLAP antibody epitopes during lysate preparation, or 
(iv) degradation of PcSLAP during lysate preparation. The first explanation (i) could be 
true if PcSLAP is only expressed within a very short window of time, if it is a protein 
only required and synthesised by the parasite in very small quantities, or if maximal 
PcSLAP expression takes place at a different stage in the life cycle, and what is seen are 
low levels of non-induced expression. Explanations (ii), (iii) and (iv) are technical: the 
method to prepare the parasite lysate uses saponin to lyse the erythrocyte membranes, 
after which parasite constituents are immediately centrifuged down and collected. 
However, if saponin is left in with the infected erythrocytes too long, it starts breaking up 
the parasite parasitophorous vacuole membrane, and any soluble proteins located in the 
parasitophorous vacuole, or anchored to its membrane, are lost (ii). It is also possible that 
some of the proteins in the preparation will adopt non-native configurations when 
extracted from the erythrocyte, thereby losing some epitopes recognized by the anti- 
PcSLAP plasmas (iii), or if very sensitive to degradation, that PcSLAP may even have 
been broken down by the time the lysate was ready to use (iv). Although showing a 
relatively low level of reactivity, this assay demonstrated that PSLAP is expressed during 
the intra-erythrocytic stages of the Plasmodium life cycle.
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In order to further analyse the presence of PcSLAP in blood-stage parasites, Western 
analysis was performed. All four PcSLAP-specific plasmas were tested for reactivity 
with i) a lysate of parasites isolated from P. chabaudi-infeciQÔ. mouse blood, and ii) a 
lysate of whole erythrocytes from P. chabaudi-infcciQd mouse blood. However, no 
specific bands were reproducibly obtained with either of the preparations despite several 
repeats of the assay. The obvious explanation for the negative result would be that the 
PcSLAP protein was absent in the tested preparations. This appears unlikely though, 
since all plasmas had previously shown reactivity with a similar parasite extract in 
ELISAs, and the two assays work on the same principle: the binding of specific 
antibodies to a mixture of immobilized proteins containing the target molecule. The most 
likely explanation for the absence of reactivity would be that only a very low amount of 
PcSLAP protein was present in the lysate, in combination with too low a concentration of 
PcSLAP-specific plasma in the test samples. The plasmas were used at dilutions of 
1:1000 and 1:500 due to the high sensitivity of the detection reaction. However, it may be 
that a dilution of 1:50 or 1:100 would have been required for PcSLAP-detection.
It is also possible that the interaction with solid phases altered the conformation of the 
protein, producing steric restrictions to antibody binding or loss of epitopes. This problem 
could be circumvented by using a different technique, such as immunoprécipitation. 
Immunoprécipitation provides the same information as Western analysis, ie size of an 
antigen and whether it is present in a protein mixture or not, but allows antibody-antigen 
interactions to take place in solution rather than on a solid support.
Immunofluorescence microscopy was subsequently used to study PcSLAP and its 
location within the parasite. Both the mouse plasmas and the rabbit sera were tested for 
reactivity with P. chabaudi blood-stage parasites. The mouse-derived antibodies reacted 
exclusively with parasite-infected erythrocytes. However, the rabbit immune sera stained 
both infected and un-infected cells. Despite adsorption of the sera onto un-infected mouse 
erythrocytes, as well as a lowering of the concentration of primary and secondary 
antibodies, the non-specific reactivity of the sera could not be eliminated. It is possible 
that using even lower concentrations of sera and fluorochrome-conjugated antibody could 
have reduced the high background. Careful titrations of both primary and secondary 
antibodies down to concentrations where no fluorescence is seen would have verified
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this. Alternatively, the sera could have been affinity purified. This method involves 
conjugation of the target protein onto a column matrix, over which the serum is passed, 
allowing any target-specific antibodies to bind and subsequently be eluted and collected, 
while non-specific antibodies are washed off and discarded. Alternatively, antibodies 
could have been raised against other regions of PcSLAP. This would have increased the 
chances of obtaining plasma that recognized the protein in Western analysis, as well as 
strengthened the findings from the immunofluorescence assays regarding the expression 
and location of PcSLAP.
Using indirect immunofluorescence, the anti-PcSLAP plasmas produced a pattern with a 
punctate appearance that suggested the protein is stored in subcellular vesicles. This is 
consistent with the presence of a 22-residue long signal sequence at the amino terminal of 
the molecule, which would direct it into the endoplasmic reticulum, from where it may be 
translocated into vesicles (Section 3.3.4). The fluorescence was not distributed 
throughout the infected erythrocyte but appeared to be contained within clear boundaries, 
indicating that PcSLAP is retained inside the parasite rather than exported into the red 
cell cytoplasm. Whether this is the final location of PSLAP or whether it is subsequently 
transported out of the parasite remains to be investigated.
Interestingly, only a small proportion of blood-stage infected cells stained positive for 
PSLAP in indirect immunofluorescence assays. Northern analysis, performed to analyse 
the transcription profile of pslap, suggested that this was due to PSLAP being expressed 
in gametocytes. Examination of P. chabaudi and P. berghei blood-stage parasites 
indicated that the highest level of transcription was seen in a preparation of P. berghei 
gametocytes. Although a weaker signal was also detected in samples of P. chabaudi rings 
and trophozoites, these preparations contained approximately 0.33% and 0.5% 
contaminating gametocytes respectively, consequently the signal could originate from 
these parasites. However, it cannot be excluded that pslap transcripts are also present in 
asexual stage parasites, and a recent report by Claudianos et al. (2002) showed 
transcription of P. berghei slap by reverse transcriptase (RT)-PCR, in gametocytes as 
well as in asexual stages from a clone unable to produce sexual parasites.
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Because transcription of a gene does not invariably equate with presence of the protein, 
analysis of the PSLAP protein was continued. Co-localisation studies were performed 
using 85RF.45.3, a monoclonal antibody against the sexual-specific antigen P/s48/45 
(Roeffen et al., 2001). P/s48/45 is expressed in stage II to V P. falciparum gametocytes, 
as well as in gametes and zygotes (Vermeulen et al., 1985). The assays were performed 
using blood films made from P. berghei infected mice treated with pyrimethamine in 
order to eliminate asexual parasites and obtain a preparation highly enriched for sexual 
parasites. The results showed that PSLAP was co-expressed in the same cells as the 
sexual-stage antigen P48/45, demonstrating that PSLAP is a sexual-stage protein. 
Interestingly, however, some cells stained positive with the PcSLAP-specific plasmas but 
not with 85RF.45.3. In P. falciparum, P48/45 is first seen in stage II gametocytes. The 
protein is present inside the gametocyte but is later expressed on the surface of the 
emerging gamete (Vermeulen et al., 1985). It may be that some of the gametocytes on the 
blood films were approaching the gamete stage and that the epitope recognized by 
85RF.45.3 is inaccessible once the protein is being, or has been, translocated, and 
therefore these parasites could not be labeled in the assay. It is also possible that because 
85RF.45.3 was raised against the P. falciparum P48/45 protein, the distortion caused by 
fixing the cells could have made the P. berghei P48/45 protein on some cells 
unrecognizable to the antibody. Alternatively, the P. berghei P48/45 homologue may 
have a more restricted expression that starts later in gametocyte delopment than the P. 
falciparum homologue, and therefore gametocytes at the earliest stages are only labeled 
with the anti-PSLAP antibodies.
Surprisingly, the transcription profiles of slap in rodent Plasmodia and the homologue in 
the human parasite P. falciparum differ. A parallel project in the division where the 
present work was carried out, showed that transcription of the P. falciparum homologue 
of pcslap takes place in gametocytes but not in asexual parasites (Delrieu et al., 2002). 
Nonetheless, subsequent immunofluorescence assays showed that expression and sub­
cellular location of P/SLAP was very similar between the species: P/SLAP was detected 
exclusively in gametocytes, with fluorescence of a punctate appearance, reminiscent of 
vesicular distribution. However, an additional pattern of staining was observed in P. 
falciparum: a circle of punctate staining running along the erythrocyte membrane. This
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suggested that PSLAP stored in vesicles in the parasite cytosol may be translocated to the 
inside of the erythrocyte membrane, perhaps upon a developmental signal. The time of 
expression and location of PSLAP in the parasite are suggestive of a role in the mosquito, 
and it is possible that, upon transmission to the mosquito and initiation of gametogenesis, 
as the erythrocyte membrane is lost the vesicles are released and the protein inside 
secreted. Indeed, a recent study investigating P. berghei SLAP reported expression of the 
protein throughout the parasite life cycle, including the stages within the mosquito 
(Truman et al., manuscript in preparation).
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Figure 4.1
Sequence of PcSLAP used in immunisations for generation of polyclonal antisera
A 90 residue sequence of PcSLAP was expressed and purified in an E. coli system, and 
subsequently used to immunize four BALB/c mice for production of polyclonal 
antibodies. The sequence, designated PcSLAP^o comprised the C-terminal half of SRCR- 
2 and the following 28 residues. It is noteworthy that the sequence did not include any 
part of the LCCL-2 module, as LCCL motifs have been identified in other proteins in 
Plasmodium, and antibodies raised against them could potentially react with proteins 
other than PcSLAP, producing abberant results in subsequent assays.
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Figure 4.2
Expression and purification of PcSLAPgo.
(A) A culture of E. coli transformed with the pTrcHisC-/?c^/fl/?27o construct was sampled 
hourly, for seven hours, after induction of expression with IPTG. Samples were 
centrifuged and pellets (?) and supernatants (S) analysed separately on a 12.5% 
polyacrylamide gel under reducing conditions. Maximum expression was observed at 
five hours post-induction (arrow).
(B) The purified PcSLAPgo protein was analysed on a 12.5% polyacrylamide gel 
(reducing conditions) to ensure that no contaminants were present in the preparation.
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Figure 4.3
ELISA to m easure levels of anti-PcSLAP antibodies in plasm a from  immunised 
mice
Four BALB/c mice (Ml- M4) were immunised with PcSLAPgg and plasma collected to 
test for presence of anti-PcSLAP antibodies. The plasma was titrated in duplicate using 
2-fold serial dilutions starting at 1:200. Normal mouse plasma (NP) was included as a 
negative control and diluted identically to the plasmas from the immunised mice. Plasma 
from mice 1 and 2 were assayed on a separate plate from plasma from mice 3 and 4, 
hence two normal plasma controls were required (NP control for Ml & M2, and NP 
control for M3 & M4).
The assay also included duplicate wells of diluent in place of plasma. An average value 
of the readings from these was used to subtract from the OD^Q -^readings obtained from 
the immune- and normal plasma samples on the same plate, and is therefore not shown in 
the figure.
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Figure 4.4
ELISA to measure levels of anti-FcSLAP antibodies in sera from immunised rabbits
Two rabbits (419 and 431) were immunised with P cSLAFçq and serum collected to test 
for presence of anti-PcSLAP antibodies. The sera were titrated using 2-fold serial 
dilutions starting at 1:200. Pre-immune serum from each rabbit, collected before the start 
of the immunizations, was included as a negative control and diluted identically to the 
immune sera (419 pre-immune control and 431 pre-immune control).
The assay also included duplicate wells of diluent in place of serum (“blanks”). An 
average value of the readings from these was used to subtract from the OD^Q -^readings 
obtained from the immune- and pre-immune sera samples on the same plate, and is 
therefore not shown in the figure.
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Figure 4.5
Malaria-specific ELISA to investigate fcSLAP blood-stage expression
The plasmas from the PcSLAPgo-immunised mice were tested for reactivity with a lysate 
made from blood-stage P. c. chabaudi parasites. The plasmas were titrated in duplicate 
using two-fold serial dilutions, starting at 1:4. Normal mouse plasma (NP) was included 
as a negative control and diluted identically to the plasmas from the immunised mice. 
Plasmas from mice 1 and 2 were assayed on a separate plate from plasmas from mice 3 
and 4, hence two normal plasma controls (NP control for Ml & M2, and NP control for 
M3 & M4), as well as two hyperimmune plasma controls (HIP control for Ml & M2, and 
HIP control for M3 & M4) were required.
Both plates also included duplicate wells of diluent in place of plasma. An average value 
of the readings from these wells was used to subtract from the OD^os-readings obtained 
from immune-, hyperimmune- and normal plasma on the same plate, and is therefore not 
shown in the figure.
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Figure 4.6
IFA with fixed P. chabaudi blood stage parasites and anti-PcSLAP plasma
Parasitised erythrocytes were stained with DAPI (blue) and the following primary 
antibodies:
(A) Anti-PcSLAP plasma
(B) Same field as (A), manually increased fluorescence intensity
(C) NIMP23 (anti-MSP-1, mouse IgG), positive control for the assay
(D) Purified mouse IgG, negative control for (C).
(E) Normal mouse plasma, negative control for (A).
(F) Diluent, negative control for the secondary antibody
Goat anti-mouse IgG-FITC (green) was used as secondary antibody on all samples apart 
from (C), which was directly FITC-conjugated (green). The cells were visualised on an 
Olympus DeltaVision fluorescence microscope under 1000 x magnification with oil.
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Figure 4.7
PcSLAP staining patterns in IFA with fixed P. chabaudi hlood stage parasites and 
anti-PcSLAP plasma
Staining of parasitised erythrocytes with DAPI (blue) and anti-PcSLAP plasma.
(A) Examples of the different patterns of staining observed with the anti-PcSLAP plasma.
(B) A manual increase in fluorescence intensity visualised the outline of the infected 
erythrocytes and the distribution of fluorescence within the host cells.
Cells were stained with goat anti-mouse IgG-FITC (green) as secondary antibody and 
viewed on an Olympus DeltaVision fluorescence microscope under 1000 x magnification 
with oil.
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Figure 4.8
Few parasitised cells stained positive for PcSLAP in IFA
Staining of parasitised erythrocytes with DAPI (blue) and anti-PcSLAP plasma followed 
by goat anti-mouse IgG-FITC (green). Of the total number of infected cells, as identified 
by DAPI-staining, very few were also labeled with the anti-PcSLAP plasmas. 
Approximately 0.3% of the total number of parasitised cells stained positive for PcSLAP. 
The image shows a representative field with ten infected erythrocytes, one of which 
stained for PcSLAP.
The cells were viewed on an Olympus DeltaVision fluorescence microscope under 1000 
X magnification with oil.

Figure 4.9
Plasmodium chabaudi chabaudi (AS) and Plasmodium berghei ANKA infections -  
levels of asexual and gametocyte infected erythrocytes
Female BALB/c mice were inoculated with 10  ^parasitised erythrocytes from either P. c. 
chabaudi (AS) (top graph) or P. berghei ANKA (bottom graph), and the infections 
followed by microscope analysis of Giemsa-stained thin blood smears for 14 days. The 
percentages of asexual and sexual-stage parasites in each infection are shown in blue and 
red, respectively.
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Figure 4.10
Alignment of P. chabaudi pcslap25 2 and the homologous sequence in P. berghei
Alignment of pcslap2S2 from P. chabaudi with the homologous sequence in P. berghei, 
pbslap2S2- The comparison was carried out in order to ensure that there was sufficient 
identity between the two sequences for Northern analysis hybridisation of pcslap2S2 to F. 
berghei RNA. The result showed an overall identity of 93.3%, with 17 mismatches out of 
a total of 252 bases.
Red colour denotes identity between sequences, blue colour denotes difference between 
sequences.
The alignment was generated with the MegAlign sequence alignment program using the
ClustalW algorithm.
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Figure 4.11
N orthern  analysis of pslap transcription
Total RNA was isolated from whole mouse blood (BALB/c), P. berghei ANKA mixed 
asexual parasites (PbA asex) and gametocytes (PbA gam), and P. chabaudi ring-stage 
parasites (Pc rings), trophozoites (Pc trophs) and schizonts (Pc schiz). An RNA marker 
was included in the analysis and run in the left-most lane (M).
(A) The RNA was separated on a 1% agarose gel containing guanidine thiocyanate. Both 
parasite and mouse ribosomal RNA bands are clearly visible (red and black arrows, 
respectively).
(B) The RNA was transferred to a nylon membrane and probed with pcslap2S2  ^ resulting 
in a signal at approximately six kilobases.
The radiograph shows the results of one of two experiments with similar results.
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Figure 4.12
Relative location of pcslap 252 within the pcslap gene
The probe used in Northern analysis, pcslap2S2 , was located between LCCL-2 and LCCL- 
3. It was chosen so that it would not include regions of the gene coding for any of the 
identified domains in the PcSLAP protein, so as to avoid hybridization to other proteins 
than PcSLAP that may carry the same types of domains.
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Figure 4.13
Staining of fixed P, berghei ANKA blood stage parasites with anti-P/s48/45 
monoclonal antibody
Staining of a mixed-stage infection of P. berghei ANKA parasites with 85RF.45.3, a 
monoclonal antibody against the sexual-stage antigen P/s48/45 from P. falciparum. 
Parasitised erythrocytes were stained with DAPI (blue) and the following primary 
antibodies:
(A) 85RF.45.3 (anti-P/s48/45, rat IgG). Fields 1 and 2 show two examples of the 
observed pattern of fluorescence
(B) Purified rat IgG, negative control for (A).
(C) Diluent, negative control for the secondary antibody
Goat anti-rat IgG-Alexa®488 (green) was used as secondary antibody. The preparations 
were visualised on an Olympus DeltaVision fluorescence microscope under 1000 x 
magnification with oil.
Field 1 Field 2
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Figure 4.14
Alignment of P. chabaudi PcSLAPpo and the homologous sequence in P. berghei
An alignment of PcSLAPgo and P6SLAPgo was perfomed in order to assess the likelihood 
that a polyclonal plasma raised against the P. chabaudi sequence would react with the 
homologous sequence in P. berghei. The comparison showed an overall identity of 88%, 
with a 41 residue central stretch of complete identity (residues 22-62).
Red colour denotes identity between residues, blue colour denotes difference between 
residues.
The alignment was generated with the MegAlign sequence alignment program using the
ClustalW algorithm.
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Figure 4.15
IFA with fixed P. berghei ANKA blood stage parasites and anti-PcSLAP plasma
P. berghei parasitised erythrocytes were tested for reactivity with the anti-PcSLAP 
plasmas raised to the P. chabaudi PcSLAPqq sequence. The cells were stained with DAPI 
(blue) and the following primary antibodies:
(A) Fields 1-3 show examples of the different patterns of fluorescence observed with the 
anti-PcSLAP plasma
(B) Same fields as in (A), manually increased fluorescence intensity
(C) Normal mouse plasma, negative control for (A).
(D) Diluent, negative control for the secondary antibody
Goat anti-mouse IgG-Alexa®594 (red) was used as secondary antibody. The cells were 
viewed on an Olympus DeltaVision fluorescence microscope under 1000 x magnification 
with oil.
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Figure 4.16
P. berghei ANKA gametocyte préparations used in IFA
P. berghei ANKA-infected mice were treated with 10 milligram pyrimethamine per kilo 
body weight on four consecutive days, for elimination of asexual parasites in order to 
obtain an infection with only gametocytes. Blood was subsequently collected and thin 
blood films made to be used in indirect immunofluorescence assays. Smears were also 
stained with Giemsa to assess the quality of the preparations. Two independent 
preparations were made and representative images are shown in (A) and (B ), 
respectively.
(A) Giemsa-staining of Preparation 1. A female gametocyte can be seen at the center of 
the image.
(B) Giemsa-staining of Preparation 2. A male gametocyte is positioned at the center of 
the image.
The images were acquired using a Nikon Coolpix 5000 digital camera and the bright field 
setting on an Olympus DeltaVision fluorescence microscope, at 1000 x magnification 
with oil.
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Figure 4.17
Co-localisation IF  A using anti-PcSLAP plasm a and the 85RF.45.3 anti-/y*s48/45 
antibody
P. berghei gametocytes were double stained with the anti-PcSLAP plasma (red, left-hand 
side panels) and the 85RF.45.3 monoclonal antibody against P. falciparum sexual-stage 
protein P/s48/45 (green, center panels). A merging of the staining produced with the two 
antibodies demonstrated that the labelled proteins are expressed in the same cells but with 
distinct patterns (right-hand side panels). Fields 1 and 2 show two examples of the 
observed fluorescence.
Goat anti-mouse IgO-Alexa®594 (red) and goat anti-rat IgO-Alexa®488 (green) were 
used as secondary antibodies. The cells were viewed on an Olympus DeltaVision 
fluorescence microscope under 1000 x magnification with oil.
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Figure 4.18
Sequences of Plasmodium falciparum SLAP used in immunizations for generation of 
polyclonal antisera
Three sequences, marked by black bars below the full protein sequence, corresponding to 
the structural motifs LCCL-1, LCCL-2 and SRCR-1 of P. falciparum SLAP, were 
expressed in an E. coli expression system. Following purification, the proteins were used 
to immunize five BALB/c mice for production of polyclonal antibodies.
I
Figure 4.19
Co-localisation IFA using P/SLA P antisera and the 85RF.45.3 anti-P/s48/45 
antibody
P. falciparum gametocytes were double stained with the P/SLAP antisera (red, left-hand 
side panels) and the 85RF.45.3 monoclonal antibody against P. falciparum sexual-stage 
protein P/s48/45 (green, center panels). A merging of the patterns produced with the two 
antibodies demonstrated that the labelled proteins are expressed in the same cells (right- 
hand side panels).
(A) P/SLAP anti-serum against LCCL-1
(B) P/SLAP anti-serum against SRCR-1
Goat anti-mouse IgG-Alexa®594 (red) and goat anti-rat IgG-Alexa®488 (green) were 
used as secondary antibodies. The cells were viewed on an Olympus DeltaVision 
fluorescence microscope under 1000 x magnification with oil.
I}
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Chapter Five
Disruption of the pslap gene in Plasmodium berghei ANKA
5.1 Introduction
A useful approach to study the function and importance of a particular gene is to subject 
it to genetic manipulation. The techniques needed to do this have been available for many 
years for organisms such as the bacterium Escherichia coli and the yeast species 
Saccharomyses cerevisiae. However, protocols for genetic modification of Plasmodium 
spp. have been particularly difficult to develop for a number of reasons. One is the 
inaccessibility of the parasite nuclear material, due to the presence of four membranes 
separating the external environment from the intra-erythrocytic parasite nucleus. This is 
believed to be a major factor contributing to the inefficiency of Plasmodium  
transfections, as compared with other systems. The difficulty of in vitro culturing of 
many of the parasite’s developmental stages, and cloning problems due to the extreme 
AT-richness of Plasmodial DNA, are another two.
However, efforts made to overcome these problems eventually resulted in the first 
successful transfection of a malaria parasite in 1993, using the avian species Plasmodium 
gallinaceum (Goonewardene et al., 1993, transient transfection and expression of firefly 
luciferase in gametes and zygotes). This was soon followed by another two laboratories 
simultaneously, but independently of each other, succeeding in transfecting Plasmodium 
falciparum  (Wu et al., 1995, transient transfection and expression of bacterial 
chloramphenicol acetyltransferase in ring-stage parasites and schizonts) and Plasmodium 
berghei (van Dijk et al., 1995, stable transfection of P. berghei dhfr-ts gene in 
merozoites). Since then, stable genetic transformation has been achieved in the simian 
parasites Plasmodium knowlesi and Plasmodium cynomolgi (van der Wei et al, 1997; 
Kocken et al, 1999, both transfection of T. gondii dhfr-ts gene in schizonts), and most 
recently, also in the rodent species Plasmodium yoelii (Mota et al, 2001, transfection and 
expression of green fluorescent protein, and disruption of thrombospondin-related 
anonymous protein gene).
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Plasmodium transfection experiments have since provided insights into a number of 
areas including promoter structures, reporter gene expression, the requirements for stage- 
specific localisation of malaria proteins, organelle targeting and imunomodulation by 
parasite expression of host cytokines (Crabb et al., 1997; de Koning-Ward et al., 1999; de 
Koning-Ward et al., 1998; Margos et al., 1998; Kocken et al., 1998; Waller et al., 1998; 
Ozwara et al., 2003).
Genetic manipulation is the alteration (mutation, substitution or disruption) of a specific 
sequence in the genome of an organism. It mostly relies on homologous recombination 
between two identical sequences, one present in the incoming DNA and the other in the 
genome. For selection of successfully transformed parasites, a transfection construct also 
contains a selectable marker gene. Most constructs used for Plasmodium gene targeting 
carry a pyrimethamine resistant form of the Toxoplasma gondii dihydrofolate reductase- 
thymidylate synthase (dhfr-ts) gene (Waters et al., 1997). The DHFR enzyme catalyses 
reduction of dihydrofolate to tetrahydrofolate, the latter of which is required for single 
carbon transfer reactions in the synthesis of purines. Pyrimethamine is a folate antagonist 
that binds to the DHFR-TS protein and inhibits its reductase activity, thereby causing 
disruption of DNA synthesis (Ferone et al, 1977). However, two point mutations in the T. 
gondii dhfr gene result in the amino acid changes Ser^^flArg and Thr^^flAsn, and an 
enzyme that is highly resistant to pyrimethamine (Donald & Roos, 1993). The T. gondii 
dhfr-ts gene is preferred over Plasmodium dhfr-ts genes because it reduces the chances of 
unwanted recombination with the endogenous copy of the dhfr-ts gene. The T. gondii 
dhfr-ts gene also appears to confer a 10- to 100-fold higher resistance to pyrimethamine 
than the P. berghei homolog, and when co-administered into P. knowlesi parasites, the T. 
gondii dhfr-ts constructs were preferentially selected for in vivo (van der Wei, et al., 
1997). To ensure efficient and reliable expression from this heterologous gene once it is 
inside the P. berghei parasite, it is placed under the control of the P. berghei dhfr-ts 5'- 
and 3' un-translated regions (UTRs), containing promoter sequences and transcriptional 
stop signals, respectively (Waters et al., 1997).
Two types of transfection constructs have been used for Plasmodium transfections.
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insertion constructs and replacement constructs (Figure 5.1). The difference between the 
two is in the length of the inserted sequence and the route of entry into the genome. The 
insertion vector contains just one target sequence that integrates through a single cross­
over event, inserting the entire plasmid into the target locus (Menard and Janse, 1997). 
Although reports from several eukaryotic systems suggest that this vector type integrates 
at a higher frequency than replacement constructs, the integration is reversible and 
therefore not very stable (Hasty et al., 1991). This is due to the fact that no gene sequence 
is lost in the integration, resulting in two identical copies of the target sequence being left 
in the transfected parasite (Figure 5.1, left schematic). These can pair up and recombine 
again and thereby exclude the construct sequence in the same way it was once inserted. 
The replacement construct, on the other hand, carries two sequences from the gene of 
interest and so requires a double cross-over for integration. No plasmid backbone is 
integrated with this type of vector (Figure 5.1, right schematic). Once replacement has 
taken place, the construct sequence is permanently inserted since the wild-type sequence 
has been removed and lost (Menard and Janse, 1997).
The parasite maturation stage used for transfection is the bloodstage merozoite. The 
asexual blood-stages are not only of most clinical relevance but are also the phase in the 
life cycle where the parasite population undergoes the most rapid expansion. The cycle of 
invasion-development-multipllcation-release-invasion allows for selection and growth of 
very few individuals up to detectable levels within a short period of time. The merozoite 
is a suitable target cell for several reasons: it is no longer dependent on its host cell for 
growth and therefore damage to the erythrocyte membrane caused by electroporation is 
not a problem, it appears to withstand the stress from electroporation well without losing 
viability, and it is easy to collect from cultures in relatively large quantities due to the fact 
that rodent malaria parasites do not re-invade uninfected erythrocytes when cultured in 
vitro, but instead halt at the mature schizont stage (Janse and Waters, 2002).
The aim of the work described in this chapter was to disrupt the pslap gene. PSLAP is, 
because of its multi-domain composition and high degree of inter-species conservation, 
without a doubt an interesting novel molecule. As has been shown previously by us, 
Plasmodium falciparum SLAP is expressed in blood stage gametocytes and has been 
proposed as a potential candidate for a transmission blocking vaccine (Delrieu et al..
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2002). Disrupting the gene would show whether SLAP is essential for parasite survival
.If this is not the case, a rodent model would allow studies on the interactions between
parasite and host, such as parasite growth and development in both the vertebrate host
and the insect vector.
As there is no protocol available for transfections of Plasmodium chahaudi, it was 
decided to attempt disruption of the gene in Plasmodium berghei ANKA. Transfection 
and selection procedures described in the present chapter follow the protocol outlined by 
Waters et al. (1997; Section 2.13).
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5.3 Results
5.3.1 Susceptibility of Plasmodium berghei ANKA to pyrim etham ine
In order to assess the susceptibility to pyrimethamine of the strain of Plasmodium berghei 
ANKA that was to be used for the transfection experiments, a drug sensitivity test was 
performed. The dose of ten milligram pyrimethamine per kilogram bodyweight of host 
animal was used, as this is standard in transfection experiments using P. berghei ANKA 
(refs). Three groups of four BALB/c mice were infected with 10  ^ P. berghei infected 
erythrocytes each. On day 1 of infection (24 hours post infection), one of the groups of 
mice was treated with pyrimethamine (ten milligram per kilogram bodyweight), one 
group was injected with saline and one group left untreated (Section 2.13.8). These 
treatments were repeated on days 2, 3 and 4, and the parasitemia followed daily in all 
mice by Giemsa-stained thin blood smears. Non-pyrimethamine treated animals were 
monitored for 12 days after which they were culled due to sickness, whereas drug-treated 
mice were monitored for an additional two days.
The experiment showed that the parasites were highly susceptible to pyrimethamine. A 
few parasitised reticulocytes were detected in the pyrimethamine treated animals on days 
two and three (up to 0.2% parasitemia), however, all asexual stage parasites had been 
eradicated by day four (Figure 5.2, top graph). In contrast, all animals that received saline 
or no injections had parasitemias of 2% or higher at the same time (Figure 5.2, center and 
bottom graphs, respectively). Drug-treated animals were parasite free up until day ten, 
while saline injected and non-treated mice had parasitemias of between 13 and 35% on 
the same day, with a continued rise in parasitemia up to levels of 50% by day 12.
The result o f the assay demonstrated susceptibility of P. berghei ANKA to 
pyrimethamine at a dose of ten milligram per kilogram bodyweight. However, the 
emergence of parasites in treated animals by day ten and after showed that the drug did 
not eradicate the parasites completely.
5.3.2 Transfection vectors to d isrup t pbslap
Two transfection vectors were constructed for the subsequent disruption of pbslap, one 
insertion vector and one replacement vector, designated pSLAPIns and pSLAPRep, 
respectively. Both vectors were made from the pBSK-dhfr-ts plasmid, a pBluescript SK 
II (+) backbone (Stratagene) with the DHFR-TS transcription unit cloned in between the
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H indlll and EcoRI restriction sites in the multiple cloning cassette (Figure 5.3; Section 
2.13.1).
For the insertion vector, pSLAPIns, a 911 basepair fragment corresponding to the 
sequence between bases 835 and 1745 of pbslap was used. The pSLAPRep replacement 
construct carried fragments corresponding to the sequences from position 439 to position 
1298 (Fragment 1), and from position 1300 to 1640 (Fragment 2) in the pbslap gene 
(Figures 5. 4 and 5.5). All three fragments were amplified using the high fidelity Pfx 
system, as, although not known for Plasmodium, it has been shown in mammalian 
systems that even a single nucleotide mismatch between target gene and target construct 
can decrease the efficiency of recombination dramatically (Deng et al, 1992, teRiele et 
al, 1992).
5.3.2.1 Isolation of Plasmodium berghei ANKA genomic DNA
The pbslap gene fragments for the transfection vectors were to be amplified by PCR from 
genomic DNA (gDNA) from P. berghei ANKA, the same strain that was going to be 
used for the transfections. Therefore, female BALB/c mice were inoculated with 
Plasmodium berghei infected erythrocytes, blood collected at a parasitemia of 
approximately 30% and parasite gDNA extracted (Section 2.4.1). To test the DNA, it was 
used as a template in a PCR with the forward and reverse primers designed to amplify the 
insertion vector fragment (SLAPInsForw and SLAPInsRev, respectively; Table 2.7, 
Section 2.13.1). The result was analysed by gel electrophoresis and showed a band at 
approximately 911 bases (Figure 5.6). This product was blunt-cloned into the 
pCR4B lunt-T0P0 sequencing vector (Invitrogen), sequenced and found to have the 
correct sequence of the P. berghei slap gene (data not shown).
5.3.2.2 pSLAPIns insertion construct
Since the sequence of the cloned Insertion vector fragment (InsF) had already been 
amplified and verified, it was used for the subsequent construction of the pSLAPIns 
vector. The pCR4Blunt-T0P0 vector cloning site had two flanking EcoRI sites, which 
were used to excise the fragment and re-clone it into the EcoRI site in the pBSK-J/i/r-r^ 
vector (Figure 2.1, Figure 5.7, Section 2.13.2). The pSLAPIns vector was propagated.
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purified and the sequence confirmed, initially by restriction digestion and later by 
sequencing (Figures 5.8 and 5.9).
5,3,23 pSLAPRep replacement construct
Two sets of primers were designed in order to amplify Fragments 1 and 2 for the 
replacement construct. SLAPRepFl and SLAPRepRl were used to generate Fragment 1, 
and SLAPRepF2 and SLAPRepR2 to obtain Fragment 2 (Table 2.7). Restriction sites 
were added onto the 5' ends of the primers to allow directional cloning into the pBSK- 
dhfr-ts vector: Apal and H indlll sites were added to the forward and reverse primers, 
respectively, for Fragment 1; and EcoRI and Xbal sites to the forward and reverse 
primers, respectively, for Fragment 2 (Table 2.7).
The two fragments were amplified by PCR and the products analysed by gel 
electrophoresis (data not shown). The sequences were cloned into the pB^lL-dhfr-ts 
vector sequentially, starting with Fragment 2, followed by Fragment 1 (Section 2.13.3; 
Figure 5.10). Restriction digests and vector sequencing confirmed that the correct 
fragments had been cloned (Figures 5.11, 5.12 and 5.13).
5.3.3 Parasite transfection and selection procedures
The transfection and selection procedures used in the present work follow the protocol by 
Waters et al. (1997). However, with valuable advice from Dr. R. Tewari (Imperial 
College, London) some amendments were made, due to the use of mice throughout the 
experiment rather than rats (Section 2.13).
Briefly, it was agreed that three to four mice be used in place of one rat, as is suggested in 
the standard protocol. Although this is not an equivalence in terms of blood volume, P. 
berghei infections reach higher parasitemias in mice than in rats, and thus the same 
number of parasites were obtained this way. Therefore, four female BALB/c mice were 
inoculated with 10  ^P. berghei-mÏQcXj^à. erythrocytes five days prior to transfection (Day 
0). The day before electroporation, at 15-20% parasitemia, the animals were culled and 
the blood collected. A “donor” culture was set up and incubated overnight to allow all 
parasites to develop into schizonts. To prepare the transfection vectors for 
electroporation, 50 pg of construct was digested overnight: pSLAPRep with Apal and
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Xbal, to release the transfection part of the vector (the DHFR-TS unit and the flanking 
pbslap sequences) from the plasmid backbone, and pSLAPIns with Avail, to produce a 
single cut for linearisation. The following day, the maturation of the culture was carefully 
followed by Giemsa-stained thin blood films. When the majority of parasites had matured 
into schizonts, the culture was harvested, the parasitised cells purified on a Nycodenz 
density gradient and mixed with either of the digested transfection vectors. The mixture 
was electroporated by delivery of a single electric pulse, divided into two equal aliquots 
and injected intravenously or intraperitoneally into two female BALB/c mice (Figure 
5.14).
In order to allow the parasites to complete one cycle of asexual division in the absence of 
drug pressure, pyrimethamine treatment was initiated on day one (24 hours) post­
injection, and continued on days two, three and four (48, 72 and 96 hours), at ten 
milligram per kilo bodyweight. At the beginning of the selection, asexual parasites were 
frequently observed, however, as the drug started to take effect, only gametocytes were 
detected. The growth of the parasites were monitored daily by Giemsa-stained thin blood 
smears. When parasites emerged they were passaged to new mice for a second round of 
selection (Figure 5.15). If parasites appeared after the second selection it was considered 
a high probablility that they were truly transfected, and they were subsequently cloned by 
limiting dilution.
5.3.4 Screening assays for transfected parasites
In order to screen for successful transfections, DNA was isolated from growing parasites 
and analysed by PCR and Southern analysis (Sections 2.13.9 and 2.13.10). The two 
methods complement each other in that the PCR would confirm the presence of the T. 
gondii dhfr-ts gene, but would not differentiate between genomicly integrated and 
episomally maintained DNA. The Southern analysis, on the other hand, is based on 
restriction digestion that produces fragments of differing sizes depending on whether the 
hybridising DNA is episomal, genomic wild type or genomic transfected.
5.3.4.1 Screening by PCR
For the PCR analysis, isolated parasite DNA was used as a template for amplifications 
with four sets of primers (Figure 5.16). Two of the sets (primer 1 + primer 2, and primer
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3 + primer 4) contained one primer based on the dhfr-ts sequence (primers 2 and 3), and 
would therefore only amplify regions present in transfected parasites, resulting in 
products of 1026 basepairs and 464 basepairs (“Transfection products”). The other two 
sets (primer 1 + primer 5, and primer 4 + primer 6) amplified regions present in both wild 
type and transfected parasites, producing 860 basepair- and 341 basepair long products 
(“Control products”). Some of the above primers were used previously under different 
names, but have been numbered from 1 to 6 in this section and on Figure 5.17 for clarity. 
All primer sequences are listed in Table 2.3.
To verify the validity of the assay the following DNA template controls were included: 
pSLAPRep transfection vector as a positive control for amplification of both transfection 
products and control products, and wild-type P. berghei ANKA DNA as a negative 
control for amplification of transfection products, but positive control for the control 
products. Reactions without template DNA were also run to control for non-specific 
contamination.
5.3.4.2 Southern analysis
For the Southern analysis, two p,g of parasite DNA was digested with Hindlll and EcoRI 
restriction enzymes, separated on an agarose gel and blotted onto a nylon membrane. The 
DNA was probed with a 1202 bp sequence comprising the two pbslap fragments used to 
construct the pSLAPRep vector (Fragment 1 and Fragment 2), and the single nucleotide 
separating these two fragments in the pbslap gene (Figures 5.17 and 5.5). The probe was 
amplified by PCR from P. berghei ANKA gDNA, using the forward primer for Fragment 
1, SLAPRepFl, and the reverse primer for Fragment 2, SLAPRepR2, isolated and radio­
labelled (Section 2.13.10 and Table 2.3).
Hybridisation with F1-F2 produced different band patterns in transfected and wild-type 
parasites. In P. berghei wild type DNA, the F1-F2 probe hybridises to the identical pslap 
gene sequence, producing one band in a Southern analysis. However, in a transfected 
parasite, where the dhfr-ts sequence has been inserted into the slap gene. Fragments 1 and 
2 would have been separated by the restriction digest, and therefore the probe would 
hybridise to two fragments, generating two bands in the analysis (Figure 5.17).
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The sizes of the mentioned bands depend on the location of EcoRI and Hindlll sites 
within pbslap and in the sequence surrounding the gene. An EcoRI site is present at 
position 219 in the gene (Figure 5.17). However, no other EcoRI or Hindlll sites exist 
within the pbslap sequence. Because the P. berghei genome is not yet fully sequenced, 
the position of next EcoRJ/Hindlll downstream of the gene is not known. In an attempt to 
identify this restriction site, a BLAST search was performed. Sequence up to 1785 bases 
downstream of the pbslap stop codon was obtained and a restriction map of this region 
produced (data not shown). Still, no EcoRI or Hindlll sites were found, demonstrating 
that the next EcoRJ/Hindlll site is further downstream than 1785 bases from the 3' end of 
the pbslap open reading frame. Therefore, the absolute sizes of the fragments produced in 
the digest cannot be exactly calculated, but their minimum lengths can be determined. 
Despite the lack of information on all restriction sites, the result of this analysis is clearly 
diagnostic of whether disruption has taken place or not due to the difference in the 
number of bands generated (one for wild-type, two for disruption). Expected sizes of 
hybridising fragments for transfected and wild type parasites are shown in Figure 5.17. 
Wild-type P. berghei ANKA DNA was included as a positive control for the assay, and 
as a size comparison for DNA from non-transfected parasites, and the pSLAPRep 
transfection vector as a size comparison for episomal DNA.
5.3.5 Analysis of results of pbslap transfection experiments
Initially both transfection constructs were used for transfections. However, it was later 
decided to continue only with the replacement construct, as it generates a more stable 
integration (Section 5.1). A total of five attempts were made to try and disrupt the 
Plasmodium berghei slap gene. Three of these resulted in parasite growth after the first 
round of pyrimethamine selection and are described below. All of these were obtained 
using the pSLAPRep transfection vector.
5.3.5.1 Transfection experiment 1
Parasites were cultured, electroporated and injected into two female BALB/c mice, as 
described (Section 5.3.3). Asexual parasites were observed in peripheral blood in both 
recipient mice on day one or two (Mouse 1 and Mouse 2, respectively; Figure 5.18 A).
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However, by day three the parasitemia had been reduced to non-detectable levels by the 
drug pressure. On day seven parasites re-appeared in Mouse 2, and so were passaged into 
three new mice (Figure 5.18 A). No parasites were observed after the second round of 
treatment, indicating that the transferred parasites were not transfected, and therefore not 
pyrimethamine resistant (Figure 5.18 B).
However, in the first round of selection, parasites in Mouse 2 had appeared relatively 
soon after drug treatment (three days after the last injection; Figure 5.18 A). This 
suggested that the population was resistant and DNA was therefore isolated and screened. 
PCR reactions were set up with the parasite DNA as a template to amplify the products 
with the primers specified in Section 5.3.4.1. However, analysis by gel electrophoresis 
showed that control products but not transfection products had been amplified (Figure 
5.19 A). Moreover, only one band of the same size as the wild type control sample was 
seen in Southern analysis (Figure 5.19 B). These results showed that disruption of the 
pbslap gene had not taken place.
5.3.5.2 Transfection experiment 2
Following injection of electroporated parasites into three female BALB/c mice, one 
animal subsequently developed an infection 12 days post infection (Mouse 0, Figure 5.20
A). Although this was a very late appearance, it was decided to passage this population 
for a second round of pyrimethamine selection. Two mice were infected with the 
transferred parasites and subjected to four days of drug treatment (Figure 5.20 B). Mouse 
0 subsequently became parasitémie on day nine, and Mouse 1 on day ten, post infection. 
However, screening by PCR failed to amplify either of the transfection products whereas 
amplification of both control products verified that the assay worked (Figure 5.21 A). 
Similarly, a single band was observed in the Southern analysis (Figure 21 B) showing 
that again the transfection had not been successful. DNA was isolated and screened at an 
early stage from these animals, thus the parasites were not cloned despite having passed 
through two rounds of selection.
5.3.5.3 Transfection experiment 3
Parasites were cultured, electroporated and injected into one mice as described (Section 
5.3.3). Newly invaded parasites could be seen on day one (24 hours post transfection) but
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were undetectable on day three, after two days’ pyrimethamine treatment (Figure 5.22
A). Six days post transfection, asexual parasites emerged and were subsequently 
transferred to four female BALB/c mice for a second round of drug selection (Figure 5.22
B). One of these mice (Mouse 3) developed an infection that was detectable eight days 
post transfer. The remaining three mice stayed parasite free for a total of three weeks, at 
which point they were culled. In order to generate a homogeneous population, the 
parasites growing in Mouse 3 were cloned by limiting dilution. Infected blood was 
extensively diluted and groups of 10 female BALB/c mice were inoculated with 0.6,1 or 
3 parasitised erythrocytes each. Three animals, Mouse 0 (MO), Mouse 1 (Ml) and Mouse 
2 (M2), all inoculated with 3 infected cells, subsequently developed infections. The 
parasite populations from each of these mice were recovered, as well as from the 
uncloned parental population (UC = Mouse 3 in Figure 5.22 B), and parasite genomic 
DNA was extracted for screening.
Despite having been subjected to two rounds of pyrimethamine selection, PCR analysis 
showed no amplification of either Transfection product 1 (expected size 1026 bp) or 
Transfection product 2 (expected size 464 bp) from the DNA extracted from any of the 
cloned parasites (Figure 5.23 A). Amplification of both of these products from the 
pSLAPRep transfection vector (TV) confirmed that both sets of primers worked. Both 
control products, 860 bp and 341 bp, could be amplified from the same parasite DNAs, 
showing that the absence of Transfection product amplification was not due to a problem 
with the extracted DNA (too much or too little template DNA, inhibiting contaminants 
etc), but because the parasites had not been successfully transfected.
This result was confirmed in Southern analysis (Figure 5.23 B) of the uncloned parasite 
population (UC) by the presence of only one band of approximately 7 kilobases, the same 
size as the band in the P. berghei wild type control sample, indicating that integration of 
the dhfr-ts gene had not taken place. A band at approximately 4 kilobases in the digested 
pSLAPRep transfection vector (TV) sample confirmed that the restriction digest had 
worked.
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5.4 Discussion
Two transfection vectors were constructed for disruption of the pslap  gene in 
Plasmodium berghei ANKA parasites. The insertion vector pSLAPIns contained a single 
pbslap sequence of 911 basepairs, and was designed for integration via a single cross­
over event. The pSLAPRep construct carried two sequences, 860 and 341 basepairs, from 
pslap, and would require double homologous recombination to integrate into the parasite 
genome. Furthermore, susceptibility of the Plasmodium berghei ANKA parasite strain to 
the anti-malarial pyrimethamine was assessed and verified. An inoculum of 10^  
parasitised erythrocytes was followed by drug administration at ten milligrams per kilo 
bodyweight on four consecutive days, which eliminated detectable levels of asexual 
parasites from peripheral blood for a total of ten days. However, as analysed by PCR and 
Southern blot, a successful disruption of P. berghei slap using the described transfection 
constructs was not achieved.
Why was disruption of pbslap not successful?
There are several factors that may have contributed to the failure of generating a pbslap 
knock out parasite. Some general conditions were changed from the standard transfection 
procedure, which may have decreased the overall efficiency and success rate of the 
experiments:
A critical stage in the protocol is the invasion of fresh erythrocytes of the recipient animal 
by the newly electroporated parasites. To increase the efficiency of this event, recipient 
animals are treated with phenylhydrazine, a chemical that increases the production of 
reticulocytes, the preferred cell type of P. berghei for invasion and growth. This drug was 
however not administered in the present study due to animal project license regulations. 
For the same reason, BALB/c mice were used throughout the experiments rather than 
Wistar rats for donor cultures and as recipients of electroporated parasites. Furthermore, 
injection of electroporated parasites is usually performed through the intravenous route. 
This part of the protocol was followed to begin with, however, due to unexpected deaths 
of several injected mice, future injections had to be administered intraperitoneally. No 
published reports were found where this has resulted in successful parasite 
transformation, although it has been shown to work, albeit with lower transfection 
efficiency than normally observed with intravenous injections (Rita Tewari, personal
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communication). This is probably due to the fact that the peritoneal cavity is a more 
hostile environment for pathogens due to the presence of an abundant population of 
peritoneal macrophages.
Although few, there are a small number of reports describing successful transfections 
using mice in place of rats, such as Mota et al (2001). Although P. berghei successfully 
infects both mice and rats, the parasitemia in the latter does not exceed a few percent, 
whereas in mice more than half of the population of erythrocytes can be parasitised. The 
standard protocol uses one rat (5-10 millliliter blood) with a parasitemia of 1-3% per 
transfection experiment. However, in order to obtain similar numbers of parasites in the 
present work, three mice (approximately 1.5 millliliter blood) at 15-20% parasitemia 
were used. Although this equals the number of parasites used per experiment, it results in 
a different cell density in the culture, as well as changes the ratio of infected versus 
uninfected erythrocytes. Cells tend to grow best in cultures that mimic their normal 
environment so it is possible that the low density affected the overall health and viability 
of the cultured parasites in a negative manner.
Most published transfection work to date on P. berghei follows the guidelines outlined by 
Waters et al (1997). Interestingly, alongside their standard method, these authors also 
suggested a simplified transfection procedure. This version uses Swiss mice throughout 
the experiment. The in vitro culturing step is omitted, and instead a parasite preparation 
consisting of mainly trophozoites is used, which after electroporation is intraperitoneally 
injected into mice. This protocol is similar to the one used in the present project. 
However, its usefulness is doubtful as the authors admitted that they had had no success 
at integrating any constructs into the P. berghei genome, and no work has since been 
published using this technique (Waters et al 1997).
It is also possible that the shorter one of the target sequences used in the pSLAPRep 
replacement vector, the 341 basepair Fragment 1, was insufficiently long for efficient 
recombination to take place. Although it has been shown in the parasite Leishmania 
enriettii that as little as 200 basepairs is enough in for homologous integration to take 
place, transfection efficiency was low (Tobin and Wirth, 1992). Successful 
transformations in Plasmodium have used fragments of approximately 500 basepairs,
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with an upper limit of 1000 basepairs, as longer sequences tend to cause problems with 
stability (Ménard and Janse, 1997).
Why did non-transfected parasite populations appear after pyrimethamine selection?
The assay on pyrimethamine sensitivity, carried out at the beginning of this study, 
verified that the asexual P. berghei ANKA parasites that later were used in the 
transfection experiments were susceptible to pyrimethamine at a dose of ten milligrams 
per kilo bodyweight (Section 5.3.1). However, it also demonstrated that elimination of 
the infection was not complete, as parasites started appearing ten days post inoculation. 
The administered dose is part of the standard protocol for P. berghei transfections and 
has been carefully chosen for drug selection in order to eliminate a potentially large 
population of non-transformed, susceptible parasites, without eradicating a comparatively 
very small proportion of resistant individuals (van Dijk et al., 1994). Therefore this 
amount of drug may not, as was shown in the present study, completely wipe out non- 
resistant parasites. It is true that non-transfected parasites in some cases appeared at 
earlier time points in the described transfection experiments than in the pyrimethamine 
sensitivity experiment, such as after the first injection of electroporated parasites in 
Transfection experiment 1 (six days). However, the inoculum of parasites in the drug 
sensitivity study was known to be 10  ^whereas the number of live parasites injected into a 
recipient animal after electroporation is difficult to estimate. It is likely that with a greater 
number of parasites injected, more are able to avoid elimination by the drug and can 
therefore expand to detectable levels sooner. Thus, a direct comparison between the 
pyrimethamine sensitivity study and the pbslap transfection experiments cannot be made.
Lastly, there is also a possibility that non-targeted parasites became truly resistant to 
pyrimethamine. Drug-insensitive clones can arise both from spontaneous mutations in the 
endogenous dhfr-ts gene, and from replacement of the endogenous dhfr-ts gene by the 
incoming mutated copy in the transfection construct. The latter is to some degree avoided 
by the use of a heterologous selectable marker, rather than the gene from P. berghei. 
However, although the dhfr-ts coding sequence originates from Toxoplasma gondii, the 5' 
and 3' UTRs flanking the gene are endogenous (Figure 5.3). They can therefore pair up
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with the identical sequences in the P. berghei genome, resulting in integration of the 
DHFR-TS transcription unit into the dhfr-ts locus, rather than into the target gene.
Does pbslap have a function that is essential for parasite survival during the blood 
stages?
An obvious explanation for the failure in creating a pbslap knock out parasite would be 
that the SLAP protein is essential for asexual blood stage development or survival. If this 
was true, transformed parasites would never expand to detectable levels, as an individual 
lacking the protein could not grow or multiply. However, this is not the case, as during 
the present study, a paper was published reporting on the effects of pbslap disruption on 
parasite development within the mosquito (Claudianos et al., 2002). The slap gene had 
been knocked out using a replacement construct carrying a 606 basepair long sequence at 
the 5' end of the gene and a 481 basepair sequence towards the 3' end (Figure 5.25). The 
report stated that the SLAP protein was exclusively expressed in sporozoites, and 
disruption of pbslap showed that it is essential for sporozoite development, as sporozoite 
formation was abrogated in developing oocysts. (A 35% increase in oocyst size as 
compared with wild type parasites was also observed.) However, the work presented in 
Chapter Four of the present project, clearly indicates that the SLAP protein of both P. 
falciparum  and P. berghei is expressed in blood stage gametocytes. The presence of 
P/SLAP in sexual stage parasites has recently also been confirmed by a high-accuracy 
mass spectrometric analysis of protein expression at different maturation stages 
(Lasonder et al., 2002). Protein expression in Plasmodium is tightly regulated and 
organized on several levels, with transcriptional and translational control, as well as 
chromosomal clustering of genes involved in common processes (Florens et al., 2002). 
This regulation is also reflected in the distinct proteomes (protein expression profiles) of 
the different developmental stages (Lasonder et al., 2002; Florens et al., 2002). It 
therefore appears unlikely that a protein that is expressed already in the gametocyte does 
not play a functional role in the parasite until the sporozoite stage. For example, 
expression of the sexual specific protein P/s48/45 is initiated in stage III gametocytes. A 
subsequent disruption of the pfs48/45 gene was shown to affect the next developmental 
stage, the gamete, with an impairment in male gamete fertility that resulted in a reduction
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of the numbers of zygotes that were formed (van Dijk et al., 2001). Similarly, synthesis 
of the mosquito stage protein MAEBL has been shown to begin in sporozoites as they are 
developing inside oocysts. Disruption of the maebl gene was later shown to produce an 
accumulation of maebl' sporozoites in the mosquito hemocoel but an almost complete 
absence in the salivary glands, strongly indicating a role for MAEBL in sporozoite 
salivary gland invasion (Kariu et al., 2002).
Although PSLAP clearly plays a role in sporozoite formation, it is fully possible that a 
protein with an extensive and unique domain composition like PSLAP could have more 
than one function. Complex protein structures resulting in multi-functional molecules are 
not uncommon and include a number of proteins and protein families, such as the 
proteases of the Disintegrin And Metalloprotease (ADAM) family (Evans, 2001) and 
thrombospondins (Adams, 2001).
Indeed, disruption studies of the genes encoding the two Plasmodial proteins P25 and P28 
revealed not only that they to a large degree have redundant functions, but also that the 
proteins play multiple roles during more than one developmental stage: in double knock­
out parasites (p25'Vp28' '^) ookinate formation was significantly inhibited, those ookinates 
that did develop had a much reduced capacity to traverse the midgut epithelium, and the 
few that did cross showed a compromised ability to continue their maturation into 
oocysts (Tomas et al., 2001).
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Figure 5.1
Insertion and replacement transfection vectors
Genetic modification of a gene can be achieved with two types of vectors that use 
different modes of integration. The insertion construct (shown on the left) enters the 
parasite genome via a single cross-over event. This is achieved through a single 
homologous recombination between one parasite gene sequence (yellow) cloned into the 
vector, and the identical sequence in the parasite genome (also yellow), resulting in the 
insertion of a duplicated target sequence, the selectable marker (the dhfr-ts gene, shown 
in red) and the vector backbone (white).
The replacement construct (shown on the right), on the other hand, carries two sequences 
from the target gene (green and blue), flanking the selectable marker. For integration to 
take place a double cross-over is required. The result is a loss of the original genomic 
gene sequences, (and any sequence in between these two), replaced by the sequences in 
the vector with the selectable marker gene in the middle.
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Figure 5.2
Pyrimethamine sensitivity of Plasmodium berghei ANKA blood stage parasites
Groups of four mice were inoculated intraperitoneally with 10^  Plasmodium berghei- 
infected erythrocytes. Starting on day 1 (24 hours post innoculation), one group was 
treated with pyrimethamine (lOmg/kg bodyweight; top graph), one group received saline 
injections (center graph) and the third group was left un-treated (bottom graph). The 
injections (indicated by arrows) were repeated on days 2, 3 and 4, and the parasitemia 
monitored daily on Giemsa stained thin blood smears.
Arrows indicate days of injections of pyrimethamine or saline 
The cross (t) denotes the death of an animal.
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Fig 5.3
The pBSK-dhfr-ts plasmid used for constructing pbslap transfection vectors
The pBSK-dhfr-ts plasmid was created by cloning of the 5.2 kilobases DHFR-TS 
transcription unit between the Hindlll and EcoRI restriction sites in the multiple cloning 
cassette (MCS, black) of the pBluescript SK II (+) phagemid vector (Stratagene). The 
DHFR-TS transcription unit consisted of the pyrimethamine resistant form of the 
Toxoplasma gondii dihydrofolate reductase-thymidilate synthase {dhfr-ts) gene (dark 
grey), flanked by the Plasmodium berghei 5’- and 3’ dhfr-ts UTR sequences (light grey). 
Restriction sites that were subsequently used for construction of the pSLAPIns and 
pSLAPRep transfection vectors are shown in the schematic.
The ipBKS-dhfr-ts vector was a gift from Dr. Rita Tewari, Imperial College, London.
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Figure 5.4
Location of fragments used in the pbslap transfection constructs in relation to 
nucleotide sequence coding for structural motifs in the SLAP protein
The fragments chosen for the transfection constructs (represented by black bars below the 
pbslap gene) were located towards the 5’ end of the gene so that in the event that 
transcription took place despite the disruption, only a very short polypeptide with very 
few structural or functional motifs would be translated.
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Figure 5.5
Alignment of pbslap and sequences used in transfection vectors
Multiple sequence alignment showing the exact positions of the Insertion vector fragment 
from pSLAPIns, and Fragments 1 and 2 from the pSLAPRep vector, in relation to the 
pbslap gene.
The alignment was performed using CLUSTAL W. Sequence identity is represented as a 
coloured bar above the aligned sequences, where blue represents two identical sequences 
and green three identical sequences.
Overlapping stretches of sequences are represented by blue colour and non-overlapping 
sequence is either without colour (beginning of gene) or green (end of gene).
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Figure 5.6
Isolated Plasmodium berghei ANKA genomic DNA used as template in PCR
P. berghei genomic DNA was used as template in PCR for amplification of the 911 base 
pair long Insertion vector fragment (InsF), using primers SLAPInsF and SLAPInsR 
(Table 2.7). Ten p,L product was analysed by gelelectrophoresis.
M. Marker IX, Roche
InsF Insertion vector fragment amplification
A band of the correct size, 911 basepairs, was amplified (arrow).
M InsF
bp
1353-
1079-
872-
603-
Figure 5.7
Schematic of construction of the pbslap insertion vector
The SLAPInsFor and SLAPInsRev primers were used to amplify the 911 basepair InsF 
sequence of the pbslap gene from P. berghei gDNA. The fragment, shown in yellow, was 
blunt-cloned into the pCR4Blunt-T0P0 vector for sequencing. Once the correct 
sequence was verified it was re-cloned into the EcoRI site of the pBluQScript-dhfr-ts 
vector, analysed by restriction digestion and sequenced.
Insertion vector Fragment (InsF) amplified by 
PCR from P. berghei ANKA genomic DNA
InsF
i
Insertion vector Fragment (InsF) cloned into 
pCR4BIunt-TOPO for sequencing
EcoRI
pCR4Blunt-
TOPOInsF
EcoRI
i
Insertion vector Fragment excised from pCR4Blunt-TOPO 
and cloned into pBSK-dhfr-ts
InsF
EcoRI
EcoRI
; pSLAPIns Ë dhfr-ts
i
Sequence verified by restriction digest and sequencing (Figure 5.8)
Figure 5.8
Analysis of the Insertion vector fragment sequence
(A) EcoRI digest of the pSLAPIns vector after cloning of the 911 nucleotide sequence 
into the EcoRI site of pBKS-dhfr-ts.
M 1 kb marker, Invitrogen
InsF EcoRI digest of the pSLAPIns vector
A band of the expected size was excised from the vector (arrow) indicating that the 
correct fragment had been cloned into the pSLAPIns vector.
(B) Sequencing of the pSLAPIns vector verified that the cloned fragment was the InsF 
sequence of pbslap.
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< CJ Eh Eh CJ E h Eh CJ Eh Eh < E h
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Figure 5.9
pSLAPIns insertion vector
A 911 base pair long sequence (shown in yellow) from the P. berghei slap gene was 
cloned into the EcoRI site of the pBSK-dhfr-ts vector, to create the pSLAPIns 
transfection construct.
Hindlll 0.00
pBluescript
pBluescript
backbone
M CS
/
\
EcoRI
P. berghei slap 
Insertion vector Fragment
EcoRI
pBluescript
M CS
pSLAPIns
P. berghei dhfr-ts 
5’ UTR
9011 bp h—  B e ll 2 .50
T. gondii dhfr-ts
P. berghei 
dhfr-ts
Sm al 5 .30  B e ll 4 .30
Figure 5.10
Schematic of construction of the pbslap replacement vector
The fragments for the pSLAPRep vector were amplified by PCR using the primers 
SLAPRepFl + SLAPRepRl for Fragment 1 (FI, shown in green), and SLAPRepF2 and 
SLAPRepR2 for Fragment 2 (F2, shown in blue). To create the pSLAPRep vector, the 
fragments were cloned sequentially into pBSK-dhfr-ts, starting with F2 being inserted 
between the EcoRI and Xbal sites, followed by FI between the Apal and Hindlll sites.
Fragment 1 (FI) and Fragment 2 (F2) amplified by PCR
Hindlll Xbal
Fragment 2 cloned into pBSK-dhfr-ts
dhfr-ts
Xbal
F2
EcoRI
Fragment 1 cloned into Fragment 2-containing clone
Apal  ^HindlllFI
pSLAPRep]
F 2 ^  #  dhfr-ts
Sequences verified by restriction digest and sequencing 
(Figures 5.11 and 5.12)
Figure 5.11
Analysis of the cloned pSLAPRep Fragm ent 2 sequence
(A) The pSLAPRep construct was digested with EcoRI and Xbal to verify that the 341 
base pair long Fragment 2 (F2) had been cloned.
F2 FcoRI and Xbal digest of the pSLAPIns vector
M 1 kb ladder, Invitrogen
A band corresponding to the size of F2 was excised from the vector (arrow) indicating 
that the correct sequence had been cloned.
(B) Sequencing of the pSLAPRep vector verified that the cloned fragment was the F2 
sequence of pbslap.
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Figure 5.12
Analysis of the cloned pSLAPRep Fragment 1 sequence
(A) The pSLAPRep construct was digested with Apal and Hindlll to verify that the 860 
base pair Fragment 1 (FI) had been cloned.
M 1 kb ladder, Invitrogen
F2 Apal and Hindlll digest of the pSLAPIns vector
A band corresponding to the size of FI was excised from the vector (arrow) indicating 
that the correct sequence had been cloned.
(B) Sequencing of the pSLAPRep vector verified that the cloned fragment was the FI 
sequence of pbslap.
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Figure 5.13
pSLAPRep replacement vector
Two sequences, Fragment 1 (860 nucleotides, shown in green) and Fragment 2 (341 
nucleotides, shown in blue), were cloned from the P. berghei slap gene into the pBSK- 
dhfr-ts vector, to construct the pSLAPRep transfection vector.
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Plasm odium  berghei transfections
The transfection constructs pSLAPIns and pSLAPRep were digested over night, purified 
and mixed with Plasmodium berghei ANKA schizonts from a 20 hour in vitro culture. 
The mixture was electroporated and injected into female BALB/c mice. The parasites 
were allowed one cycle of asexual division before put under selective pressure by 
administration of pyrimethamine (ten milligram per kilo bodyweight) 24 hours post 
electroporation.
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Protocol for selection of transfected parasites
To select for transformed parasites infected mice were treated with pyrimethamine 
(arrows; ten milligrams per kg body weight) on four consecutive days, starting 24 hours 
post infection. Emerging asexual parasites were transferred to new mice and subjected to 
a second round of pyrimethamine. Parasites appearing after a second selection were 
cloned by limiting dilution.
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Figure 5.16
Screening for parasites transfected with pSLAPRep by PCR
Plasmodium berghei DNA was isolated from infected mice from the transfection 
experiments, and used as template in PCR. Four sets of primers were used for the 
screening (see below). Combinations 1 + 2  and 3 + 4 amplify sequences that are partly 
from the dhfr-ts gene and therefore only present in transfected parasites (“Transfection 
products”). Combinations 1 + 5  and 4 + 6 amplify sequences that are present in both 
transfected and wild type parasites and were used as controls (“Control products”).
The above primers are listed under the following names in Table 2.3:
Primer 1 - SLAPRepFl, Primer 2 - DHFR3, Primer 3 - DHFR2, Primer 4 - SLAPRepR2, 
Primer 5 - SLAPRepRl, Primer 6 - SLAPRepF2.
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Screening for parasites transfected with pSLAPRep by Southern analysis
Plasmodium berghei DNA was isolated from infected mice from the transfection 
experiments, and digested alongside wild type P. berghei gDNA, using EcoRI and 
H indlll restriction enzymes. The DNA was blotted onto a nylon membrane and probed 
with a sequence comprising FI (green) and F2 (blue), shown in the figure as F1-F2 
probe. With transfected parasite DNA, the probe would hybridise to two fragments, 
giving rise to two bands on the blot. With wild type parasite DNA on the other hand, the 
probe would only hybridise to one fragment, appearing as a single band on the blot. 
Expected bands in the Southern analysis are shown as black bars underneath the genes.
Colour key
Green pSLAPRep Fragment 1 (FI)
Blue pSLAPRep Fragment 2 (F2)
Grey pbslap gene
Red dhfr-ts transcription unit
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Transfection experiment 1 - parasite growth
(A) Parasites were electroporated and injected into two female BALB/c mice on day zero 
(long vertical arrow). The animals were treated with pyrimethamine on days one, two, 
three and four (short vertical arrows). Parasites in the peripheral circulation were 
observed on day six post inoculation and were passaged into three new BALB/c mice. As 
before, these mice, shown in (B), received pyrimethamine on days one, two, three and 
four (short vertical arrows). No parasites emerged after the second drug treatment.
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Transfection experiment 1 -  screening
An un-cloned parasite population was isolated after one round of pyrimethamine 
treatment from Mouse 2 (uncloned=UC), gDNA extracted and screened:
(A) Results from PCR amplification using gDNA from the uncloned (UC) parasite 
population from Mouse 2, from the transfection vector (TV) and from wild type P. 
berghei gDNA, analysed by gelelectrophoresis (1% agarose). The two top panels show 
amplification of a product of the correct size from the transfection vector only (arrows). 
The two lower panels show amplification of products of the expected sizes from all 
templates (arrows). A sample without DNA template (no template=NT) was used as a 
negative control.
(B) Southern analysis of the uncloned (UC) parasite population, using the F1-F2 
sequence as a probe (Figure 5.17). The blot shows a single band of approximately 7 kilo 
bases (arrow, left panel), the same size as the band in the P. berghei wild type negative 
control sample. Transfection vector (TV) was included as a positive control for the 
restriction digest and produced a band at the expected 4 kilo bases (arrow, right panel).
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Transfection experiment 2 - parasite growth
(A) Parasites were electroporated and injected into two female BALB/c mice on day zero 
(long vertical arrow). The animals were treated with pyrimethamine on days one, two, 
three and four (short vertical arrows). Twelve days post inoculation parasites were 
observed in Mouse 0 and so were passaged to two new mice. These mice, shown in (B ) ,  
also received pyrimethamine on days one, two, three and four (short vertical arrows). 
Both animals subsequently developed infections, detectable on day nine and ten post­
transfer. Parasites from both mice were screened by PCR and Southern blot (“U C l” and 
“UC2” in Fig 5.21).
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Figure 5.21
Transfection experiment 2 -  screening
Two un-cloned parasite populations were isolated from Mouse 1 (UCl) and Mouse 2. 
(UC2) after two rounds of pyrimethamine treatment, DNA extracted and screened by 
PCR and Southern analysis.
(A) Products from PCR amplifications using template DNA from un-cloned parasites 
from Mouse 1 (UCl) and Mouse 2 (UC2), the pSLAPRep transfection vector (TV), and 
wild-type P. berghei DNA (wt) were analysed by gelelectrophoresis (1% agarose). The 
two top panels show amplification of products of the expected sizes (1026 basepairs and 
464 basepairs) from the transfection vector only (arrows).The lower panels show 
amplification of the expected products (860 basepairs and 341 basepairs) from all 
templates (arrows). No amplification has taken place in the reactions without template 
(NT).
(B) Southern analysis of DNA from Mouse 1 and 2 (UCl and UC2, respectively). A 
single band of approximately seven kilobases (arrow, left panel), identical to the band in 
the P. berghei wild type negative control sample, was generated by both samples. The 
transfection vector (TV) was included as a positive control for the restriction digest and 
produced a band at the expected 4 kilo bases (arrow, right panel).
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Transfection experiment 3 - parasite growth
(A) Parasites were electroporated and injected into one BALB/c mouse on day zero (long 
vertical arrow). The mouse was treated with pyrimethamine on days one, two, three and 
four (short vertical arrows). Peripheral parasites were observed on day six post 
inoculation and were transferred to four new BALB/c mice. These mice, shown in (B), 
also received pyrimethamine on days one, two, three and four (short vertical arrows). 
Mouse 3 subsequently developed an infection, detectable on day eight post-transfer. 
Parasites from Mouse 3 were cloned by limiting dilution and screened by PCR and 
Southern blot (“UC” in Fig 5.23).
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Transfection experiment 3 -  screening
Parasites were isolated after two rounds of pyrimethamine treatment from Mouse 3 
(uncloned=UC), and from three mice after cloning by limiting dilution (MO, M l and 
M2).
(A) Results from PCR amplification using gDNA from the uncloned (UC) parasite 
population, from cloned parasites from three different mice (MO, M l and M2), from the 
transfection vector and from wild type P. berghei gDNA. In the two top panels 
amplification products can be seen only from the transfection vector template. The two 
lower panels show amplification of products of the correct sizes from all templates. A 
sample without DNA template (no template=NT) was used as a negative control.
(B) Southern analysis of the uncloned (UC) parasite population showed a single band of 
approximately 7 kilo bases (arrow, left panel), identical to the band in the P. berghei wild 
type negative control sample. The transfection vector (TV) was included as a positive 
control for the restriction digest and produced a band at the expected 4 kilo bases (arrow, 
right panel).
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Locations of gene sequences used in pbslap disruption constructs
A paper by Claudianos et al. (2002) reported on a disruption of the pbslap gene, using a 
replacement vector containing sequences from nucleotide 274 to 880 and 2776 and 3255. 
The schematic shows the location of these sequences in relation to the sequences used in 
the present study for the pSLAPRep vector.
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Chapter Six
Conclusions and Future work
It is clear that a more detailed knowledge of the unique biology of Plasmodium  is 
required to in order to control malaria. Understanding the life cycle of the parasite and 
how it interacts with its vectors is essential for developing new strategies to combat the 
disease. The recently completed sequencing projects of the genomes of Plasmodium  
falciparum  and Anopheles gambiae now provide an invaluable source of information for 
malaria research. The availability of the genomic data has also allowed the development 
of new approaches to study transcription and expression on a whole organism level. 
However, in order to gain a detailed understanding of the role and significance of a 
specific gene product, there is still a need for analysis of individual proteins.
This project aimed to identify the full sequence of a previously unknown gene in 
Plasmodium chabaudi chabaudi (AS), and to analyse the structure, expression and 
function of the encoded protein.
Using Vectorette and conventional PCR, pcslap was found to be a single exon gene of 
3897 basepairs. Southern analysis demonstrated that the gene was present in a single 
copy in the P, chabaudi chabaudi (AS) genome, as well as in P. yoelii yoelii (17X strain) 
and P. berghei ANKA. Translation of the nucleotide sequence revealed a 1298 residue 
protein with a complex and unique domain structure. Two regions show similarity to 
Scavenger Receptor Cysteine-Rich (SRCR) domains, an ancient superfamily found in a 
diverse range of organisms, that includes both vertebrates and invertebrates. Although no 
unifying function or ligand has yet been identified, many SRCR-domain-bearing 
molecules are involved in immunity and the domains themselves are thought to mediate 
receptor-ligand interactions. Flanking the two SRCR domains are two Limulus factor C, 
Coch-5b2 and Lgll (LCCL) modules, with a third LCCL module located near the C- 
terminal of the protein. The LCCL module is a recently identified motif with an unknown 
function, although recent studies suggest it is involved in ligand binding. The third motif
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identified in PcSLAP is the N-terminal LH2/PLAT domain, found in many membrane- 
associated molecules and believed to mediate protein-protein or protein-lipid interactions. 
The presence of an N-terminal signal sequence and the lack of a transmembrane region or 
GPI-binding site suggest that PcSLAP is a secreted molecule.
Interestingly, multiple sequence alignments showed that PSLAP is highly conserved 
across Plasmodium spp., with a 79% identity between the PSLAP proteins of P. 
chabaudi, P. yoelii and P. berghei, and 63% identity between the P. chabaudi and the P. 
falciparum  homologous proteins. This strongly implies that PSLAP has the same 
function within Plasmodium spp. and allowed some of the expression- and localization 
studies in this project to be performed on species related to P. chabaudi. However, 
despite the high degree of conservation within Plasmodium, the only orthologue found so 
far is the recently identified Toxoplasma gondii Scavenger Receptor 1 (TgSRl). PgSRl is 
made up of a set of domains identical to PSLAP, but has an additional LCCL domain at 
the C-terminal. Alignments show an overall identity of 30% with P. falciparum  SLAP, 
but 37-56% identity between the structural motifs. This indicates that PSLAP and its 
homologues may possess a function that is both vital and specific to apicomplexan 
biology.
To study the stage of expression of PSLAP, as well as its location, antibodies were raised 
against the protein and used in indirect immunofluorescence assays. Using a monoclonal 
antibody against the sexual-stage antigen P/s48/45 for co-localisation studies, it was 
demonstrated that P. berghei and P. falciparum  PSLAP are expressed in blood-stage 
gametocytes. The fluorescence of PSLAP within the infected erythrocyte displayed a 
granular expression pattern, suggesting that the protein may be stored in vesicles, perhaps 
for later secretion. This is consistent with the identification of a signal sequence that 
would direct the protein through a secretory pathway. However, the distribution of the 
protein appeared to be restricted to the parasite, indicating that, at the gametocyte stage, 
PSLAP is not transported into the erythrocyte cytoplasm but retained inside the parasite. 
Finally, in order to analyse the function of PSLAP, an attempt was made to eliminate the 
protein in P. berghei by targeted gene disruption. Two types of transfection vectors were 
successfully constructed, however, disruption of the gene was unsuccessful.
The findings in this project, together with data from recent reports in the literature, raise 
interesting questions regarding the role of PSLAP and related molecule(s) in
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Apicomplexa, and allow some speculation on possible functions for this novel protein, 
and how these questions could be addressed.
Towards the end of this project, a highly relevant study was published reporting on a 
successful disruption of the pslap gene in P. berghei ANKA (Claudianos et al 2002). The 
report confirmed the hypothesis previously put forward by us that PSLAP is likely to 
play a role in the mosquito due to its expression in the transmission stages of the 
erythrocytic life cycle (Delrieu et al., 2002). The study demonstrated that despite normal 
development up until the early oocyst stage, P^SLAP-deficient parasites were unable to 
produce sporozoites. The report stated that P6SLAP-negative parasites developed fully 
through the erythrocytic cycle and formed normal numbers of gametocytes in mice. 
There was no reduction in viability in gametocytes and analysis of the mosquito stages of 
the life cycle showed that ookinetes and early oocysts, as analysed by confocal 
microscopy, developed in numbers comparable to those in wild-type parasites. However, 
from day 10 post parasite ingestion and onwards, there was a clear difference between 
wild-type and disrupted parasites. Although DNA staining showed normal nuclear 
organization within all oocysts, in SLAP-deficient parasites there was no evidence of 
cytokinesis (division of cytoplasm) and subsequent sporozoite growth. The absence of 
sporozoites was confirmed by mosquitoes fed on PZ?SLAP-negative parasites being 
unable to transmit the infection to mice. In addition, five days post infection, oocyst 
growth curves started diverging, and by day 15, P^SLAP-deficient oocysts were on 
average 35% larger (measurement of mean diameter of 100 oocysts) than wild-type 
oocysts.
Although this data clearly shows that PSLAP plays an essential role in the oocyst to 
sporozoite transformation, the actual function of the protein is still not understood.
Does PSLAP function in development or in immunity?
Disruption of the slap  gene resulted in a failure of maturing oocysts to support the 
development of growing sporozoites. Although the result of an absence of PSLAP is 
clear, the cause of the phenotype is not.
Perhaps PSLAP is a developmental molecule, required for the initiation of sporozoite 
morphogenesis within the oocyst? Sporogony is a complex developmental process that is
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highly dependent on interactions between the developing oocyst and the mosquito basal 
lamina. It begins in the young oocyst, which is surrounded by an electron-dense capsule. 
As the oocyst develops, it enlarges progressively and the nucleus divides repeatedly. The 
plasma membrane starts retracting from the capsule, giving rise to subcapsular vacuoles. 
These enlarge and neighboring vacuoles merge into larger clefts that penetrate and divide 
the oocyst cytoplasm, forming the sporoblast. Sporozoites evaginate along the surface of 
the membranes of the sporoblast, and a nucleus and cytoplasmic components are 
transferred into the sporozoites, before they bud off from the sporoblast “like rays from 
the sun” (Figure 6.1; Menard et al., 1997; Vanderberg et al., 1967).
However, considering the structural features of PSLAP, it is also possible that the protein 
plays a protective role against mosquito immune factors that target the parasite and 
inhibit sporozoite growth. The oocyst is an extracellular stage of the parasite life cycle 
that develops in the mosquito hemocoel, and is therefore highly exposed to the insect 
immune response. Malaria infections induce strong innate immune defense reactions in 
the mosquito, with temporal and spatial activation of immune-related genes in a pattern 
that follows the development of the parasite (Dimopoulos et al., 1998; Section 1.8.4). The 
anti-pathogenic response includes up-regulation of genes encoding pattern-recognition 
receptors, serine proteases and antimicrobial peptides.
To study the effects of the mosquito response to PSLAP-deficient parasites and 
specifically oocyst- and sporozoite development, an in vitro culturing system would be 
useful. Methods for culturing of the whole parasite life cycle, including the 
developmental phases in the mosquito, have recently been described and would provide 
an environment to study parasite development and survival without interference from an 
activated insect inunune system (Al-Olayan et al., 2002). This would allow an analysis of 
whether the arrested development of sporozoites in PSLAP-deficient parasites is due to 
damaging effects of the mosquito immune response, or whether it is a result of a 
developmental defect.
What are the ligands interacting with PSLAP?
Another question is that of potential ligands for PSLAP. What molecule(s) is PSLAP 
interacting with, and which structural motif(s) is/are involved in the interaction(s)? The
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complex structure of PSLAP and the fact that all identified domains have previously been 
implicated in ligand-binding, strongly suggests a role in inter-molecular interactions. 
Analysis of a molecule by gene disruption is an “all or nothing” approach, resulting in a 
null mutant that completely lacks the protein in question. However, in order to elucidate 
specifically what domain(s) of P6SLAP that is/are involved in the processes supporting 
sporozoite development, generation of parasites with partial gene deletions, “domain 
knockouts”, are likely to be more informative. This approach was successfully employed 
by Tewari et al. (2002) for analysis of the functions of regions I and II of the Plasmodium 
circumsporozoite protein (CSP). Region I is based around a short, conserved amino acid 
motif and region II is a sequence with homology to the type I repeat in human 
thrombospondin (TSP). It was found that, while parasites lacking region I showed no 
impairment in locomotion or host cell invasion, removal of region II abolished sporozoite 
motility and greatly reduced the ability of parasites to invade mosquito salivary glands 
and vertebrate hepatocytes.
Once the domain(s) in PSLAP responsible for binding has/have been determined, the 
molecular interactions may be characterised in further detail by transfection of pslap 
genes with mutated versions of the binding region, in order to pinpoint the specific 
residues contributing to the interaction.
Does PSLAP function at stages other than in oocysts/sporozoites?
It is still unclear whether PSLAP functions at several stages in the parasite life cycle. It is 
surprising that pslap  gene disruption only produced a phenotype different from that of 
wild type parasites in oocysts/sporozoites, as studies by us and others on the expression 
pattern of PSLAP have demonstrated protein synthesis in all stages from blood stage 
gametocytes through to salivary gland sporozoites (Delrieu et al., 2002; Lasonder et al., 
2002; Truman et a l,  manuscript in preparation). Because of its multi-domain structure, it 
is not unreasonable to think that PSLAP may also have multiple functions.
Development through the insect stages of the parasite life cycle require specific 
interactions between parasite and mosquito molecules, as they involve a series of 
differentiation and migration events, such as attachment to and traversion of the mosquito 
midgut epithelium, interactions with the midgut basal lamina for oocyst formation, and 
sporozoite entry into the mosquito salivary glands (Figure 6.1). However, disruption of
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the pbslap gene showed no reduction in viability in either ookinetes or (early) oocysts, 
indicating that PbSLAV is not involved in these stages of parasite maturation (Claudianos 
et a l ,  2002), Still, in advanced biological systems there is frequently redundancy and 
complementation between molecules, and this also appears to be true for Plasmodium. 
Knock out studies on the sexual-stage proteins P25 and P28 in P. berghei (Pbs25 and 
Pb&2S) showed that disruption of either one of the two genes produced essentially no 
phenotype, whereas disruption of both genes had multiple deleterious effects on several 
stages of parasite development (Tomas et al., 2001). However, while the P25 and P28 
proteins have great structural similarities, and therefore would be expected to perform 
somewhat similar functions, the domain composition of PSLAP is unique. Still, although 
the full repertoire of motifs in PSLAP seems to be unique, individual domain types have 
been identified in other Plasmodial molecules. While the SRCR motif appears to be an 
exclusive feature of PSLAP, the LCCL module is present in additional proteins. A mass 
spectrometry study of the P. falciparum  blood-stage proteome by Lasonder et al. (2002) 
reported on four LCCL-containing proteins, one of which was P/SLAP. All four proteins 
were expressed in sexual-stage parasites (gametocytes and gametes), and all contained 
signal sequences, predicting that they are secreted like PSLAP. A fifth gene coding for an 
LCCL-containing protein was recently identified by Truman et al. (manuscript in 
preparation), prompting these authors to propose that the molecules belong to a small 
protein family characterized by the presence of LCCL or lectin-like motifs. Together with 
a sixth molecule carrying an “anthrax protective antigen”-domain (but no LCCL module) 
they make up the LCCL/Lectin Adhesive-like Protein (LAP) family. MudPIT analysis of 
P. berghei showed that four out of the five LCCL-bearing members of the family are 
expressed in gametocytes and ookinetes, and two also in oocysts. These results are 
suggestive of a specific role for the LCCL module during the parasite stages in the 
mosquito midgut. It is therefore possible that if PSLAP is indeed a multi-functional 
protein, a role dependent on the LCCL motif could perhaps also be performed by another 
LCCL-containing molecule. If this were the case, a disruption of the slap gene would not 
produce a phenotype during these stages of the life cycle.
In the report by Claudianos et al. (2002) the effects of PSLAP depletion in the 
developmental stages beyond the late oocyst stage, such as sporozoite release and
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migration, mosquito salivary gland infection and hepatocyte invasion in the vertebrate
host, were not investigated. However, a recent study used functional complementation to
address this issue (Truman et al., manuscript in preparation). Functional
complementation makes use of the heterokaryotic state of the ookinete: gametocytes of
different genotypes are mixed in vitro and fed to mosquitoes, where they through
fertilisation produce parasites with a heterozygous genotype. Depending on the role of
the protein encoded by the disrupted gene, this may or may not complement the loss of
function and rescue diploid individuals. In the case of phslap, pbslap'/pbslap^ parasites
were able to develop fully through the oocyst stage, producing both pbslap' and pbslap^
sporozoites. Transmission of the these sporozoites to mice, and analysis by diagnostic
PCR of parasite gDNA isolated from the mice, showed that the animals had been
successfully infected with the pbslap' genotype. These results demonstrated that P6SLAP
is not essential for sporozoite migration to, or invasion of, mosquito salivary glands, or
for infection of vertebrate (murine) hepatocytes.
Is PSLAP a gametocyte sequestration receptor?
Studies on the stage-specific expression of PSLAP in the present project showed that the 
protein was present in blood-stage gametocytes, a finding that was later confirmed by a 
high-accuracy mass spectrometry study of the P. falciparum proteome (Delrieu et al., 
2002; Lasonder et al., 2002). The last event in blood-stage maturation before 
transmission of Plasmodium to its insect host can take place is gametocytogenesis -  the 
sexual differentiation of asexual parasites into male and female gametocytes. In P. 
falciparum, an interesting characteristic of these sexual forms is their ability to sequester 
in the microvasculature of the vertebrate host, primarily in the spleen and bone marrow 
(Thomson, 1914; Gamham, 1931; Smalley et al., 1981). This phenomenon is thought to 
play a critical role in the development and survival of the sexual stages. Cytoadhesion of 
asexual-stage parasites to the host endothelium of organs such as the spleen, brain and 
kidneys is well documented and involves the parasite-encoded molecule Plasmodium 
falciparum Erythrocyte Membrane Protein-1 (/yEMP-1), expressed on the infected 
erythrocyte surface, and several host receptors including lCAM-1 and CD36 (Section 
1.7.1). However, sequestration of sexual stage parasites is less well understood. It appears 
that very young P. falciparum gametocytes (stages I and Ila) retain the adhesive
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properties of asexual parasites, such as expression of P/EMP-1, knob (electron dense 
macromolecular complexes surrounding P/EMP-1) formation and ability to bind CD36. 
However, from stage lib onwards these characteristics change or are lost, and so the 
nature of adhesion is altered (Day et al., 1998; Hayward et al., 1999). A study by Rogers 
et al (2000) found that, out of a panel o f monoclonal antibodies with different 
specificities, that against ALCAM (CD 166) was the one which most strongly inhibited 
binding of gametocytes to two bone marrow cell lines. Interestingly, ALCAM is the 
ligand for the lymphocyte antigen CD6, a membrane-bound molecule composed of three 
SRCR domains. The interaction between ALCAM and CD6 has been characterized in 
some detail and found to involve the most membrane proximal SRCR domain of CD6 
and the most membrane distal Ig-like domain of ALCAM (Bowen et a l ,  2000). This 
raises the question of whether PSLAP could be the so far un-identified receptor on 
gametocyte-infected erythrocytes that mediates adhesion to human bone marrow. Is it 
possible that the SRCR domains of PSLAP interact with the Ig domains on ALCAM? 
Gametocyte sequestration is also a feature of murine Plasmodia, and has been observed in 
P. chabaudi, P. yoelii and P. vinckei. Examination of these species have shown that the 
stage of gametocytes that sequesters also appears to be that with the highest degree of 
infectivity to mosquitoes (Landau et al., 1979; Gautret et a l ,  1996). If PSLAP is 
involved in gametocyte adhesion it would be expected to see a difference in infectivity in 
PSLAP-negative parasites, as compared with wild-type parasites. In the report on the 
disruption of the slap gene in P. berghei by Claudianos et al (2002) the authors stated 
that PbSLAP KO parasites formed normal numbers of gametocytes in mice, and that they 
developed into oocysts in numbers comparable to wild-type parasites. Oocyst counts 
were obtained from assays where mosquitoes had been fed either on gametocyte-infected 
mice or on ookinetes from membrane feeders. However, a closer examination of the 
oocyst counts reveal greater numbers from knock out- than from wild type parasites when 
using gametocytes as feed (Table 6.1). If PSLAP plays a role in gametocyte 
sequestration, it would be expected that a lack of the protein would have reduced the 
number of sequestered gametocytes in an infected mouse, and thereby increased the 
number of highly infective gametocytes in the circulation, resulting in a rise in the 
numbers of oocysts formed in mosquitoes fed on these gametocytes, as was observed in 
the study by Claudianos et al. (2002).
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Table 6.1 Effect of pbslap disruption on P. berghei infectivity to A. stephensi, as analysed by 
numbers of oocyst formed in mosquitoes. Modified from Claudianos et at, (2002).
Exp Feed WT P6SLAPKO % increase/decrease in KG compared to WT
1 Gametocytes 18 39.2 118% increase
2 111 143 29% increase
3 Ookinetes 38.7 43.7 13% increase
4 46.6 41.7 11% decrease
Exp = experiment, WT = wild type, KO = knoclcout
In order to function as a gametocyte sequestration receptor, PSLAP would have to be 
expressed on the surface of the infected red blood cell. Although there is as yet no 
evidence for this, it is still possible that the level of expression is too low to be detected 
by the methods used so far. PSLAP does not carry a transmembrane domain or a typical 
GPI anchor site but could be attached to a membrane protein via an interaction with one 
of its many adhesive structures, perhaps the LH2 domain, a type of motif often found in 
membrane or lipid-associated proteins (Bateman and Sandford 1999). Although this 
would be a weak interaction, parasites sequestered in the bone marrow are protected from 
the forces of shear flow encountered in the microvasculature of major organs, and 
therefore may still be able to successfully sequester in this environment through such an 
interaction. Moreover, it is consistent with the lower avidity observed in in vitro adhesion 
assays reported for gametocyte sequestration, as compared with similar assays using 
asexual parasites (Rogers et al., 2000).
To address the question of whether PSLAP may be involved in gametocyte sequestration 
the same in vitro adhesion assays used by Rogers et al (2000) could be employed. 
Antibodies directed against the two SRCR domains of PSLAP could be used with the 
objective of determining whether binding of gametocyte-infected erythrocytes is 
inhibited or not, to investigate whether the interaction is mediated by the PSLAP SRCR 
domains.
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Is PSLAP a modulator of the mosquito immune response?
Parasite survival in the insect host requires not only a carefully tuned developmental 
program, but also efficient and successful protection from the mosquito immune 
response. The mosquito is capable of mounting a range of anti-parasitic reactions, 
including both humoral and cellular responses. These are initiated approximately 24 
hours post parasite ingestion, at the time of ookinate midgut invasion, and continue 
throughout the parasite residence in the insect (Dimopoulos et ah, 1998). A central role in 
invertebrate immunity is played by serine proteases, which regulate anti-pathogenic 
defense mechanisms such as melanotic encapsulation, hemolymph coagulation and 
antimicrobial peptide synthesis (Gorman and Paskewitz, 2001). It is therefore interesting 
to find structural motifs that are shared between a mosquito immune molecule and a 
Plasmodial protein expressed during the insect-stages of development. Sp22D is a serine 
protease composed of two SRCR domains, two Chitin-binding type 2 domains (CBDs), 
two Low-density lipoprotein receptor class A (LDLRA) domains and a Trypsin-like 
serine protease domain (Gorman et al., 2000; Figure 3.22). Although the function of 
Sp22D is still unknown, Gorman et al. (2000) suggest a role in immunity due to the fact 
that most of its domains are similar to immune-related proteins, it is up-regulated in 
response to bacterial challenge but not to wounding, and it is constitutively transcribed in 
hemocytes, fat body, and midgut epithelium -  all tissues with important immune 
functions. A general feature of invertebrate immunity is the use of defense systems that 
respond to antigens exposed on the surface of invading pathogens. The composition of 
Sp22D resembles a pathogen-recognition molecule: SRCR domains were recently shown 
to bind a wide repertoire of gram positive and -negative bacteria and CBDs bind chitin, a 
surface component of fungi and nematode eggs (Bikker et al., 2002; Shen and Jacobs- 
Lorena, 1999). This suggests that Sp22D could be involved in detection of a broad range 
of micro-organisms, including parasites. To avoid destruction while inside its insect host, 
it is likely that Plasmodium would have developed mechanisms to deflect the mosquito 
immune response. Structural and functional mimicry is a wide-spread strategy for 
immune evasion among pathogens and involves the use of a self molecule that 
functionally and/or structurally resembles a host protein. Thus, PSLAP may act as such 
an immunomodulator, competing for the same ligand as Sp22D, thereby impairing the 
parasite eradication process and increasing the chances of survival.
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Does PSLAP have a function similar to Circumsporozoite Protein?
Studies on the expression pattern of PSLAP have shown protein synthesis from 
gametocytes through to sporozoites (Delrieu et al., 2002; Truman et al., manuscript in 
preparation). Surprisingly, however, slap gene disruption only produced a phenotype 
different from that of wild type parasites in sporozoites. Early oocyst development was 
normal, but there was no evidence of cytokinesis and subsequent sporozoite formation 
(Claudianos et al., 2002). Interestingly, disruption of the gene encoding the P. berghei 
circumsporozoite protein (CSP), produced a similar phenotype: oocyst development up 
until day ten was identical in CSP-negative and wild-type parasites, however, starting on 
day 11 as sporozoites began appearing in wild-type oocysts, CSP-negative oocysts 
displayed an empty, vacuolated structure. Due to its expression in the unsegmented 
oocyst and on the membrane invaginations in the sporoblast cytoplasm, the authors 
suggested that CSP may have a regulatory function in early oocyst growth, perhaps 
guiding membrane formation during sporogony by interacting with receptors in the 
intersporozoite matrix (Menard et al., 1997; Figure 6.1). Considering the many adhesive­
like domains of PSLAP and similarities between the CSP- and PSLAP- deficient 
phenotypes, it seems possible that the two proteins could have similar functions. This is 
also supported by the follow-up to the pbslap-dismption  study that used functional 
complementation to restore the P^SLAP-negative phenotype. Complementation of the 
loss of function in pbslap' was successful and diploid pbslap'/pbslap^ parasites were able 
to develop fully through the oocyst stage. However, infection of mosquitoes with a mixed 
population of pbslap' and pbslap'^ homozygous ookinetes did not rescue pbslap  oocysts 
(Truman et al., manuscript in preparation). This finding suggests that P6SLAP functions 
inside the immature oocyst, an idea that is more compatible with a developmental rather 
than immuno-regulatory function.
A possible approach to investigating the role of PSLAP in oocyst differentiation would 
be to carry out ultrastructural studies using recombinant parasites with reduced 
production of PSLAP, and compare the morphology of these with wild type and PSLAP- 
negative oocysts. This may provide a correlation between the level of development of 
specific structures within the oocyst with the amounts of protein being produced, and 
thereby identify a more specific role for PSLAP.
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Are PSLAP and Toxoplasma gondii Scavenger Receptor 1 functional orthologues?
It is interesting that an orthologue of PSLAP, TgSRl was recently identified in another 
apicomplexan parasite. Toxoplasma gondii. So far no function has been ascribed to this 
protein, but the almost identical domain organisation suggests a conserved and essential 
function for the SLAP/TgSRl proteins, specifically evolved in Apicomplexa.
Most Apicomplexans exhibit an overall general life cycle, characterised by three distinct 
processes: sporogony, merogony and gametogony. However, differences between 
Plasmodium  and Toxoplasma include host species, host cell specificity and mode of 
transmission. T. gondii infects a wide range of mammals, including birds, pigs and 
rodents, and infections are widely prevalent in humans causing the disease 
toxoplasmosis.
The parasite exhibits a predator-prey type life cycle. The definite hosts (where sexual 
replication occurs) are members of the cat family (Felidae), in which the parasite invades 
the enterocytes (intestinal cells) of the animal’s gut. After several rounds of asexual 
replication, the parasites differentiate into male and female gametocytes, which fuse and 
transform into an oocyst. The oocyst is shed into the environment with the cat’s feces and 
divides into four sporoblasts, each of which forms a sporocyst containing two 
sporozoites. These are highly resistant to damage and may persist in the soil for years 
under favorable (moist) conditions. After ingestion by a secondary, intermediate host, for 
example a mouse, the sporozoites develop into rapidly dividing tachyzoites, causing an 
acute infection. In most hosts, tachyzoites transform into the slowly dividing bradyzoites, 
thereby establishing a chronic infection that results in the formation of latent tissue cysts. 
Interestingly, tachyzoites, bradyzoites and sporozoites are all infectious, and therefore, 
carnivorous ingestion of the cysts by a second intermediate host, such as a rat, leads to 
infection of a naïve individual, allowing an indefinite non-sexual propagation of the 
parasite, or if the predator is a cat, to initiation of the sexual development and completion 
of the life cycle (Figure 6.2; Dubey, 1998).
If the role of SLAP in Plasmodium is similar to that of TgSRl in Toxoplasma, it would be 
expected that the proteins function in a situation that exists in both species. Plasmodium 
falciparum  is as yet the only apicomplexan parasite with a fully sequenced genome, and
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the extent of homology between different members of Apicomplexa is therefore not 
known. However, studies on individual genes and proteins have shown conservation of 
specific functions. One such example is the involvement of TRAP and orthologous 
proteins in other apicomplexans, in host cell invasion and parasite gliding motility. 
Members of the TRAP family of proteins have been found in Plasmodium ookinetes and 
sporozoites, as well as in the invasive stages of Toxoplasma (tachyzoite), Eimeria 
(sporozoite) and Cryptosporidium (sporozoite). Gene transfection experiments with inter­
species substitutions showed that the cytoplasmic tail of Plasmodium berghei TRAP was 
interchangeable with that of the homologous protein in T. gondii, Micronemal Protein 2 
(MIC2). Plasmodium sporozoite gliding motility and cell penetration, both processes that 
rely on TRAP, were comparable in mutant and wild-type parasites, suggesting that these 
mechanisms are conserved within Apicomplexa (Sultan et al., 1997; Kappe et al., 1999).
It is interesting to note that the life cycle of Toxoplasma does not include parasite 
maturation inside an insect vector. If PSLAP has the same function in Plasmodium as 
TgSRl in Toxoplasma, this fact indicates that the protein could not be involved in 
defense against an insect-specific anti-parasitic immune response, but is more likely to be 
required for progression of normal development. Alternatively, PSLAP may play an 
additional role in Plasmodium  in protection against mosquito immune molecules. As 
gene disruption techniques are also available for manipulation of T. gondii, it would be 
interesting to investigate what effect a disruption of TgSRl has on the development and 
survival of T. gondii parasites, as this may also shed some light on the function on 
Plasmodium SLAP.
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Figure 6.1
Developmental cycle of Plasmodium in Anopheles mosquitoes
Shortly after the mosquito ingests an infected blood meal, male and female gametocytes 
escape from the erythrocyte inside the midgut lumen (1) and mature into gametes (2). 
Fertilisation (3) occurs rapidly generating a zygote (4), which elongates to become an 
ookinete (5). The motile ookinete penetrates between or through the midgut epithelial 
cells and moves to the space between the epithelial cells and the basal lamina, where it 
transforms into an oocyst (6). The young oocyst undergoes nuclear division while its 
plasma membrane retracts from the outer capsule (7), giving rise to clefts and 
invaginations that divide the cytoplasm, forming the sporoblast (8). Sporozoites evaginate 
along the membranes of the sporoblast (8 and 9) producing a mature oocyst filled with 
needle-shaped sporozoites (10). The sporozoites are released (11) and migrate to and 
invade the mosquito salivary glands (12). Sporozoites contained within the acinar cells of 
the glands are injected into vertebrate hosts during subsequent feedings.
ML, midgut lumen; H, hemocoel; ISM, intersporozoite matrix; SG, salivary glands.
Modified from Menard et a l, 1997.
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Figure 6.2
Life cycle of Toxoplasma gondii
Toxoplasma gondii has three infectious stages: tachyzoites, bradyzoites and sporozoites 
(contained within oocysts). In cats, the definitive host, ingestion of any of these results in 
infection. Following invasion of enterocytes in the gut, the parasites replicate asexually 
and differentiate into male and female gametocytes. These fuse and develop into an 
oocyst, which is excreted with the animal’s feces. Sporogony takes place in the 
environment, within the highly resistant walls of the oocyst. The matured oocyst is 
subsequently ingested by an intermediate host, such as a mouse, and the sporozoites first 
develop into tachyzoites and later into bradyzoites, thereby establishing a chronic 
infection. Because both of these stages are transmissable, carnivorous ingestion by a 
second intermediate host results in infectious disease and allows indefinite non-sexual 
propagation of the parasite. The cycle is eventually completed as a cat ingests tachyzoites 
or bradyzoites through camivorism, or sporozoites from the environment.
Modified from Dubey, 1998.

Appendix
Media, buffers and solutions
All buffers and solutions were made up in dH20 unless otherwise stated, using chemicals 
and reagents of analytical grade purchased from BDH Chemicals Ltd., Poole, UK, or 
Sigma, Poole, UK, unless otherwise stated.
Acrylamide 10% homogenous separating gel (for 5 gels)
8 mL Lower gel buffer
10.7 mL 30% acrylamide
200 pL 10% ammonium persulphate (APS)
30 pL N,N,N’,N’-tetramethylethylenediamine (TEMED)
13.3 mL dH^O
Acrylamide stacking gel (for 5 gels)
2.5 mL Upper gel buffer
1.58 mL 30% acrylamide
40 pL 10% APS
13 pL TEMED
5.92 mL dH^O
Anode buffer 1 (lOx), Western analysis
300 mM Tris-base
20% (v/v) Methanol (100%)
Anode buffer 2 (lOx), Western analysis
3 M Tris-base
20% (v/v) Methanol (100%)
Antibody dilution buffer
To be made up in PBS 
0.1% BSA 
0.3% Tween 20
Blocking buffer, ELISA
To be made up in PBS
1% Bovine serum albumine (BSA)
0.3% Tween 20
0.05% NaNq
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Blocking buffer, Western analysis
To be made up in PBS 
1% BSA 
0.3% Tween 20
Carbonate buffer, O.IM, ELISA
8.40g NaHCOg
3.56g NazCOg
Make up to IL and adjust pH to 9.5.
Cathode buffer (lOx), Western analysis
250 mM Tris-base
400 mM 8-aminocaproic acid
20% (v/v) Methanol (100%)
Coomassie stain
45% (v/v) Methanol
10% (v/v) Ethanoic acid
0.1% (w/v) Coomassie Brilliant Blue R
Cytomix
120 mM KCl
0.15 mM CaClz
10 mM K2HPO4/KH2PO4 pH 7.6
25 mM Hepes pH 7.6
2 mM EGTA pH 7.6
5 mM MgCl2
Make up to a total volume of 100 pL.
Depurination buffer
0.25 M HCl
Destain
5% (v/v) Methanol
10% (v/v) Acetic acid
Diethanolamine buffer, ELISA
4.85% (v/v) diethanolamine pH 9.8
0.2 M MgCl2*6H20
0.1% NaNg
Extraction buffer for parasite gDNA
50mM Tris, pH 7.5
50mM Ethylenediaminetetraacetic acid (EDTA)
lOOmM NaCl
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Flow cytometry buffer (PBNE)
To be made up in PBS 
1% (w/v) BSA
5 mM EDTA
0.01% (w/v) NaNg
pH to 7.2
Gel buffer for acrylamide gels, Lower
1.5 M Tris Base
0.4% w/v Sodium dodecyl sulphate (SDS, final pH 8.8)
Gel buffer for acrylamide gels. Upper
0.5 M Tris Base
0.4% w/v SDS (final pH 6.8)
Iscove’s Modified Dulbecco’s Medium, complete
500 mL Iscove’s Modified Dulbecco’s Medium
10% ECS (heat inactivated; Globepharm, UK)
10.000 units Penicillin
10.000 pg Streptomycin
100 mM Sodium pyruvate
200 mM L-glutamine
1 M HEPES buffer
50 mM 2-mercapto-ethanol
All additives filter sterilized (except ECS) before included in the medium. 
LB Agar
To be made up in LB Broth 
15g/L Agar
LB Broth
lOg/L NaCl
1 Og/L B acto-tryptone
5g/L Yeast extract
Loading buffer (6x), DNA gels 
0.25% Bromphenol blue
40% (w/v) Sucrose
Lysis buffer for bacteria
50 mM Na^HPO /^NaHgPO^
0.5 M NaCl
10 mM Imidazole
8 M Urea
Adjust pH to 7.4
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Nycodenz, 100%
27.6g Nycodenz powder (Robins Scientific, UK) in Nycodenz buffer to a total volume of 
100 mL
Nycodenz buffer
5 mM Tris-HCl pH 7.5
3 mM KCl
0.3 mM EDTA
Parasite freezing medium
40% v/v Glycerol
0.14M Sodium lactate
5mM Potassium chloride
Adjust pH to 7.4
Parasite lysis buffer
50 mM Tris-HCl
1 mM EDTA
0.5% (v/v) SDS
Adjust pH to 7.5
PBNE See Flow cytometry buffer
Phosphate Buffered Saline (PBS)
0.1 M NaCl
80 mM Na^HPO^
20 mM NaH2P04
Adjust pH to 7.5
Pyrimethamine
25 mg powder in 6 mL DMSO
Make up to a total volume of 10 mL with SH2O
RNA transfer buffer
7.5 mM NaOH
SDS sample buffer (2x) for protein preparations
0.125 M Tris base
20% (w/v) Glycerol
4.5% (w/v) SDS
0.01% (w/v) Bromophenol blue
SDS-PAGE running buffer (Ix)
25 mM Tris-base
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192 mM Glycine
0.1% SDS
Adjust pH to 8.3
SSC, 2x, pH 7.0
0.3M
0.33M
NaCl
SSPE, Ix
120mM
15mM
13mM
ImM
NaCl
tri-Na citrate
KH2PO4
EDTA
TBE buffer
100 mM 
100 mM 
5 mM
Tris-HCl 
sodium borate 
EDTA
Adjust pH to 8.0
Transfer buffer
1.5 M NaCl
0.5 M NaOH
Wash buffer, Western analysis
To be made up in PBS 
0.3% Tween 20
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